0001213900-20-011182.txt : 20200506 0001213900-20-011182.hdr.sgml : 20200506 20200506164154 ACCESSION NUMBER: 0001213900-20-011182 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GI DYNAMICS, INC. CENTRAL INDEX KEY: 0001245791 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55195 FILM NUMBER: 20853228 BUSINESS ADDRESS: STREET 1: 320 CONGRESS STREET STREET 2: 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 781-357-3310 MAIL ADDRESS: STREET 1: 320 CONGRESS STREET STREET 2: 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: GI DYNAMICS INC DATE OF NAME CHANGE: 20030623 10-Q 1 f10q0320_gidynamics.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-55195

GI DYNAMICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		84-1621425
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

320 Congress Street, 3^rd Floor
Boston, Massachusetts		02210
(Address of Principal Executive Offices)		(Zip Code)

(781) 357-3300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act: None

Securities registered pursuant to Section 12(g) of the Exchange Act: Common Stock, $0.01 par value per share

Title of each class		Trading symbol(s)		Name of each non-U.S. exchange on which registered
Common Stock, par value $0.01		GID.ASX		Australia Securities Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

The registrant’s common stock is publicly traded on the Australian Securities Exchange (the “ASX”) in the form of CHESS Depositary Interests (“CDIs”) convertible at the option of the holders into shares of the registrant’s common stock on a 1-for-50 basis. The total number of shares of the registrant’s common stock outstanding on May 1, 2020, including shares of common stock underlying CDIs, was 36,598,291.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements as defined in Section 27A of the United States Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. These forward-looking statements concern Company business, operations, financial performance and condition as well as plans, objectives and expectations for Company business, operations and financial performance and condition. Any statements contained in this Quarterly Report on Form 10-Q that are not of historical facts may be deemed to be forward-looking statements. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about the Company’s:

●

expectations with respect to the Company’s intellectual property position;

●

expectations with respect to clinical trials for EndoBarrier^®;

●

expectations with respect to regulatory submissions and receipt and maintenance of regulatory approvals;

●

ability to commercialize products;

●

ability to develop and commercialize new products;

●

expectation with regard to product manufacture and inventory; and

●

estimates regarding capital requirements and need for additional financing.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “aims,” “assumes,” “goal,” “intends,” “objective,” “potential,” “positioned,” “target,” “continue,” “seek,” “vision,” or the negative thereof and similar expressions intended to identify forward-looking statements.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which the Company operates and management’s beliefs and assumptions. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control. As a result, any or all forward-looking statements in this Quarterly Report on Form 10-Q may later become inaccurate. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made. The Company has included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the “Risk Factors” section (which incorporates by reference the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC), that could cause actual results or events to differ materially from the forward-looking statements made by the Company.

You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. You should read this Quarterly Report on Form 10-Q and the documents filed as exhibits to the Company’s Annual Report on Form 10-K completely and with the understanding that actual future results may be materially different from what is stated as expectation. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks described in the reports the Company will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q.

GI DYNAMICS, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2020

TABLE OF CONTENTS

		Page

	PART I – FINANCIAL INFORMATION	1

Item 1.	Financial Statements (unaudited)	1
	Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019	1
	Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019	2
	Consolidated Statements of Changes in Stockholders’ Deficit for the Three Months Ended March 31, 2020 and 2019	3
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019	4
	Notes to Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	25

	PART II – OTHER INFORMATION	26

Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 6.	Exhibits	26
	Signatures	27

References

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “GI Dynamics” and “the Company” refer to GI Dynamics, Inc. and its directly and indirectly consolidated subsidiaries.

Dates

Unless indicated otherwise in this Quarterly Report on Form 10-Q, all dates are stated as the date representing business hours in the Eastern Daylight Time zone or Eastern Standard Time zones. Any dates stated in the Australian Eastern Daylight Time zone or the Australian Eastern Standard Time zone will be denoted as “AEDT” or “AEST,” respectively.

Currency

Unless indicated otherwise in this Quarterly Report on Form 10-Q, all references to “$,” “US$” or “dollars” refer to United States dollars, the lawful currency of the United States of America. References to “A$” refer to Australian dollars, the lawful currency of the Commonwealth of Australia. References to “€” or “euros” means euros, the single currency of Participating Member States of the European Union.

Trademarks

EndoBarrier^®and various company logos are the trademarks of the Company, in the United States and other countries. All other trademarks and trade names mentioned in this Quarterly Report on Form 10-Q are the property of their respective owners.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

GI Dynamics, Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(unaudited)

	March 31,			December 31,
	2020			2019
Assets
Current assets:
Cash	$	3,854		$	2,499
Restricted cash		30			30
Prepaid expenses and other current assets		1,377			1,230
Total current assets		5,261			3,759
Property and equipment, net		34			42
Right-of-use assets, net of amortization		352			386
Total assets	$	5,647		$	4,187
Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable	$	521		$	636
Accrued expenses		886			1,353
Short term debt to related party		5,000			5,000
Derivative liabilities		—			10
Short term lease liabilities		170			169
Total current liabilities		6,577			7,168
Long term debt to related party, net of debt discount		1,950			—
Long term lease liabilities		182			217
Total liabilities		8,709			7,385
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.01 par value – 75,000,000 shares authorized; 36,598,291 shares issued and outstanding		366			366
Additional paid-in capital		283,905			280,928
Accumulated deficit		(287,333	)		(284,492	)
Total stockholders’ deficit		(3,062	)		(3,198	)
Total liabilities and stockholders’ deficit	$	5,647		$	4,187

The accompanying notes are an integral part of these unaudited consolidated financial statements

GI Dynamics, Inc. and Subsidiaries

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(unaudited)

	Three Months Ended March 31,
	2020			2019
Operating expenses:
Research and development	$	1,173		$	810
Sales and marketing		—			16
General and administrative		1,543			1,344
Total operating expenses		2,716			2,170
Loss from operations		(2,716	)		(2,170	)

Other income (expense):
Interest income		—			3
Interest expense		(284	)		(177	)
Foreign exchange loss		(10	)		(9	)
Gain on write-off of accounts payable		—			29
Gain on write-off of accrued product return liability		164			—
Re-measurement of derivative liabilities		—			(1	)
Other income		10			—
Other expense, net		(120	)		(155	)
Loss before income taxes		(2,836	)		(2,325	)
Provision for income taxes		5			6
Net loss	$	(2,841	)	$	(2,331	)

Basic and diluted net loss per common share	$	(0.08	)	$	(0.12	)
Weighted-average number of common shares used in basic and diluted net loss per common share		36,598,291			19,277,545

The accompanying notes are an integral part of these unaudited consolidated financial statements

GI Dynamics, Inc. and Subsidiaries

Consolidated Statements of Changes in Stockholders’ Deficit

(In thousands, except share)

(unaudited)

	Common Stock
THREE MONTHS ENDED MARCH 31, 2020	Shares		Par Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at January 1, 2020		36,598,291	$	366	$	280,928	$	(284,492	)	$	(3,198	)
Stock-based compensation expense		—		—		212		—			212
Relative fair value of warrants and beneficial conversion feature in connection with August 2019 Note		—		—		2,765		—			2,765
Net loss		—		—		—		(2,841	)		(2,841	)
Balance at March 31, 2020		36,598,291	$	366	$	283,905	$	(287,333	)	$	(3,062	)

	Common Stock
THREE MONTHS ENDED MARCH 31, 2019	Shares		Par Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at January 1, 2019		19,277,545	$	193	$	263,521	$	(267,159	)	$	(3,445	)
Stock-based compensation expense		—		—		59		—			59
Net loss		—		—		—		(2,331	)		(2,331	)
Balance at March 31, 2019		19,277,545	$	193	$	263,580	$	(269,490	)	$	(5,717	)

The accompanying notes are an integral part of these unaudited consolidated financial statements

GI Dynamics, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands)

(unaudited)

	Three Months Ended March 31,
	2020			2019
Operating activities:
Net loss	$	(2,841	)	$	(2,331	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		8			8
Re-measurement of derivative liabilities		—			1
Reclassification of warrant from derivative liabilities to other income		(10	)		—
Non-cash interest expense		282			175
Stock-based compensation expense		212			59
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(147	)		(26	)
Accounts payable		(115	)		(583	)
Accrued expenses		(631	)		(768	)
Net cash used in operating activities		(3,242	)		(3,465	)
Investing activities
Purchases of property and equipment		—			(5	)
Net cash used in investing activities		—			(5	)
Financing activities
Debt issuance costs		—			(50	)
Proceeds from short term and long term debt, related party		4,597			1,000
Net cash provided by financing activities		4,597			950
Net decrease in cash and restricted cash		1,355			(2,520	)
Cash and restricted cash at beginning of period		2,529			3,836
Cash and restricted cash at end of period	$	3,884		$	1,316
Supplemental disclosures of cash flow information and non-cash activities
Income taxes paid	$	5		$	6
Interest paid		—			394
Warrants issuance recorded to APIC and debt discount		2,330			—
Beneficial conversion feature discount associated with August 2019 Note		435			—

The accompanying notes are an integral part of these unaudited consolidated financial statements

GI Dynamics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(unaudited)

1. Nature of Business

GI Dynamics^® is a clinical stage medical device company focused on the development and commercialization of EndoBarrier, a medical device intended to treat patients with type 2 diabetes and to reduce obesity.

Being overweight is a condition where the patient’s BMI is greater than 25 (kg/m²); obesity is a condition where the patient’s BMI is greater than 30. Obesity and its comorbidities contribute to the progression of type 2 diabetes. Many experts believe obesity contributes to higher levels of insulin resistance, which creates a feedback loop that increases the severity of type 2 diabetes.

When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes.

EndoBarrier^®is intended for the treatment of type 2 diabetes and to reduce obesity in a minimally invasive and reversible manner.

The current treatment paradigm for type 2 diabetes is lifestyle therapy combined with pharmacological treatment, whereby treating clinicians prescribe a treatment regimen of one to four concurrent medications that could include insulin for patients with higher levels of blood sugar. Insulin carries a significant risk of increased mortality and may contribute to weight gain, which in turn may lead to higher levels of insulin resistance and increased levels of blood sugar. Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled efficacy gap.

The GI Dynamics vision is to make EndoBarrier the essential nonpharmacological and non-anatomy-altering treatment for patients with type 2 diabetes. The Company intends to achieve this vision by providing a safe and effective device, focusing on optimal patient care, supporting treating clinicians, adding to the extensive body of clinical evidence around EndoBarrier, gaining appropriate regulatory approvals, continuing to improve its products and systems, operating the Company in a lean fashion, and maximizing stockholder value.

EndoBarrier^®is intended for the treatment of type 2 diabetes and to reduce obesity in a minimally invasive and reversible manner and is designed to mimic the mechanism of action of duodenal-jejunal exclusion created by gastric bypass surgery.

Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company currently operates in one reportable business segment.

Going Concern Evaluation

As of March 31, 2020, the Company’s primary source of liquidity is its cash and restricted cash balances. GI Dynamics is currently focused primarily on its clinical trials, which will support future regulatory submissions and potential commercialization activities. Until the Company is successful in gaining regulatory approvals, it is unable to sell the Company’s product in any market at this time. Without revenues, GI Dynamics is reliant on funding obtained from investment in the Company to maintain business operations until the Company can generate positive cash flows from operations. The Company cannot predict the extent of future operating losses and accumulated deficit, and it may never generate sufficient revenues to achieve or sustain profitability.

GI Dynamics has incurred operating losses since inception and at March 31, 2020, had an accumulated deficit of approximately $287 million and a working capital deficit of $1.3 million. The Company expects to incur significant operating losses for the next several years. At March 31, 2020, the Company had approximately $3.9 million in cash and restricted cash.

The Company will need to restructure the terms of the Senior Secured Convertible Promissory Note, issued on June 15, 2017 (as amended from time to time, the “2017 Note”), before May 15, 2020 or the 2017 Note will be in default and subject to a call notice at the discretion of Crystal Amber. If the 2017 Note terms are restructured or the note is not called, the Company must raise additional capital before May 31, 2020 in order to continue to pursue its current business objectives as planned and to continue to fund its operations. The Company and Crystal Amber Fund Limited (“Crystal Amber”, a Related Party for ASX purposes) are currently in discussions regarding the 2017 Note maturity extension. The Company is looking to raise additional funds through any combination of additional equity and debt financings or from other sources. However, the Company has no guarantee that the 2017 Note will be restructured or if in default, will not be called. If the Note is called, the Company has no guaranteed source of capital that will accommodate repayment of the 2017 Note. If the 2017 Note terms are restructured or the 2017 Note is in default, but not called, the Company anticipates that operating cash will be exhausted by May 31, 2020 and therefore additional financing will be required to be able to continue its operations after this date. There can be no assurance that any potential financing opportunities will be available on acceptable terms, if at all. If the Company is unable to raise sufficient capital on the Company’s required timelines and on acceptable terms to stockholders and the Board of Directors, it could be forced to reduce or cease operations, including activities essential to support regulatory applications to commercialize EndoBarrier. If access to capital is not achieved before May 31, 2020, it will materially harm the Company’s business, financial condition and results of operations to the extent that the Company may be required to cease operations altogether, file for bankruptcy, or undertake any combination of the foregoing.

In addition, if the Company does not meet its payment obligations to third parties as they become due, the Company may be subject to litigation claims and its credit worthiness would be adversely affected. Even if the Company is successful in defending these claims, litigation could result in substantial costs and would be a distraction to management and may have other unfavorable results that could further adversely impact the Company’s financial condition.

These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

The accompanying consolidated financial statements have been prepared assuming GI Dynamics will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

2. Significant Accounting Policies and Basis of Presentation

The consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been omitted pursuant to such rules and regulations. These interim consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 27, 2020. The Company's balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by GAAP for complete financial statements.

In our opinion, the consolidated financial statements included herein contain all adjustments necessary to present fairly our financial position as of March 31, 2020 and the results of our operations and cash flows for the three months ended March 31, 2020 and 2019. Such adjustments are of a normal recurring nature. In addition, certain reclassifications of prior period balances have been made to conform to the current period presentation.

Recently Adopted Accounting Pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13, which provides guidance focused on the disclosure requirements for disclosing fair value estimates, assumptions, and methodology. Requirements removed include the requirement to disclose details around amount and reasoning for level 1 to level 2 transfers, timing policies for transfer between levels and the valuation processes for level 3 fair value measurements. Modified requirements include details regarding net asset redemption restrictions and timing related to uncertainty disclosures. Requirements added include disclosures of changes in unrealized gains and losses for recurring level 3 measurements held as of the reporting date and disclosures around the range and weighted average of significant inputs used to develop level 3 fair value measurements. These amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption was permitted upon issuance of this update, however the Company has declined early adoption. The Company adopted this ASU on January 1, 2020 and concluded that it had no impact on its consolidated financial statements.

3. Net Loss per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, stock options and other stock-based awards are excluded, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. For diluted net loss per share purposes, derivatives to purchase shares of common stock or CDIs are treated identically because shares of common stock and CDIs are interchangeable at the sole election of the stockholder. For diluted net loss per share purposes, options and warrants conferring the right to purchase shares of common stock or CDIs are excluded from diluted net loss per share calculations as inclusion would have an anti-dilutive effect. During the three months ended March 31, 2020 and 2019, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted weighted- average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive:

	Three Months Ended March 31,
	2020		2019
Warrants to purchase common stock		4,625,425		3,552,672
Options to purchase common stock and other stock-based awards		3,376,154		1,545,719
Total		8,001,579		5,098,391

4. Warrants to Purchase Common Stock or CDIs

The following series of warrants were outstanding and exercisable at March 31, 2020 and 2019 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio):

		Number of underlying		Exercise price		March 31,
Warrant Series	Issue Date	shares		per share		2020		2019
Consultant warrant	May 4, 2016		28,532	$	0.64		28,532		28,532
2018 Warrant (1)	May 24, 2018		1,944,444	$	0.72		-		1,944,444
August 2019 Warrant (2)	January 13, 2020		4,596,893	$	1.00		4,596,893		-
Total Outstanding and Exercisable							4,625,425		1,972,976
Weighted average exercise price						$	1.00	$	0.72

(1)

Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018

(2)

Financing arranged August 2019, but funding did not occur until January 13, 2020

On May 4, 2016, the Company entered into a consulting agreement pursuant to which a consulting firm provides strategic advisory, finance, accounting, human resources and administrative functions, including chief financial officer services, to the Company. In connection with the consulting agreement, the Company granted the consulting firm a warrant (“Consultant Warrant”) to purchase up to 28,532 shares of the Company’s common stock at an exercise price per share equal to $0.64. The Consultant Warrant is fully vested and expires on May 4, 2021. As of March 31, 2019, the Consultant Warrants had not been exercised.

On August 21, 2019, GI Dynamics and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant (totaling 8,248,549 shares of common stock purchased for approximately $5.4 million) and the issue and sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI issued on exercise. On December 16, 2019, stockholders approved the issuance of the August 2019 Warrant, which was then issued on January 13, 2020.

5. Fair Value Measurements

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability.

On March 31, 2020, the classification of the Consultant Warrant was reevaluated and the Company re-classified it as an equity instrument. On March 31, 2020, this reclassification resulted in a credit to Other Income.

Cash, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses, short-term debt to related party and other current liabilities at March 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments.

6. Concentrations of Credit Risk and Related Valuation Account

Financial instruments that subject GI Dynamics to credit risk primarily consist of cash and restricted cash. Cash balances are maintained with high quality financial institutions, and consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s short-term investments potentially subject the Company to concentrations of credit risk. GI Dynamics has adopted an investment policy that limits the amounts it may invest in any one type of investment and requires all held investments to hold at least an A rating from a recognized credit rating agency, thereby reducing credit risk concentration.

7. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	March 31,		December 31,
	2020		2019
Payroll and related liabilities	$	188	$	531
Professional fees		176		335
Credit refunds		—		164
Interest payable		415		250
Other		107		73
Total	$	886	$	1,353

In 2017, following notification by the Medicines and Healthcare Products Regulatory Agency (“MHRA”), the Company notified its customers to return their inventory on hand. The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers. Through December 31, 2019, this reserve had various claims and adjustments of $115 thousand. On March 31, 2020, the Company reversed the remaining accrual for $164 thousand and recognized Other Income as the Company concluded that the likelihood that further claims will be made was remote, given the amount of time without such claims after product expiry.

In December 2018, the maturity of the 2017 Note was extended to March 31, 2019 in exchange for payment of $394 thousand, which was the total accrued interest on the 2017 Note at December 31, 2018. Accrued interest at March 31, 2020 includes interest on the 2017 Note since January 1, 2019 and the August 2019 Note since January 13, 2020.

8. Notes Payable

2017 Convertible Note Financing

On June 15, 2017, the Company entered into a Note Purchase Agreement (“2017 NPA”) by and between the Company and Crystal Amber, a Related Party. Pursuant to the 2017 NPA, the Company issued and sold to Crystal Amber, a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”).

The 2017 Note accrues interest at an annually compounded rate of 5% per annum, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on the original maturity date of December 31, 2018, and, as amended, is currently scheduled to mature on May 15, 2020.

The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, Crystal Amber, is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if Crystal Amber were the absolute owner thereof.

The ASX provided the Company with a waiver to allow all asset liens (the “Security”) to be granted to Crystal Amber, without the customary requirement of having to obtain stockholder approval for the grant of a security to a Related Party of the Company. As a result of the waiver, the Security contains a provision that provides that if an event of default occurs and Crystal Amber exercises its rights under the Security, neither Crystal Amber nor any of its associates can acquire any legal or beneficial interest in an asset of the Company or its subsidiaries in full or partial satisfaction of the Company’s obligations under the Security, or otherwise deal with the assets of the Company or its subsidiaries, without the Company first having complied with any applicable ASX Listing Rules, including ASX Listing Rule 10.1, other than as required by law or through a receiver, manager, or analogous person appointed by Crystal Amber exercising its power of sale under the Security and selling the assets to an unrelated third party on arm’s length commercial terms and conditions and distributing the cash proceeds to Crystal Amber or any of its associates in accordance with their legal entitlements.

The entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CDIs (i) prior to the maturity date, at the option of Crystal Amber at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs traded on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing.

In the event that the Company issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective Optional Conversion Price, Crystal Amber has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that Crystal Amber may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains Crystal Amber’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing.

In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the 2017 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends.

The 2017 NPA contains customary events of default including a failure to perform obligations under the 2017 NPA, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 NPA and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

For the three months ended March 31, 2020 and 2019, the Company recognized interest expense of $65 and $62 thousand, respectively, related to the 2017 Note.

August 2019 Securities Purchase Agreement

On August 21, 2019, the Company entered into the August 2019 SPA by and between the Company and Crystal Amber. The August 2019 SPA detailed a timeline wherein Crystal Amber would exercise the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant. Additionally, pursuant to the August 2019 SPA, the Company issued and sold to Crystal Amber a senior unsecured convertible promissory note in an aggregate principal amount of approximately $4.6 million, or such lesser amount as may be set forth in a notice delivered by the Company to Crystal Amber (the “August 2019 Note”), to be funded on December 6, 2019, or such earlier or later date as may be requested by the Company (the “Funding Date”). In conjunction with the August 2019 Note, the Company agreed to issue to Crystal Amber a Warrant (the “August 2019 Warrant”) to purchase CDIs, subject to the receipt of required stockholder approval approving the issuance of the August 2019 Warrant and the funding of the August 2019 Note (see Note 4).

The August 2019 Note accrues interest at a rate equal to 10% per annum from the August 2019 Note Funding Date, compounded annually, other than during the continuance of an event of default, when the August 2019 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the fifth anniversary of the Funding Date. The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI. In the event that the Company issues additional CDIs to a stockholder other than Crystal Amber in a subsequent equity financing at a price per CDI that is less than the conversion price under the August 2019 Note, the conversion price shall be reduced to the lowest such price per CDI. In addition, upon a change of control of the Company resulting in cash proceeds, Crystal Amber may, at its option, demand that the Company prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. The Company may not prepay the August 2019 Note without the consent of Crystal Amber, a Related Party. If the stockholder approvals required to issue the August 2019 Warrant or to approve the conversion rights under the August 2019 Note are not obtained, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance on the earlier of the Funding Date or the date that is six months following the date of the stockholder meeting at which the requisite approvals were not obtained. The Company considers the change in control premium and the stockholder approval premium to each represent a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premiums, the fair value was considered immaterial upon issuance and through the end of this reporting period.

The August 2019 SPA contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the August 2019 Note may be accelerated. The August 2019 SPA and related August 2019 Note and August 2019 Warrant documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

Prior to December 6, 2019, the Company notified Crystal Amber that it had elected to receive the full amount of approximately $4.6 million under the August 2019 Note, but agreed to timing extensions.

On December 16, 2019, stockholder approval was obtained pursuant to ASX Listing Rule 10.11, for the August 2019 Note conversion feature and the issuance of the August 2019 Warrant, contingent on receipt of the August 2019 Note proceeds.

On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note was immediately convertible. On January 13, 2020, the Company issued to Crystal Amber an immediately exercisable August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).

On issuance, having already obtained the required stockholder approval to reserve the CDIs underlying the conversion feature and the August 2019 Warrant, the August 2019 Warrant was determined to be a freestanding instrument meeting the requirements for equity classification in accordance with ASC 480-10 Distinguishing Liabilities from Equity, ASC 815-40 Contracts in an Entity’s Own Equity and ASC 470-20 Debt with Conversion and Other Options. Accordingly, proceeds from the August 2019 SPA were allocated to the August 2019 Note and Warrant based on their relative fair values. The relative fair value of the August 2019 Warrant of approximately $2.3 million was recorded as a debt discount with the offset to additional paid-in capital. Additionally, the Company analyzed the conversion features of the August 2019 Note to determine whether a beneficial conversion feature (BCF) existed. The Company determined a BCF with a value of $435 thousand existed and was recorded as a debt discount with the offset to additional paid-in capital. The total debt discount will be amortized to interest expense through the January 2025 maturity of the August 2019 Note.

For the three months ended March 31, 2020, the Company recorded $98 thousand of accrued interest expense. For the three months ended March 31, 2020, the Company recognized interest expense of $100 thousand from the amortization of the debt discount.

9. Commitments and Contingencies

Lease Commitments

In December 2018, the Company entered into a 6-month membership agreement with WeWork for 985 square feet of office space located in Boston, Massachusetts. The committed lease term expired in May 2019. The WeWork agreement contained no explicit or guaranteed extension provisions.

On April 22, 2019, the Company entered into a right-of-use lease for 3,520 square feet of office space in Boston, Massachusetts. The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. The lease has defined escalating rent payments and contains no extension or expansion rights. On lease execution, the Company recorded the approximately $463 thousand present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset. The right-of-use asset will be amortized to lease expense and the liability will be reduced by the rent payments over the term of the lease.

The Company’s leases generally do not provide an implicit interest rate and therefore the Company uses 10% as an estimate of its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company had no leases currently classified as finance leases or previously classified as capital leases in either reporting period.

The Company’s operating lease is reflected in the balance sheets. In the three months ended March 31, 2020, $44 thousand of lease expense was incurred and an additional $3 thousand of tax expense was accrued for property taxes associated with the leased facility. Other information related to leases was as follows (in 2019, leases were all short term and excluded from the adoption of ASU 2016-2):

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Operating cash flows from operating leases in lease liability measurement	$	53		$	—
Operating cash flows from short term leases		44			—
Remaining long-term lease term in years		2.2			—
Discount rate		10	%		—

The maturity of the Company’s operating lease liability as of March 31, 2020 is as follows:

	March 31, 2020
	(in thousands)
2020		134
2021		182
2022		76
Total future minimum lease payments		392
Less: imputed interest		40
Total liabilities	$	352

Rent expense on non-cancelable operating leases was approximately $44 and $56 thousand for the three months ended March 31, 2020 and 2019, respectively.

10. Stockholders’ Deficit

On December 19, 2019, GI Dynamics stockholders approved an increase of its authorized shares of common stock from 50 million to 75 million.

As of March 31, 2020, the authorized capital stock of the Company consists of 75.5 million shares, of which 75 million shares are designated as common stock and 500 thousand shares are designated as preferred stock.

11. Share-Based Compensation

The Company has two stock-based compensation plans. The Board of Directors adopted the 2003 Omnibus Stock Plan (the “2003 Plan”), which provides for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants to purchase up to an aggregate of 922,086 shares of the Company’s common stock.

In August 2011, the Board of Directors adopted the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”, together with the 2003 Plan, the “Plans”) as the successor to the 2003 Plan. Under the 2011 Plan, the Company may grant incentive stock options, nonqualified stock options, restricted and unrestricted stock awards and other stock-based awards. As of March 31, 2020, an additional 554,866 shares of common stock were available for grant under the Company’s 2011 Plan.

In addition, the 2011 Plan allows for an annual increase in the number of shares available for issue under the 2011 Plan commencing on the first day of each fiscal year during the period beginning in fiscal year 2012 and ending in fiscal year 2020. The annual increase in the number of shares shall be equal to the lowest of:

●

500 thousand shares;

●

4% of the number of common shares outstanding as of such date; and

●

an amount determined by the Board of Directors or the Company’s compensation committee. Accordingly, during the quarters ended March 31, 2020 and March 31, 2019, 500 thousand shares were added to the 2011 Plan.

Stock-Based Compensation

Stock-based compensation is reflected in the consolidated statements of operations as follows for the three months ended March 31, 2020 and 2019 (in thousands):

	Three Months Ended March 31,
	2020		2019
Research and development	$	13	$	16
General and administrative		199		43
	$	212	$	59

The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant.

The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three months ended March 31, 2020 and 2019:

	Three Months Ended March 31,
	2020			2019
Expected volatility		164.9	%		122.0	%
Expected term (in years)		5.84			6.05
Risk-free interest rate		0.9	%		2.3	%
Expected dividend yield		0	%		0	%

Stock Options

The following table summarizes share-based activity under the Company’s stock option plans:

	Shares of Common Stock Attributable to Options			Weighted- Average Exercise Price		Weighted- Average Contractual Life		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding at December 31, 2019		3,096,154		$	1.47		8.3	$	—
Granted		90,000		$	0.25			$	—
Cancelled		(60,000	)	$	0.74			$	—
Outstanding at March 31, 2020		3,126,154		$	1.46		8.6	$	—
Vested or expected to vest at March 31, 2020		3,126,154
Exercisable at March 31, 2020		781,360		$	1.46		6.7

The majority of the Company’s option grants vest 25% on the first anniversary of the grant date, and in a quarterly straight-line rate thereafter until fully vested on the fourth anniversary of the grant date. The weighted average grant date fair value for options granted in the three-month period ended March 31, 2020, was $0.18. The unrecognized stock compensation expense at March 31, 2020 was $2.0 million and was expected to be recognized over a weighted average period of 3.07 years from March 31, 2020.

The Company has recorded non-employee stock-based compensation expense of approximately $50 thousand and $4 thousand during the three-month period ended March 31, 2020 and 2019, respectively, which is included in total stock-based compensation expense. The unrecognized compensation expense associated with outstanding non-employee grants was $119 and $21 thousand at March 31, 2020 and 2019, respectively.

On February 28, 2020, the Company’s Board of Directors approved, subject to stockholder approval per ASX Listing Rule 10.14, the grant of stock options (“NED Options”) conferring the right to purchase up to 30,000 shares of the Company’s common stock to Praveen Tyle, a non-executive director pursuant to the Company’s 2011 Plan. The exercise price is $0.20 per share of common stock and the NED Options will vest in full on February 28, 2021 if Dr. Tyle remains a director of the Company through that date. The NED Options will vest immediately on a change in control event. The NED Options are immediately exercisable, subject to repurchase rights if purchased prior to vesting. The NED Options will be cancelled immediately upon termination of service as a director, unless such termination is the result of a defined change in control event, in which case the NED Options will be cancelled 12 months after such termination. As of March 31, 2020, stockholders had not yet approved the NED Options.

On February 15, 2020, the Company granted a consultant an option to purchase up to 10 thousand shares of common stock at a price of $0.40 per share. The option vests in equal monthly amounts over a 24-month period and expires in 10 years.

At March 31, 2020, the Company had unvested outstanding options to purchase 167,673 shares of common stock granted to non-employees.

Performance Stock Units

Each performance stock unit (“PSU”) represents a contingent right to receive one share of the Company’s common stock. There is no consideration payable on the vesting of PSUs issued under the Plans. Upon vesting, the PSUs are exercised automatically and settled in shares of the Company’s common stock. During the three months ended March 31, 2020, the Company awarded no PSUs to employees and directors of the Company.

The following table summarizes information related to PSU activity for the three months ended March 31, 2020:

	Number of Units		Weighted- Average Contractual Life		Aggregate Intrinsic Value
			(in years)		(in thousands)
Outstanding at December 31, 2019		250,000		6.23	$	149
Granted		—
Exercised		—
Cancelled		—		—		—
Outstanding at March 31, 2020		250,000		5.98	$	23

The aggregate intrinsic value at March 31, 2020 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of PSUs outstanding. The fair value of each PSU award equals the closing price of the Company’s common stock on the date of grant.

At March 31, 2020, 250,000 of the PSUs outstanding vest on the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company will expense the compensation of the respective stock award over the implicit service period.

At March 31, 2020, the Company recognized no stock-based compensation related to performance-based vesting of PSUs.

As of March 31, 2020, there was approximately $200 thousand of unrecognized stock-based compensation expense related to non-vested PSU awards that have performance-based vesting.

12. Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity.

Geographic Reporting

The Company has historically reported various geographic segments but does not do so currently as the right-of-use asset of approximately $463 thousand and all long-lived assets, comprised of property and equipment of approximately $34 thousand are all held in the U.S. at March 31, 2020. Additionally, the Company did not have revenue in any geography for the three months ended March 31, 2020 and 2019, respectively.

Major Customers

The Company did not recognize any revenue for the three months ended March 31, 2020 and 2019, respectively.

13. Subsequent Events

On March 27, 2020, the CARES Act was signed into law in the United States providing economic assistance for American workers and families, small businesses, and preserves jobs for American industries. GI Dynamics qualifies for the Payroll Protection Program (“PPP”) administered by the United States Small Business Administration (“SBA”) and existing lending institutions. On April 4, 2020, GI Dynamics submitted an application to a lending institution for a loan of approximately $200 thousand under the PPP. In accordance with the provisions of the PPP, the loan accrues interest at a rate of 1% and all or a portion of the loan may be forgiven if it is used to pay for qualifying costs such as payroll, rent and utilities. Amounts that are not forgiven will be repaid 2 years from the date of the loan. Due to backlog, the application was not received by the SBA before funding for the CARES Act was exhausted. Additional CARES Act funds were allocated on April 23, 2020 and GI Dynamics was notified by our lending institution that the application was approved by the SBA on April 30, 2020.

The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Information

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements that involve significant risks, uncertainties and assumptions. As a result of many factors, such as those set forth under “Risk Factors” Item 1A. of the Company’s Annual Report on Form 10-K, which are incorporated herein by reference, actual results may differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis.

Overview

GI Dynamics is a clinical stage medical device company located in Boston, Massachusetts. The Company has developed EndoBarrier, a medical device intended to treat patients with type 2 diabetes and to reduce obesity. GI Dynamics is taking the steps necessary to obtain the regulatory approvals required to market this product. In order to market EndoBarrier in the U.S., GI Dynamics must obtain approval from the FDA. In order to market EndoBarrier outside of the U.S., GI Dynamics is required to comply with various regulations imposed by the countries in which it seeks to sell the product.

In 2010, EndoBarrier received CE Marking for sale in the European Union and in 2011, EndoBarrier was listed on the Australian Register of Therapeutic Goods. As a result, during 2013 and 2014, the Company received approximately $2.8 million and $2.3 million, respectively, in revenue from the sale of EndoBarrier in Europe, South America and the Asia Pacific region. In the U.S. in 2013, the Company began enrollment of patients in the initial pivotal trial of EndoBarrier, which is referred to as the ENDO trial.

In the third quarter of 2015, the Company announced its decision to discontinue the ENDO trial because patients were experiencing a higher than previously observed level of hepatic (liver) abscesses. In the fourth quarter of 2016, GI Dynamics received formal notification from the TGA of the Australian government of the cancellation of EndoBarrier’s inclusion on the ARTG. In the fourth quarter of 2017 the Company received formal notification of CE mark withdrawal from its notified body in Europe, preventing the sale of EndoBarrier in Europe and select Middle Eastern countries. The Company undertook comprehensive cost-cutting measures throughout 2015 and 2016, including significantly reducing the number of its employees.

Following the decision to discontinue the ENDO trial, GI Dynamics undertook significant investigational and scientific analyses with the goal of reducing the incidence rate and severity of hepatic abscess concurrent with the EndoBarrier treatment. This investigational work focused on understanding the root cause of hepatic abscess and how to reduce the rate of occurrence. This included: DNA analysis of normal EndoBarrier removals as well as hepatic abscess EndoBarrier removals, numerous meta-analyses and responder cohort analyses, investigation into the contributing factors represented by proton pump inhibitors (PPIs), leaky gut syndrome and microbiome analyses, among other research. This allowed the Company to modify the medications utilized with EndoBarrier, most notably discontinuation of chronic double-dose PPI usage during EndoBarrier implant.

As a result of the efforts described above, in August 2018, GI Dynamics received an IDE from the FDA to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending IRB approval, which was received on February 13, 2019. In this report, the Company refers to this pivotal trial as the GI Dynamics STEP-1 clinical trial. On January 27, 2020, the first patient was randomized into the STEP-1 Trial Protocol.

For financial reporting purposes, the Company have one reportable segment, which designs, manufactures and plans to market EndoBarrier.

To date, GI Dynamics has devoted substantially all of its efforts to research and development, business planning, clinical research, clinical study management, reimbursement development, product commercialization, acquiring operating assets and raising capital. GI Dynamics has incurred significant operating losses since its inception in 2003. As of March 31, 2020, the Company had an accumulated deficit of approximately $287 million. The Company expects to incur net losses for the next several years while it continues to evaluate which markets are appropriate to continue pursuing reimbursement, market awareness and general market development efforts, and continues to restructure its business and costs, establish new priorities, continue limited research, and evaluate strategic options.

GI Dynamics has raised net proceeds of approximately $278 million through sales of the Company’s equity and placement of debt, of which $9.3 million was raised through the Company’s 2019 financings.

On August 21, 2019, the Company and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”). The initial $5.4 million was comprised of existing warrant exercises scheduled between August 25, 2019 and November 15, 2019. The remaining amount of the August 2019 funding was represented by a Convertible Term Promissory Note (“August 2019 Note”) of up to approximately $4.6 million and a related Warrant (“August 2019 Warrant”). Under the terms of the August 2019 SPA and August 2019 Note, the Company, at its sole discretion, could elect to request any of the $4.6 million to be funded at any date on or before December 6, 2019. The conversion feature allows the conversion of the August 2019 Note’s unpaid principal and interest at $0.02 per CDI and the August 2019 Warrant, upon its issue, allowed the purchase for $0.02 per CDI a number of CDIs represented by the August 2019 Note principal divided by $0.02 per CDI.

On August 21, 2019, the maturity date of the 2017 Note was extended to March 31, 2020.

On March 31, 2020, the maturity date of the 2017 Note was extended to May 1, 2020.

On December 2, 2019, GI Dynamics provided notice to Crystal Amber that the Company elected to place the August 2019 Note at the full amount, on or before December 6, 2019. In December, the Company and Crystal Amber agreed to confer the right to tranche the funding of the August 2019 Note in amounts and per timing chosen solely by Crystal Amber, provided the August 2019 Note total was funded on or before January 15, 2020.

On December 16, 2019, GI Dynamics’ stockholders approved the August 2019 Note conversion feature and the issuance of the August 2019 Warrant, pending funding of the August 2019 Note by Crystal Amber.

On January 13, 2020, GI Dynamics received approximately $4.6 million in cash representing the full funding of the August 2019 Note. As stockholder approval had been obtained in December 2019, the August 2019 Note became convertible at Crystal Amber’s sole discretion until maturity in January 2025. Additionally, the August 2019 Warrant was issued to Crystal Amber, providing for the purchase of up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) at $0.02 per CDI.

The Company’s costs include employee salaries and benefits, compensation paid to consultants, materials and supplies for research, costs associated with development activities including materials, sub-contractors, travel and administration, legal expenses, sales and marketing costs, general and administrative expenses, and other costs associated with an early stage, publicly-traded medical technology company. As of March 31, 2020, GI Dynamics has 15 full-time employees. The number of employees required to support the Company’s activities as it moves the EndoBarrier through the GI Dynamics STEP-1 clinical trial, as well as in the areas of research and development, sales and marketing, and general and administrative functions, may increase. GI Dynamics expects to continue to incur consulting expenses related to technology development that will increase as it enters into the recruitment phase of the STEP-1 and India clinical trials, and the Company expects to continue to incur expenses to protect its intellectual property.

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. As a result, economic uncertainties have arisen which, as of March 31, 2020, have negatively impacted GI Dynamics short term-operations, for example in delays in timing of regulatory audits and other key operational activities due to widespread sequestration and in facing enrollment pauses in our clinical trials due to the clinic-level restriction of elective procedures, for which EndoBarrier implantation qualifies. When operational activities are delayed, expenditures on certain items may decrease, such as travel. There is no certainty which reduced expenditures will result in higher than usual expenditures as activities resume and which will return to the expected rate. If the restrictions are limited in duration, the Company anticipates an ability to overcome delays and return to original timing estimates, but there can be no guarantee the duration and operational impact will be limited to the degree required. Additionally, market-level impacts may affect the timing or the negotiation of terms in the Company’s financing efforts. These and other financial impacts that could occur may appear as positive or negative impacts to the Company’s future financial statements.

The amount that GI Dynamics spends for any specific purpose may vary significantly from quarter to quarter or year to year, and could depend on a number of factors including, but not limited to, the pace of progress of the GI Dynamics STEP-1 and India clinical trials, commercialization and development efforts and actual needs with respect to development and research.

Research, development, and commercial acceptance of new medical technologies are, by their nature, unpredictable. Although the Company will undertake development and commercialization efforts with reasonable diligence, there can be no assurance that the net proceeds from the Company’s securities offerings will be sufficient to enable the Company to develop the Company’s technology to the extent needed to create future sales to sustain operations. If the net proceeds from these offerings are insufficient for this purpose, GI Dynamics will consider other options to continue its path to commercialization, including, but not limited to, additional financing through follow-on equity offerings, debt financing, co-development agreements, sale or licensing of developed intellectual or other property, or other alternatives.

GI Dynamics cannot assure that its technology will be accepted, that it will ever earn revenues sufficient to support its operations, or that it will ever be profitable. Furthermore, the Company has no committed source of financing and cannot assure that it will be able to raise money as and when it needs it to continue operations. If the Company cannot raise funds as and when it needs them, it may be required to scale back development plans by reducing expenditures for employees, consultants, business development and marketing efforts or to otherwise severely curtail, or even to cease, business operations.

The Company’s corporate headquarters are located in Boston, Massachusetts. The Company leases 3,520 square feet of office space with a lease expiration in May 2022. This space is adequate for current operations.

Critical Accounting Policies and Estimates

The Company’s discussion and analysis of its financial condition and results of operations is based upon the Company’s consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. GI Dynamics believes that its application of the following accounting policies, each of which require significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating the Company’s reported financial results. The Company’s significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies and Basis of Presentation”, to the Company’s consolidated financial statements appearing elsewhere in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to these policies since December 31, 2019.

Results of Operations

The following is a description of significant components of Company operations, including significant trends and uncertainties that are believed to be important to an understanding of the Company’s business and results of operations.

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Operating expenses:
Research and development	$	1,173		$	810
Sales and marketing		—			16
General and administrative		1,543			1,344
Total operating expenses		2,716			2,170
Loss from operations		(2,716	)		(2,170	)
Other income (expense):
Interest income		—			3
Interest expense		(284	)		(177	)
Foreign exchange gain (loss)		(10	)		(9	)
Gain on write-off of accounts payable		—			29
Gain on write-off of accrued product return liability		164			—
Re-measurement of derivative liabilities		—			(1	)
Other income		10			—
Other expense, net		(120	)		(155	)
Loss before income tax expense		(2,836	)		(2,325	)
Provision for income taxes		5			6
Net loss	$	(2,841	)	$	(2,331	)

Basic and diluted net loss per common share		(0.08	)	$	(0.12	)
Weighted-average number of common shares used in basic and diluted net loss per common share		36,598,291			19,277,545

Three months ended March 31, 2020 compared to three months ended March 31, 2019

Revenue. The Company did not record any revenues or associated cost of revenue during the three months ended March 31, 2020 and 2019, respectively.

Operating expenses

	Three Months Ended
	March 31,				Change
	2020		2019		$			%
	( in thousands)
Research and development	$	1,173	$	810	$	363			44.8	%
Sales and marketing		—		16		(16	)		(100.0	)%
General and administrative		1,543		1,344		199			14.8	%
Total operating expenses	$	2,716	$	2,170	$	546			25.2	%

Research and Development Expense. The increase in research and development expense for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily due to an increase in spending on internal and external resources as the Company initiated the STEP-1 trial in the United States, submitted the protocol for the I-Step trial (under joint venture with Apollo Sugar) in India to the regulatory agency and preparing to file for CE Mark designation under the Medical Device Directive standard revision.

Sales and Marketing Expense. The decrease in sales and marketing expense for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily due to a reclassification of existing overseas employee efforts from sales and marketing support to research and development.

General and Administrative Expense. The increase in general and administrative expense for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily due to increased headcount and employee-related expenses as well as corporate insurance expenses due to a higher directors’ and officers’ premium.

The Company continues to look for ways to realize a more efficient cost structure in order to extend the Company’s cash runway. Cost reductions may not be achievable in all instances as the Company executes clinical development in support of commercial regulatory approvals. Additionally, on March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. As a result, economic uncertainties have arisen which, as of March 31, 2020, have negatively impacted GI Dynamics short term-operations, for example in delays in timing of regulatory audits and other key operational activities due to widespread sequestration and in facing enrollment pauses in our clinical trials due to the clinic-level restriction of elective procedures, for which EndoBarrier implantation qualifies. When operational activities are delayed, expenditures on certain items may decrease, such as travel. There is no certainty which reduced expenditures will result in higher than usual expenditures as activities resume and which will return to the expected rate. If the restrictions are limited in duration, the Company anticipates an ability to overcome delays and return to original timing estimates, but there can be no guarantee the duration and operational impact will be limited to the degree required. Additionally, market-level impacts may affect the timing or the negotiation of terms in the Company’s financing efforts. These and other financial impacts that could occur may appear as positive or negative impacts to the Company’s future financial statements.

Other income (expense)

	Three Months Ended
	March 31,						Change
	2020			2019			$			%
	( in thousands)
Other income (expense):
Interest income	$	—		$	3		$	(3	)		(100.0	)%
Interest expense		(284	)		(177	)		(107	)		60.5	%
Foreign exchange gain (loss)		(10	)		(9	)		(1	)		11.1	%
Gain on write-off of accounts payable		—			29			(29	)		100.0	%
Gain on write-off of accrued product return liability		164			—			164			(—)	%
Re-measurement of derivative liabilities		—			(1	)		1			(100.0	)%
Other income		10			—			10			(—)	%
Total other expense, net	$	(120	)	$	(155	)	$	35			(22.6	)%

Other income (expense). The change to other expense, net, for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 is primarily due to the changes in gain on write off of accounts payable, increases in non-cash interest, reclass of derivative liabilities to equity and the elimination of the right of product return reserves of $164 thousand, which is included in other income.

Liquidity and Capital Resources

The Company will need to restructure the terms of the Senior Secured Convertible Promissory Note, issued on June 15, 2017 (as amended from time to time, the “2017 Note”), before May 15, 2020 or the 2017 Note will be in default and subject to a call notice at the discretion of Crystal Amber. If the 2017 Note terms are restructured or the note is not called, the Company must raise additional capital before May 31, 2020 in order to continue to pursue its current business objectives as planned and to continue to fund its operations. The Company and Crystal Amber Fund Limited (“Crystal Amber”, a Related Party for ASX purposes) are currently in discussions regarding the 2017 Note maturity extension. The Company is looking to raise additional funds through any combination of additional equity and debt financings or from other sources. However, the Company has no guarantee that the 2017 Note will be restructured or if in default, will not be called. If the 2017 Note is called, the company has no guaranteed source of capital that will accommodate repayment of the 2017 Note. If the 2017 Note terms are restructured or the 2017 Note is in default, but not called, the Company anticipates that operating cash will be exhausted by May 31, 2020 and therefore additional financing will be required to be able to continue its operations after this date. There can be no assurance that any potential financing opportunities will be available on acceptable terms, if at all. If the Company is unable to raise sufficient capital on the Company’s required timelines and on acceptable terms to stockholders and the Board of Directors, it could be forced to reduce or cease operations, including activities essential to support regulatory applications to commercialize EndoBarrier. If access to capital is not achieved before May 31, 2020, it will materially harm the Company’s business, financial condition and results of operations to the extent that the Company may be required to cease operations altogether, file for bankruptcy, or undertake any combination of the foregoing.

These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

During the three months ended March 31, 2020 the Company’s cash and restricted cash balance increased by approximately $1.4 million primarily due to receipt of the relevant funding amount under the convertible note issued to Crystal Amber and funded on January 13, 2020 less cash payments related to, among other things, research and development and general and administrative expenses as GI Dynamics continued to focus on clinical and regulatory strategies that exceeded its various financings.

The following table sets forth the major sources and uses of cash for each of the periods set forth below:

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(3,242	)	$	(3,465	)
Investing activities		—			(5	)
Financing activities		4,597			950
Net increase (decrease) in cash and restricted cash	$	1,355		$	(2,520	)

Cash Flows Used in Operating Activities

The primary uses of cash for operating activities for the three months ended March 31, 2020 were:

●

to fund the Company’s net loss of approximately $2.8 million;

●

a net negative adjustment to cash flow from changes in working capital of approximately $893 thousand resulting primarily from an increase in prepaid expenses offset by decreases in accounts payable and accrued expenses and;

●

a net positive adjustment to cash flow from non-cash items of approximately $492 thousand, primarily from non-cash interest expense, a reclassification of warrant from derivative liabilities to other income and stock-based compensation.

The primary uses of cash for operating activities for the three months ended March 31, 2019 were:

●

to fund the Company’s net loss of approximately $2.4 million and;

●

a net negative adjustment to cash flow from changes in working capital of approximately $1.2 million resulting primarily from decreases in accounts payable and accrued expenses.

Cash Flows Used in Investing Activities

No cash was used in investing activities for three months ended March 31, 2020. Cash used in investing activities for the three months ended March 31, 2019 was approximately $5 thousand related to capital expenditures.

Cash Flows Provided by Financing Activities

Cash provided by financing activities for the three months ended March 31, 2020 totaled approximately $4.6 million and resulted from proceeds received from the August 2019 Note.

Cash provided by financing activities for the three months ended March 31, 2019 totaled approximately $950 thousand and primarily resulted from proceeds received in March 2019 from the March 2019 Note payable to a related party.

Funding Requirements

GI Dynamics has incurred operating losses since inception and at March 31, 2020, had an accumulated deficit of approximately $287 million and working capital of $915 thousand. The Company expects to incur significant operating losses for the next several years. At March 31, 2020, the Company had approximately $3.9 million in cash and restricted cash.

Due to the numerous risks and uncertainties associated with securing regulatory approval for EndoBarrier^®, at this time the Company is unable to estimate precisely the amounts of capital outlays and operating expenditures necessary to complete the task of obtaining regulatory approval for EndoBarrier^®. Funding requirements will depend on many factors, including, but not limited to, the following:

●

the timing and conditions related to COVID-19 restrictions on clinical development and corporate activities;

●

the timing, cost, and resulting success of research and development efforts;

●

the rate of progress and cost of commercialization activities after regulatory approval;

●

the expenses the Company may incur in marketing and selling EndoBarrier subject to future regulatory approvals;

●

the timing and decisions of payer organizations related to reimbursement;

●

the revenue generated by sales of EndoBarrier;

●

the safety and efficacy of the Company’s product in treating diabetes and reducing obesity;

●

the success of the Company’s investment in its manufacturing and supply chain infrastructure;

●

the time and costs involved in obtaining regulatory approvals for EndoBarrier in new markets;

●

the costs associated with any additional clinical trial(s) required in the U.S. and other countries on a case by case basis;

●

the ability to ship CE marked products;

●

the emergence of competing or complementary developments; and

●

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

GI Dynamics will continue to manage its capital structure and to consider all financing opportunities, whenever they may occur, that could strengthen its long-term liquidity profile. Any such capital transactions may or may not be similar to transactions in which the Company has engaged in the past and the ownership interests of existing stockholders may be materially diluted.

Off–Balance Sheet Arrangements

The Company does not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements (as that term is defined in Item 303(a)(4)(ii) of Regulation S-K) or other contractually narrow or limited purposes. As such, the Company is not exposed to any financing, liquidity, market or credit risk that could arise if the Company had engaged in those types of relationships. Guarantees are provided in the ordinary course of business related to the guarantee of the performance of the Company and its subsidiaries.

Contractual Obligations and Commitments

The disclosure of contractual obligations and commitments is set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Contractual Obligations and Commitments” in the Company Annual Report on Form 10-K for the year ended December 31, 2019.

There have been no material changes from the contractual commitments and obligations previously disclosed in the Company’s Annual Report on Form 10-K.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements please refer to Note 2, “Summary of Significant Accounting Policies and Basis of Presentation,” to the consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company conducts business in foreign countries and cash flows are thereby exposed to market risk from changes in currency exchange and interest rates.

Interest Rate Sensitivity

The Company’s cash of approximately $3.9 million at March 31, 2020, which will be used for working capital purposes. The Company does not enter into investments for trading or speculative purposes. The goals of the Company’s investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. The Company also seeks to maximize income from investments without assuming significant risk. The Company’s primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the U.S. and Australia. Because of the short-term nature of the Company’s cash and restricted cash, GI Dynamics does not believe that it has any material exposure to changes in their fair values as a result of changes in interest rates.

Foreign Currency Risk

GI Dynamics conducts business in foreign countries. For U.S. reporting purposes, all assets and liabilities of non-U.S. entities are remeasured at the period-end exchange rate and income and expenses at the average exchange rates in effect during the periods. The net effect of these remeasurement adjustments is shown in the accompanying consolidated financial statements as a component of net loss. Continued fluctuation of these exchange rates could result in financial results that are not comparable from quarter to quarter. The Company does not currently utilize foreign currency contracts to mitigate the gains and losses generated by the remeasurement of non-functional currency assets and liabilities and do not currently hold material cash reserves in currencies in which certain expenditures are denominated.

Effects of Inflation

The Company does not believe that inflation and prices fluctuations over the three months ended March 31, 2020 and 2019 had a significant impact on the results of operations.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In accordance with Exchange Act Rules 13a-15 and 15d-15(f), GI Dynamics carried out an evaluation, under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), of the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2020 in enabling GI Dynamics to record, process, summarize and report information required to be included in its periodic SEC filings within the required time period.

Changes in Internal Control Over Financial Reporting

As required by Rule 13a-15(d) of the Exchange Act, the Certifying Officers conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the first fiscal quarter of 2020 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. The evaluation performed by the Certifying Officers resulted in a conclusion that no such changes occurred.

Inherent Limitations on Controls and Procedures

Company management, including the principal executive officer and principal financial and accounting officer, does not expect that the Company’s disclosure controls and procedures or internal control over financial reporting will prevent all error and all fraud. Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. It is a process that involves human diligence and compliance and is subject to lapses in judgment or breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. While process safeguards can reduce risks, because of inherent limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

GI Dynamics is currently not involved in any litigation that it believes could have a materially adverse effect on its financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, its common stock, any of its subsidiaries or of the Company’s or its subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. From time to time, the Company may become involved legal proceedings, lawsuits, claims and regulations in the ordinary course of its business.

Item 1A. Risk Factors.

In addition to the other information contained elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 27, 2020, which could materially affect the Company business, financial condition or future results. The risks described in the Company’s Annual Report on Form 10-K are not the only risks faced by the Company. Additional risks that we do not presently know or that we currently believe are immaterial could also materially and adversely affect any of the Company business, financial condition or future results. The trading price of the Company’s CDIs may decline due to these risks.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Other than as previously disclosed on the Company’s Current Reports on Form 8-K filed with the SEC, the Company did not issue any unregistered equity securities during the three months ended March 31, 2020.

Item 6. Exhibits.

Exhibit No:		Description

10.1†		Board Member Agreement by and between GI Dynamics, Inc. and Praveen Tyle, incorporated by reference to Exhibit 10.2 of GI Dynamics, Inc.’s Current Report on Form 8-K filed with the SEC on March 3, 2020.

10.2†		Form of Indemnification Agreement, incorporated by reference to Exhibit 10.4 of GI Dynamics, Inc.’s Quarterly Report on Form 10-Q, filed with the SEC on November 10, 2014.

10.3*		Sixth Amendment to Note Purchase Agreement, dated June 15, 2017, between GI Dynamics, Inc. and Crystal Amber Fund Limited, as purchaser, dated March 31, 2020.

10.4*		Sixth Amendment to Senior Secured Convertible Promissory Note, dated June 15, 2017, by and between GI Dynamics, Inc. and Crystal Amber Fund Limited, dated March 31, 2020.

31.1*		Certification of principal executive officer pursuant to Rules 13a-14 or 15d-14 of the Exchange Act.

31.2*		Certification of principal financial officer pursuant to Rules 13a-14 or 15d-14 of the Exchange Act.

32.1‡		Certification of principal executive officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.

32.2‡		Certification of principal financial officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Database

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

*	Filed herewith.

‡	Furnished herewith.

†	Management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GI Dynamics, Inc.

Date: May 6, 2020	By:	/s/ SCOTT W. SCHORER
		Scott W. Schorer
		President and Chief Executive Officer
		(principal executive officer)

Date: May 6, 2020	By:	/s/ CHARLES R. CARTER
		Charles R. Carter Chief Financial Officer, Secretary
		(principal financial and accounting officer)

EX-10.3 2 f10q0320ex10-3_gidynamics.htm SIXTH AMENDMENT TO NOTE PURCHASE AGREEMENT, DATED JUNE 15, 2017, BETWEEN GI DYNAMICS, INC. AND CRYSTAL AMBER FUND LIMITED, AS PURCHASER, DATED MARCH 31, 2020.

Exhibit 10.3

GI DYNAMICS, INC.

SIXTH AMENDMENT TO NOTE PURCHASE AGREEMENT

THIS SIXTH AMENDMENT (the “Amendment”), dated effective as of March 31, 2020, is made to that certain NOTE PURCHASE AGREEMENT, dated June 15, 2017, by and between GI DYNAMICS, INC., a Delaware corporation (the “Company”), and CRYSTAL AMBER FUND LIMITED (the “Purchaser”), as amended on December 31, 2018, March 29, 2019, April 30, 2019, June 30, 2019 and August 21, 2019 (as so amended, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meaning given to them in the Agreement.

WHEREAS, pursuant to Section 7.6 of the Agreement, any term of the Agreement may be amended, waived or modified only with the written consent of the Company and the Purchaser; and

WHEREAS, the Company and the Purchaser desire to amend certain provisions of the Agreement to provide for an amended form of senior secured convertible promissory note, which the Company issued to the Purchaser pursuant to the Agreement and subsequently amended (as amended, the “Existing Note”), such further amendment to the Existing Note in substantially the form attached hereto as Exhibit A.

NOW, THEREFORE, the undersigned Purchaser and the Company, in consideration of the mutual premises and covenants made herein and of the mutual benefits to be derived herefrom, hereby amend the Agreement as follows:

Amendments to the Agreement.

The Existing Note shall be amended in substantially the form set forth in Exhibit A.

The Company and the Purchaser hereby acknowledge and confirm by execution of this Amendment and as of the date hereof that (i) no event constituting an Event of Default under Section 5 of the Agreement has occurred and (ii) the Purchaser shall not be entitled to any remedy under such Section 5 with respect to any event that has occurred as of the date hereof.

Except as expressly modified by this Amendment, the Agreement shall remain unmodified and in full forcea nd effect.

This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, buta ll of which together shall constitute the same instrument. Facsimile or PDF transmission of execution copies or signature pages for this Amendment shall be legal, valid and binding execution and delivery for all purposes.

This Amendment shall be governed by, and construed and enforced in accordance with, the substantive laws of the State of New York, without regard to its principles of conflicts of laws.

(Signatures Pages Immediately Follow)

IN WITNESS WHEREOF, the undersigned party has executed this Amendment as of the date first above written.

COMPANY:

GI DYNAMICS, INC.

By:	/s/ Scott Schorer
Name:	Scott Schorer
Title:	Chief Executive Officer

IN WITNESS WHEREOF, the undersigned party has executed this amendment as of the date first written above.

PURCHASER:

CRYSTAL AMBER FUND LIMITED

By: Crystal Amber Asset Management (Guernsey) Limited, as Investment Manager

By:	/s/ Laurence McNairn
Name:	Laurence McNairn
Title:	Director

EXHIBIT A

SIXTH AMENDMENT TO

SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

SIXTH AMENDMENT TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

This Sixth Amendment to Senior Secured Promissory Note by and among GI DYNAMICS, INC., a Delaware corporation (the “Payor”), and CRYSTAL AMBER FUND LIMITED (the “Holder”) is effective as of March [ ], 2020. Capitalized terms used but not defined herein have the definitions ascribed thereto in that certain Senior Secured Convertible Promissory Note issued on June 15, 2017 by the Payor to the Holder, as amended on December 31, 2018, March 29, 2019, April 30, 2019, June 30, 2019 and August 21, 2019 (as so amended, the “Existing Note”).

WHEREAS, the Payor and the Holder desire to further amend the terms of the Existing Note as set forth herein; and

WHEREAS, Section 10(f) of the Existing Note provides that any term of the Existing Note may be amended or waived only with the written consent of the Payor and the Holder.

NOW, THEREFORE, in consideration of the foregoing premises and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Payor and the Holder, intending to be legally bound, agree as follows:

1. Maturity Date Extension. Sections l(b), 2(a), 2(b) and 2(c) of the Existing Note are hereby amended with immediate effect to change the dates referred to in each such section (including, for the avoidance of doubt, the Maturity Date) from “March 31, 2020” to May 1, 2020”.

2.No Other Changes. Except as specifically amended in this amendment, all other terms of the Existing Note shall remain unchanged and in full force and effect.

3. Counterparts. This amendment may be executed in any number of counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. Facsimile or PDF transmission of execution copies or signature pages for this amendment shall be legal, valid and binding execution and delivery for all purposes.

4. Governing Law. This amendment shall be governed by, and construed and enforced in accordance with, the substantive laws of the State of New York, without regard to its principles of conflicts of laws.

[Signature Pages Immediately Follow]

IN WITNESS WHEREOF, the undersigned party has executed this amendment as of the date first written above.

PAYOR:

GI DYNAMICS, INC.

By:	EXHIBIT ONLY-DO NOT SIGN
Name:	Scott Schorer
Title:	Chief Executive Officer

IN WITNESS WHEREOF, the undersigned party has executed this amendment as of the date first written above.

HOLDER:

CRYSTAL AMBER FUND LIMITED

By: Crystal Amber Asset Management (Guernsey) Limited, as Investment Manager

By:	EXHIBIT ONLY-DO NOT SIGN
Name:	Laurence McNairn
Title:	Director

EX-10.4 3 f10q0320ex10-4_gidynamics.htm SIXTH AMENDMENT TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE, DATED JUNE 15, 2017, BY AND BETWEEN GI DYNAMICS, INC. AND CRYSTAL AMBER FUND LIMITED, DATED MARCH 31, 2020.

Exhibit 10.4

SIXTH AMENDMENT TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

This Sixth Amendment to Senior Secured Promissory Note by and among GI DYNAMICS, INC., a Delaware corporation (the “Payor”), and CRYSTAL AMBER FUND LIMITED (the “Holder”) is effective as of March 31, 2020. Capitalized terms used but not defined herein have the definitions ascribed thereto in that certain Senior Secured Convertible Promissory Note issued on June 15, 2017 by the Payor to the Holder, as amended on December 31, 2018, March 29, 2019, April 30, 2019, June 30, 2019 and August 21, 2019 (as so amended, the “Existing Note”).

WHEREAS, the Payor and the Holder desire to further amend the terms of the Existing Note as set forth herein; and

WHEREAS, Section 10(f) of the Existing Note provides that any term of the Existing Note may be amended or waived only with the written consent of the Payor and the Holder.

2. No Other Changes. Except as specifically amended in this amendment, all other terms of the Existing Note shall remain unchanged and in full force and effect.

[Signature Pages Immediately Follow]

IN WITNESS WHEREOF, the undersigned party has executed this amendment as of the date first written above.

PAYOR:

GI DYNAMICS, INC.

By:	/s/ Scott Schorer
Name:	Scott Schorer
Title:	Chief Executive Officer

IN WITNESS WHEREOF, the undersigned party has executed this amendment as of the date first written above.

HOLDER:

CRYSTAL AMBER FUND LIMITED

By: Crystal Amber Asset Management (Guernsey) Limited, as Investment Manager

By:	/s/ Laurence McNairn
Name:	Laurence McNairn
Title:	Director

(Signature Page to Sixth Amendment to Senior Secured Convertible Promissory Note)

EX-31.1 4 f10q0320ex31-1_gidynamics.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION PURSUANT

TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Scott W. Schorer, certify that:

I have reviewed this Quarterly Report on Form 10-Q of GI Dynamics, Inc. (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2020


/s/ SCOTT W. SCHORER
Scott W. Schorer
Chief Executive Officer (principal executive officer)

EX-31.2 5 f10q0320ex31-2_gidynamics.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION PURSUANT

TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Charles R. Carter, certify that:

I have reviewed this Quarterly Report on Form 10-Q of GI Dynamics, Inc. (the “registrant”);

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2020

/s/ CHARLES R. CARTER
Charles R. Carter
Chief Financial Officer, Secretary
(principal accounting and financial officer)

EX-32.1 6 f10q0320ex32-1_gidynamics.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GI Dynamics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott W. Schorer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ SCOTT W. SCHORER
Scott W. Schorer
Chief Executive Officer
(principal executive officer)
May 6, 2020

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 7 f10q0320ex32-2_gidynamics.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GI Dynamics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles R. Carter, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ CHARLES R. CARTER
Charles R. Carter
Chief Financial Officer, Secretary
(principal accounting and financial officer)
May 6, 2020

EX-101.INS 8 gidyl-20200331.xml XBRL INSTANCE FILE 0001245791 2020-01-01 2020-03-31 0001245791 2020-05-01 0001245791 2020-03-31 0001245791 2019-12-31 0001245791 2019-01-01 2019-03-31 0001245791 us-gaap:CommonStockMember 2019-12-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001245791 us-gaap:RetainedEarningsMember 2019-12-31 0001245791 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001245791 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001245791 us-gaap:CommonStockMember 2020-03-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001245791 us-gaap:RetainedEarningsMember 2020-03-31 0001245791 us-gaap:CommonStockMember 2018-12-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001245791 us-gaap:RetainedEarningsMember 2018-12-31 0001245791 2018-12-31 0001245791 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001245791 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001245791 us-gaap:CommonStockMember 2019-03-31 0001245791 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001245791 us-gaap:RetainedEarningsMember 2019-03-31 0001245791 2019-03-31 0001245791 gidyl:Type2DiabetesMember 2020-01-01 2020-03-31 0001245791 gidyl:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-03-31 0001245791 gidyl:WarrantsToPurchaseCommonStockMember 2019-01-01 2019-03-31 0001245791 gidyl:OptionsToPurchaseCommonStockAndOtherStockbasedAwardsMember 2020-01-01 2020-03-31 0001245791 gidyl:OptionsToPurchaseCommonStockAndOtherStockbasedAwardsMember 2019-01-01 2019-03-31 0001245791 2019-03-02 2019-03-15 0001245791 2018-05-24 0001245791 2018-11-30 0001245791 2016-04-27 2016-05-04 0001245791 2016-05-04 0001245791 2019-08-02 2019-08-21 0001245791 gidyl:ConsultantWarrantMember 2020-01-01 2020-03-31 0001245791 gidyl:ConsultantWarrantMember 2020-03-31 0001245791 gidyl:ConsultantWarrantMember 2019-01-01 2019-03-31 0001245791 gidyl:TwoThousandEighteenWarrantsMember 2020-01-01 2020-03-31 0001245791 gidyl:TwoThousandEighteenWarrantsMember 2020-03-31 0001245791 gidyl:TwoThousandEighteenWarrantsMember 2019-01-01 2019-03-31 0001245791 gidyl:ThousandNighteenWarrantsMember 2020-01-01 2020-03-31 0001245791 gidyl:ThousandNighteenWarrantsMember 2020-03-31 0001245791 gidyl:ThousandNighteenWarrantsMember 2019-01-01 2019-03-31 0001245791 gidyl:TwoThousandSeventeenNoteMember 2018-12-31 0001245791 gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2017-06-15 0001245791 gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2017-05-14 2017-06-15 0001245791 2017-06-15 0001245791 gidyl:ChessDepositInterestMember gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2017-01-01 2017-12-31 0001245791 gidyl:ChessDepositInterestMember gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2017-12-31 0001245791 gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2020-01-01 2020-03-31 0001245791 gidyl:TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember 2019-01-01 2019-03-31 0001245791 2019-08-31 0001245791 2019-08-02 2019-08-31 0001245791 gidyl:ChessDepositInterestMember gidyl:TwoThousandandEighteenSeniorUnsecuredConvertiblePromissoryNoteMember 2019-08-02 2019-08-31 0001245791 2019-12-06 0001245791 2020-01-02 2020-01-13 0001245791 gidyl:TwoThousandNineteenSeniorUnsecuredConvertiblePromissoryNoteMember 2020-03-31 0001245791 2019-04-22 0001245791 2019-04-01 2019-04-22 0001245791 srt:MinimumMember 2019-12-19 0001245791 srt:MaximumMember 2019-12-19 0001245791 gidyl:TwoThousandThreeStockIncentivePlanMember 2020-01-01 2020-03-31 0001245791 gidyl:TwoThousandElevenStockIncentivePlanMember 2020-03-31 0001245791 gidyl:NonEmployeesAwardsMember 2020-01-01 2020-03-31 0001245791 gidyl:NonEmployeesAwardsMember 2019-01-01 2019-03-31 0001245791 gidyl:NEDOptionsMember 2020-02-01 2020-02-28 0001245791 gidyl:ConsultantMember 2020-02-15 0001245791 gidyl:ConsultantMember 2020-02-01 2020-02-15 0001245791 gidyl:NonEmployeesMember 2020-03-31 0001245791 us-gaap:PerformanceSharesMember 2020-03-31 0001245791 gidyl:PerformanceStockUnitsMember 2020-03-31 0001245791 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001245791 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001245791 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001245791 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001245791 country:US 2020-03-31 0001245791 gidyl:MajorCustomersMember 2020-01-01 2020-03-31 0001245791 gidyl:MajorCustomersMember 2019-01-01 2019-03-31 0001245791 2020-03-01 2020-03-27 0001245791 us-gaap:SubsequentEventMember 2020-04-04 0001245791 us-gaap:SubsequentEventMember 2020-04-01 2020-04-04 0001245791 us-gaap:SubsequentEventMember 2020-05-01 2020-05-03 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqm Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018 Financing arranged August 2019, but funding did not occur until January 13, 2020 false --12-31 Q1 2020 2020-03-31 10-Q 0001245791 Yes false 000-55195 Non-accelerated Filer DE Yes GI DYNAMICS, INC. false true 36598291

3854000

2499000

30000

1377000

1230000

5261000

3759000

34000

42000

352000

386000

5647000

4187000

521000

636000

886000

1353000

5000000

10000

170000

169000

6577000

7168000

1950000

182000

217000

8709000

7385000

366000

283905000

280928000

-287333000

-284492000

-3062000

-3198000

5647000

4187000

0.01

75000000

36598291

1173000

810000

16000

1543000

1344000

2716000

2170000

-2716000

-2170000

3000

284000

177000

-10000

-9000

29000 164000

-1000

10000

-120000

-155000

-2836000

-2325000

5000

6000

-2841000

-2331000

-0.08

-0.12

36598291

19277545

36598291

366000

280928000

-284492000

212000

2765000

-2841000

36598291

366000

283905000

-287333000

19277545

193000

263521000

-267159000

-3445000

59000

-2331000

19277545

193000

263580000

-269490000

-5717000

8000

1000

-10000 282000 175000

212000

59000

-147000

-26000

-115000

-583000

-631000

-768000

-3242000

-3465000

5000

-5000

50000

4597000 1000000

4597000

950000

1355000

-2520000

2529000

3836000

3884000

1316000

5000

6000

394000

2330000 435000

1. Nature of Business GI Dynamics® is a clinical stage medical device company focused on the development and commercialization of EndoBarrier, a medical device intended to treat patients with type 2 diabetes and to reduce obesity. Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced). Being overweight is a condition where the patient’s BMI is greater than 25 (kg/m2); obesity is a condition where the patient’s BMI is greater than 30. Obesity and its comorbidities contribute to the progression of type 2 diabetes. Many experts believe obesity contributes to higher levels of insulin resistance, which creates a feedback loop that increases the severity of type 2 diabetes. When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes. EndoBarrier® is intended for the treatment of type 2 diabetes and to reduce obesity in a minimally invasive and reversible manner. The current treatment paradigm for type 2 diabetes is lifestyle therapy combined with pharmacological treatment, whereby treating clinicians prescribe a treatment regimen of one to four concurrent medications that could include insulin for patients with higher levels of blood sugar. Insulin carries a significant risk of increased mortality and may contribute to weight gain, which in turn may lead to higher levels of insulin resistance and increased levels of blood sugar. Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients. The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled efficacy gap. The GI Dynamics vision is to make EndoBarrier the essential nonpharmacological and non-anatomy-altering treatment for patients with type 2 diabetes. The Company intends to achieve this vision by providing a safe and effective device, focusing on optimal patient care, supporting treating clinicians, adding to the extensive body of clinical evidence around EndoBarrier, gaining appropriate regulatory approvals, continuing to improve its products and systems, operating the Company in a lean fashion, and maximizing stockholder value. EndoBarrier® is intended for the treatment of type 2 diabetes and to reduce obesity in a minimally invasive and reversible manner and is designed to mimic the mechanism of action of duodenal-jejunal exclusion created by gastric bypass surgery. Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company currently operates in one reportable business segment. Going Concern Evaluation As of March 31, 2020, the Company’s primary source of liquidity is its cash and restricted cash balances. GI Dynamics is currently focused primarily on its clinical trials, which will support future regulatory submissions and potential commercialization activities. Until the Company is successful in gaining regulatory approvals, it is unable to sell the Company’s product in any market at this time. Without revenues, GI Dynamics is reliant on funding obtained from investment in the Company to maintain business operations until the Company can generate positive cash flows from operations. The Company cannot predict the extent of future operating losses and accumulated deficit, and it may never generate sufficient revenues to achieve or sustain profitability. GI Dynamics has incurred operating losses since inception and at March 31, 2020, had an accumulated deficit of approximately $287 million and a working capital deficit of $1.3 million. The Company expects to incur significant operating losses for the next several years. At March 31, 2020, the Company had approximately $3.9 million in cash and restricted cash. The Company will need to restructure the terms of the Senior Secured Convertible Promissory Note, issued on June 15, 2017 (as amended from time to time, the “2017 Note”), before May 15, 2020 or the 2017 Note will be in default and subject to a call notice at the discretion of Crystal Amber. If the 2017 Note terms are restructured or the note is not called, the Company must raise additional capital before May 31, 2020 in order to continue to pursue its current business objectives as planned and to continue to fund its operations. The Company and Crystal Amber Fund Limited (“Crystal Amber”, a Related Party for ASX purposes) are currently in discussions regarding the 2017 Note maturity extension. The Company is looking to raise additional funds through any combination of additional equity and debt financings or from other sources. However, the Company has no guarantee that the 2017 Note will be restructured or if in default, will not be called. If the Note is called, the Company has no guaranteed source of capital that will accommodate repayment of the 2017 Note. If the 2017 Note terms are restructured or the 2017 Note is in default, but not called, the Company anticipates that operating cash will be exhausted by May 31, 2020 and therefore additional financing will be required to be able to continue its operations after this date. There can be no assurance that any potential financing opportunities will be available on acceptable terms, if at all. If the Company is unable to raise sufficient capital on the Company’s required timelines and on acceptable terms to stockholders and the Board of Directors, it could be forced to reduce or cease operations, including activities essential to support regulatory applications to commercialize EndoBarrier. If access to capital is not achieved before May 31, 2020, it will materially harm the Company’s business, financial condition and results of operations to the extent that the Company may be required to cease operations altogether, file for bankruptcy, or undertake any combination of the foregoing. In addition, if the Company does not meet its payment obligations to third parties as they become due, the Company may be subject to litigation claims and its credit worthiness would be adversely affected. Even if the Company is successful in defending these claims, litigation could result in substantial costs and would be a distraction to management and may have other unfavorable results that could further adversely impact the Company’s financial condition. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming GI Dynamics will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced). Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

1300000

2. Significant Accounting Policies and Basis of Presentation The consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC").  Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been omitted pursuant to such rules and regulations.  These interim consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 27, 2020. The Company's balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by GAAP for complete financial statements. In our opinion, the consolidated financial statements included herein contain all adjustments necessary to present fairly our financial position as of March 31, 2020 and the results of our operations and cash flows for the three months ended March 31, 2020 and 2019. Such adjustments are of a normal recurring nature. In addition, certain reclassifications of prior period balances have been made to conform to the current period presentation.  Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13, which provides guidance focused on the disclosure requirements for disclosing fair value estimates, assumptions, and methodology. Requirements removed include the requirement to disclose details around amount and reasoning for level 1 to level 2 transfers, timing policies for transfer between levels and the valuation processes for level 3 fair value measurements. Modified requirements include details regarding net asset redemption restrictions and timing related to uncertainty disclosures. Requirements added include disclosures of changes in unrealized gains and losses for recurring level 3 measurements held as of the reporting date and disclosures around the range and weighted average of significant inputs used to develop level 3 fair value measurements. These amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption was permitted upon issuance of this update, however the Company has declined early adoption. The Company adopted this ASU on January 1, 2020 and concluded that it had no impact on its consolidated financial statements.

Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13, which provides guidance focused on the disclosure requirements for disclosing fair value estimates, assumptions, and methodology. Requirements removed include the requirement to disclose details around amount and reasoning for level 1 to level 2 transfers, timing policies for transfer between levels and the valuation processes for level 3 fair value measurements. Modified requirements include details regarding net asset redemption restrictions and timing related to uncertainty disclosures. Requirements added include disclosures of changes in unrealized gains and losses for recurring level 3 measurements held as of the reporting date and disclosures around the range and weighted average of significant inputs used to develop level 3 fair value measurements. These amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption was permitted upon issuance of this update, however the Company has declined early adoption. The Company adopted this ASU on January 1, 2020 and concluded that it had no impact on its consolidated financial statements.

3. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, stock options and other stock-based awards are excluded, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. For diluted net loss per share purposes, derivatives to purchase shares of common stock or CDIs are treated identically because shares of common stock and CDIs are interchangeable at the sole election of the stockholder. For diluted net loss per share purposes, options and warrants conferring the right to purchase shares of common stock or CDIs are excluded from diluted net loss per share calculations as inclusion would have an anti-dilutive effect. During the three months ended March 31, 2020 and 2019, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented. The following potentially dilutive securities have been excluded from the computation of diluted weighted- average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Warrants to purchase common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,625,425</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,552,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock and other stock-based awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,376,154</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,545,719</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8,001,579</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,098,391</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

4625425

3552672

3376154

1545719

8001579

5098391

4. Warrants to Purchase Common Stock or CDIs The following series of warrants were outstanding and exercisable at March 31, 2020 and 2019 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Number of underlying </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Warrant Series</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">per share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Consultant warrant</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">May 4, 2016</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>2018 Warrant (1)</td><td> </td> <td style="text-align: center">May 24, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,944,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,944,444</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">August 2019 Warrant (2)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">January 13, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">4,596,893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,596,893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Outstanding and Exercisable</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,625,425</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,972,976</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average exercise price</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.72</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Financing arranged August 2019, but funding did not occur until January 13, 2020</td> </tr></table> On May 4, 2016, the Company entered into a consulting agreement pursuant to which a consulting firm provides strategic advisory, finance, accounting, human resources and administrative functions, including chief financial officer services, to the Company. In connection with the consulting agreement, the Company granted the consulting firm a warrant (“Consultant Warrant”) to purchase up to 28,532 shares of the Company’s common stock at an exercise price per share equal to $0.64. The Consultant Warrant is fully vested and expires on May 4, 2021. As of March 31, 2019, the Consultant Warrants had not been exercised. On August 21, 2019, GI Dynamics and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant (totaling 8,248,549 shares of common stock purchased for approximately $5.4 million) and the issue and sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI issued on exercise. On December 16, 2019, stockholders approved the issuance of the August 2019 Warrant, which was then issued on January 13, 2020.

The following series of warrants were outstanding and exercisable at March 31, 2020 and 2019 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio):

0.90

0.72

28532

0.64

2021-05-04

GI Dynamics and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant (totaling 8,248,549 shares of common stock purchased for approximately $5.4 million) and the issue and sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI issued on exercise. On December 16, 2019, stockholders approved the issuance of the August 2019 Warrant, which was then issued on January 13, 2020. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Number of underlying </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Warrant Series</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">per share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Consultant warrant</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">May 4, 2016</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,532</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>2018 Warrant (1)</td><td> </td> <td style="text-align: center">May 24, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,944,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,944,444</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">August 2019 Warrant (2)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">January 13, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">4,596,893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,596,893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Outstanding and Exercisable</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,625,425</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,972,976</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average exercise price</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.72</td><td style="text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Financing arranged August 2019, but funding did not occur until January 13, 2020</td> </tr></table> May 4, 2016 28532

0.64

28532 28532 May 24, 2018 1944444

0.72

1944444 January 13, 2020 4596893

1.00

4596893 4625425 1972976 1.00 0.72

5. Fair Value Measurements The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability. On March 31, 2020, the classification of the Consultant Warrant was reevaluated and the Company re-classified it as an equity instrument. On March 31, 2020, this reclassification resulted in a credit to Other Income. Cash, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses, short-term debt to related party and other current liabilities at March 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments.

6. Concentrations of Credit Risk and Related Valuation Account Financial instruments that subject GI Dynamics to credit risk primarily consist of cash and restricted cash. Cash balances are maintained with high quality financial institutions, and consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s short-term investments potentially subject the Company to concentrations of credit risk. GI Dynamics has adopted an investment policy that limits the amounts it may invest in any one type of investment and requires all held investments to hold at least an A rating from a recognized credit rating agency, thereby reducing credit risk concentration.

7. Accrued Expenses Accrued expenses consisted of the following (in thousands): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Payroll and related liabilities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">531</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">335</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Credit refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">107</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">73</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">886</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,353</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> In 2017, following notification by the Medicines and Healthcare Products Regulatory Agency (“MHRA”), the Company notified its customers to return their inventory on hand. The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers. Through December 31, 2019, this reserve had various claims and adjustments of $115 thousand. On March 31, 2020, the Company reversed the remaining accrual for $164 thousand and recognized Other Income as the Company concluded that the likelihood that further claims will be made was remote, given the amount of time without such claims after product expiry.  In December 2018, the maturity of the 2017 Note was extended to March 31, 2019 in exchange for payment of $394 thousand, which was the total accrued interest on the 2017 Note at December 31, 2018. Accrued interest at March 31, 2020 includes interest on the 2017 Note since January 1, 2019 and the August 2019 Note since January 13, 2020.

The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers. Through December 31, 2019, this reserve had various claims and adjustments of $115 thousand. On March 31, 2020, the Company reversed the remaining accrual for $164 thousand and recognized Other Income as the Company concluded that the likelihood that further claims will be made was remote, given the amount of time without such claims after product expiry.

394000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Payroll and related liabilities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">531</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">335</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Credit refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">107</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">73</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">886</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,353</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

188000

531000

176000

335000

164000

415000

250000

107000

73000

8. Notes Payable 2017 Convertible Note Financing On June 15, 2017, the Company entered into a Note Purchase Agreement (“2017 NPA”) by and between the Company and Crystal Amber, a Related Party. Pursuant to the 2017 NPA, the Company issued and sold to Crystal Amber, a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”). The 2017 Note accrues interest at an annually compounded rate of 5% per annum, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on the original maturity date of December 31, 2018, and, as amended, is currently scheduled to mature on May 15, 2020. The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, Crystal Amber, is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if Crystal Amber were the absolute owner thereof. The ASX provided the Company with a waiver to allow all asset liens (the “Security”) to be granted to Crystal Amber, without the customary requirement of having to obtain stockholder approval for the grant of a security to a Related Party of the Company. As a result of the waiver, the Security contains a provision that provides that if an event of default occurs and Crystal Amber exercises its rights under the Security, neither Crystal Amber nor any of its associates can acquire any legal or beneficial interest in an asset of the Company or its subsidiaries in full or partial satisfaction of the Company’s obligations under the Security, or otherwise deal with the assets of the Company or its subsidiaries, without the Company first having complied with any applicable ASX Listing Rules, including ASX Listing Rule 10.1, other than as required by law or through a receiver, manager, or analogous person appointed by Crystal Amber exercising its power of sale under the Security and selling the assets to an unrelated third party on arm’s length commercial terms and conditions and distributing the cash proceeds to Crystal Amber or any of its associates in accordance with their legal entitlements. The entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CDIs (i) prior to the maturity date, at the option of Crystal Amber at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs traded on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing. In the event that the Company issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective Optional Conversion Price, Crystal Amber has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that Crystal Amber may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains Crystal Amber’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing. In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the 2017 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends. The 2017 NPA contains customary events of default including a failure to perform obligations under the 2017 NPA, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 NPA and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. For the three months ended March 31, 2020 and 2019, the Company recognized interest expense of $65 and $62 thousand, respectively, related to the 2017 Note. August 2019 Securities Purchase Agreement On August 21, 2019, the Company entered into the August 2019 SPA by and between the Company and Crystal Amber. The August 2019 SPA detailed a timeline wherein Crystal Amber would exercise the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant. Additionally, pursuant to the August 2019 SPA, the Company issued and sold to Crystal Amber a senior unsecured convertible promissory note in an aggregate principal amount of approximately $4.6 million, or such lesser amount as may be set forth in a notice delivered by the Company to Crystal Amber (the “August 2019 Note”), to be funded on December 6, 2019, or such earlier or later date as may be requested by the Company (the “Funding Date”). In conjunction with the August 2019 Note, the Company agreed to issue to Crystal Amber a Warrant (the “August 2019 Warrant”) to purchase CDIs, subject to the receipt of required stockholder approval approving the issuance of the August 2019 Warrant and the funding of the August 2019 Note (see Note 4). The August 2019 Note accrues interest at a rate equal to 10% per annum from the August 2019 Note Funding Date, compounded annually, other than during the continuance of an event of default, when the August 2019 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the fifth anniversary of the Funding Date. The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI. In the event that the Company issues additional CDIs to a stockholder other than Crystal Amber in a subsequent equity financing at a price per CDI that is less than the conversion price under the August 2019 Note, the conversion price shall be reduced to the lowest such price per CDI. In addition, upon a change of control of the Company resulting in cash proceeds, Crystal Amber may, at its option, demand that the Company prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. The Company may not prepay the August 2019 Note without the consent of Crystal Amber, a Related Party. If the stockholder approvals required to issue the August 2019 Warrant or to approve the conversion rights under the August 2019 Note are not obtained, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance on the earlier of the Funding Date or the date that is six months following the date of the stockholder meeting at which the requisite approvals were not obtained. The Company considers the change in control premium and the stockholder approval premium to each represent a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premiums, the fair value was considered immaterial upon issuance and through the end of this reporting period. The August 2019 SPA contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the August 2019 Note may be accelerated. The August 2019 SPA and related August 2019 Note and August 2019 Warrant documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. Prior to December 6, 2019, the Company notified Crystal Amber that it had elected to receive the full amount of approximately $4.6 million under the August 2019 Note, but agreed to timing extensions. On December 16, 2019, stockholder approval was obtained pursuant to ASX Listing Rule 10.11, for the August 2019 Note conversion feature and the issuance of the August 2019 Warrant, contingent on receipt of the August 2019 Note proceeds. On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note was immediately convertible. On January 13, 2020, the Company issued to Crystal Amber an immediately exercisable August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4). On issuance, having already obtained the required stockholder approval to reserve the CDIs underlying the conversion feature and the August 2019 Warrant, the August 2019 Warrant was determined to be a freestanding instrument meeting the requirements for equity classification in accordance with ASC 480-10 Distinguishing Liabilities from Equity, ASC 815-40 Contracts in an Entity’s Own Equity and ASC 470-20 Debt with Conversion and Other Options. Accordingly, proceeds from the August 2019 SPA were allocated to the August 2019 Note and Warrant based on their relative fair values. The relative fair value of the August 2019 Warrant of approximately $2.3 million was recorded as a debt discount with the offset to additional paid-in capital. Additionally, the Company analyzed the conversion features of the August 2019 Note to determine whether a beneficial conversion feature (BCF) existed. The Company determined a BCF with a value of $435 thousand existed and was recorded as a debt discount with the offset to additional paid-in capital. The total debt discount will be amortized to interest expense through the January 2025 maturity of the August 2019 Note. For the three months ended March 31, 2020, the Company recorded $98 thousand of accrued interest expense. For the three months ended March 31, 2020, the Company recognized interest expense of $100 thousand from the amortization of the debt discount.

5000000

0.05

0.08 10000000 1.10

65000

62000

4600000

0.10

0.16

The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI.

1.10 1.10

4600000

2300000

435000

98000

100000

9. Commitments and Contingencies Lease Commitments In December 2018, the Company entered into a 6-month membership agreement with WeWork for 985 square feet of office space located in Boston, Massachusetts. The committed lease term expired in May 2019. The WeWork agreement contained no explicit or guaranteed extension provisions. On April 22, 2019, the Company entered into a right-of-use lease for 3,520 square feet of office space in Boston, Massachusetts. The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. The lease has defined escalating rent payments and contains no extension or expansion rights. On lease execution, the Company recorded the approximately $463 thousand present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset. The right-of-use asset will be amortized to lease expense and the liability will be reduced by the rent payments over the term of the lease. The Company’s leases generally do not provide an implicit interest rate and therefore the Company uses 10% as an estimate of its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company had no leases currently classified as finance leases or previously classified as capital leases in either reporting period. The Company’s operating lease is reflected in the balance sheets. In the three months ended March 31, 2020, $44 thousand of lease expense was incurred and an additional $3 thousand of tax expense was accrued for property taxes associated with the leased facility. Other information related to leases was as follows (in 2019, leases were all short term and excluded from the adoption of ASU 2016-2): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows from operating leases in lease liability measurement</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating cash flows from short term leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining long-term lease term in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The maturity of the Company’s operating lease liability as of March 31, 2020 is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">352</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Rent expense on non-cancelable operating leases was approximately $44 and $56 thousand for the three months ended March 31, 2020 and 2019, respectively.

985

3520

The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. 463000

0.10

44000

3000

44000

56000

53000

44000

P2Y73D

134000

182000

76000

392000

40000

352000

10. Stockholders’ Deficit On December 19, 2019, GI Dynamics stockholders approved an increase of its authorized shares of common stock from 50 million to 75 million. As of March 31, 2020, the authorized capital stock of the Company consists of 75.5 million shares, of which 75 million shares are designated as common stock and 500 thousand shares are designated as preferred stock.

50000000

75000000

75500000

500000

11. Share-Based Compensation The Company has two stock-based compensation plans. The Board of Directors adopted the 2003 Omnibus Stock Plan (the “2003 Plan”), which provides for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants to purchase up to an aggregate of 922,086 shares of the Company’s common stock. In August 2011, the Board of Directors adopted the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”, together with the 2003 Plan, the “Plans”) as the successor to the 2003 Plan. Under the 2011 Plan, the Company may grant incentive stock options, nonqualified stock options, restricted and unrestricted stock awards and other stock-based awards. As of March 31, 2020, an additional 554,866 shares of common stock were available for grant under the Company’s 2011 Plan.  In addition, the 2011 Plan allows for an annual increase in the number of shares available for issue under the 2011 Plan commencing on the first day of each fiscal year during the period beginning in fiscal year 2012 and ending in fiscal year 2020. The annual increase in the number of shares shall be equal to the lowest of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">500 thousand shares;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">4% of the number of common shares outstanding as of such date; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an amount determined by the Board of Directors or the Company’s compensation committee. Accordingly, during the quarters ended March 31, 2020 and March 31, 2019, 500 thousand shares were added to the 2011 Plan.</td></tr> </table> Stock-Based Compensation Stock-based compensation is reflected in the consolidated statements of operations as follows for the three months ended March 31, 2020 and 2019 (in thousands): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">199</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">212</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">59</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant. The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three months ended March 31, 2020 and 2019: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Expected volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">164.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">122.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> Stock Options The following table summarizes share-based activity under the Company’s stock option plans: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Attributable to Options</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Contractual Life</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-size: 10pt; font-style: italic"> </td> <td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center">(in years)</td><td style="font-size: 10pt; font-style: italic"> </td><td style="font-size: 10pt; font-style: italic"> </td> <td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center">(in thousands)</td><td style="font-size: 10pt; font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; font-weight: bold">Outstanding at December 31, 2019</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 9%; font-size: 10pt; text-align: right">3,096,154</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.47</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 9%; font-size: 10pt; text-align: right">8.3</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">—</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-indent: 20pt">Granted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">90,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.25</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">—</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-indent: 20pt">Cancelled</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">0.74</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">—</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,126,154</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">8.6</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">—</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt">Vested or expected to vest at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,126,154</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt">Exercisable at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">781,360</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">6.7</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The majority of the Company’s option grants vest 25% on the first anniversary of the grant date, and in a quarterly straight-line rate thereafter until fully vested on the fourth anniversary of the grant date. The weighted average grant date fair value for options granted in the three-month period ended March 31, 2020, was $0.18. The unrecognized stock compensation expense at March 31, 2020 was $2.0 million and was expected to be recognized over a weighted average period of 3.07 years from March 31, 2020. The Company has recorded non-employee stock-based compensation expense of approximately $50 thousand and $4 thousand during the three-month period ended March 31, 2020 and 2019, respectively, which is included in total stock-based compensation expense. The unrecognized compensation expense associated with outstanding non-employee grants was $119 and $21 thousand at March 31, 2020 and 2019, respectively. On February 28, 2020, the Company’s Board of Directors approved, subject to stockholder approval per ASX Listing Rule 10.14, the grant of stock options (“NED Options”) conferring the right to purchase up to 30,000 shares of the Company’s common stock to Praveen Tyle, a non-executive director pursuant to the Company’s 2011 Plan. The exercise price is $0.20 per share of common stock and the NED Options will vest in full on February 28, 2021 if Dr. Tyle remains a director of the Company through that date. The NED Options will vest immediately on a change in control event. The NED Options are immediately exercisable, subject to repurchase rights if purchased prior to vesting. The NED Options will be cancelled immediately upon termination of service as a director, unless such termination is the result of a defined change in control event, in which case the NED Options will be cancelled 12 months after such termination. As of March 31, 2020, stockholders had not yet approved the NED Options. On February 15, 2020, the Company granted a consultant an option to purchase up to 10 thousand shares of common stock at a price of $0.40 per share. The option vests in equal monthly amounts over a 24-month period and expires in 10 years. At March 31, 2020, the Company had unvested outstanding options to purchase 167,673 shares of common stock granted to non-employees. Performance Stock Units Each performance stock unit (“PSU”) represents a contingent right to receive one share of the Company’s common stock. There is no consideration payable on the vesting of PSUs issued under the Plans. Upon vesting, the PSUs are exercised automatically and settled in shares of the Company’s common stock. During the three months ended March 31, 2020, the Company awarded no PSUs to employees and directors of the Company. The following table summarizes information related to PSU activity for the three months ended March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in years)</td><td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Outstanding at December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">149</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 20pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 20pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: 20pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">250,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5.98</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value at March 31, 2020 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of PSUs outstanding. The fair value of each PSU award equals the closing price of the Company’s common stock on the date of grant. At March 31, 2020, 250,000 of the PSUs outstanding vest on the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company will expense the compensation of the respective stock award over the implicit service period. At March 31, 2020, the Company recognized no stock-based compensation related to performance-based vesting of PSUs. As of March 31, 2020, there was approximately $200 thousand of unrecognized stock-based compensation expense related to non-vested PSU awards that have performance-based vesting.

922086

554866

500000

0.04

500000

P4Y

P10Y

0.25

0.18

2000000 P3Y25D

50000

4000

119000 21000

30000

0.20

10000

0.40

P10Y

167673

250000

200000

13000

16000

199000

43000

212000

59000

1.649

1.220

P5Y306D

P6Y18D

0.009

0.023

0.00

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Attributable to Options</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Contractual Life</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-size: 10pt; font-style: italic"> </td> <td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center">(in years)</td><td style="font-size: 10pt; font-style: italic"> </td><td style="font-size: 10pt; font-style: italic"> </td> <td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center">(in thousands)</td><td style="font-size: 10pt; font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; font-weight: bold">Outstanding at December 31, 2019</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 9%; font-size: 10pt; text-align: right">3,096,154</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.47</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 9%; font-size: 10pt; text-align: right">8.3</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">—</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-indent: 20pt">Granted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">90,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.25</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">—</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-indent: 20pt">Cancelled</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">0.74</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">—</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,126,154</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">8.6</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">—</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt">Vested or expected to vest at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,126,154</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt">Exercisable at March 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">781,360</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">6.7</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

3096154

1.47

P8Y109D

90000

0.25

60000

0.74

3126154

1.46

P8Y219D

3126154

781360

1.46

P6Y255D

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in years)</td><td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Outstanding at December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">149</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 20pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 20pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: 20pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">250,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5.98</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

250000

P6Y83D

149000

250000

P5Y357D

23000

12. Segment Reporting Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity. Geographic Reporting The Company has historically reported various geographic segments but does not do so currently as the right-of-use asset of approximately $463 thousand and all long-lived assets, comprised of property and equipment of approximately $34 thousand are all held in the U.S. at March 31, 2020. Additionally, the Company did not have revenue in any geography for the three months ended March 31, 2020 and 2019, respectively. Major Customers The Company did not recognize any revenue for the three months ended March 31, 2020 and 2019, respectively.

463000

34000

13. Subsequent Events On March 27, 2020, the CARES Act was signed into law in the United States providing economic assistance for American workers and families, small businesses, and preserves jobs for American industries.  GI Dynamics qualifies for the Payroll Protection Program (“PPP”) administered by the United States Small Business Administration (“SBA”) and existing lending institutions.  On April 4, 2020, GI Dynamics submitted an application to a lending institution for a loan of approximately $200 thousand under the PPP.  In accordance with the provisions of the PPP, the loan accrues interest at a rate of 1% and all or a portion of the loan may be forgiven if it is used to pay for qualifying costs such as payroll, rent and utilities. Amounts that are not forgiven will be repaid 2 years from the date of the loan. Due to backlog, the application was not received by the SBA before funding for the CARES Act was exhausted.  Additional CARES Act funds were allocated on April 23, 2020 and GI Dynamics was notified by our lending institution that the application was approved by the SBA on April 30, 2020. The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.

200000

0.01

P2Y

The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.

EX-101.SCH 9 gidyl-20200331.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Changes in Stockholders’ Deficit (unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Nature of Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Net Loss per Common Share link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Warrants to Purchase Common Stock or CDIs link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Concentrations of Credit Risk and Related Valuation Account link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Warrants to Purchase Common Stock or CDIs (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Nature of Business (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Net Loss per Common Share (Details) - Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Warrants to Purchase Common Stock or CDIs (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Commitments and Contingencies (Details) - Schedule of other information related to leases link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of operating lease liability link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Share-Based Compensation (Details) - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Share-Based Compensation (Details) - Weighted-average Assumptions used to Estimate Fair Value of Stock Options link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Share-Based Compensation (Details) - Share-Based Activity link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Share-Based Compensation (Details) - Restricted Stock Units and Performance Stock Units Activity link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 gidyl-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 gidyl-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 12 gidyl-20200331_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Total current assets Total assets Total current liabilities Total liabilities Total stockholders’ deficit Beginning balance Ending balance Total liabilities and stockholders’ deficit Income Statement [Abstract] Total operating expenses Loss from operations Other expense, net Loss before income taxes Net loss Net loss Statement of Stockholders' Equity [Abstract] Beginning balance (in Shares) Ending balance (in Shares) Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statement of Cash Flows [Abstract] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net decrease in cash and restricted cash Cash and restricted cash at beginning of period Cash and restricted cash at end of period Cash and cash equivalents, restricted cash Accounting Policies [Abstract] Earnings Per Share [Abstract] Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares [Abstract] Antidilutive Securities [Axis] Warrants to purchase common stock [Member] Options to purchase common stock and other stock-based awards [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of warrants outstanding and exercisable [Abstract] Class of Warrant or Right [Axis] Consultant Warrant [Member] 2018 Warrant [Member] August 2019 Warrant [Member] Fair Value Disclosures [Abstract] Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Abstract] Payables and Accruals [Abstract] Schedule of Accrued Liabilities [Abstract] Total Accrued expenses Debt Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of other information related to leases [Abstract] Schedule of maturity of operating lease liability [Abstract] Total future minimum lease payments Stockholders' Equity Note [Abstract] Share-based Payment Arrangement [Abstract] Stock-Based Compensation [Abstract] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Weighted-average Assumptions used to Estimate Fair Value of Stock Options [Abstract] Share-Based Activity [Abstract] Shares of common stock attributable to options, outstanding, beginning balance Shares of common stock attributable to options, outstanding, ending balance Company granted option to purchase common stock Weighted- average exercise price, outstanding, beginning balance (in Dollars per share) Weighted- average exercise price, outstanding, ending balance (in Dollars per share) Common stock price (in Dollars per share) Aggregate intrinsic value, outstanding, beginning balance (in Dollars) Aggregate intrinsic value, outstanding, ending balance (in Dollars) Restricted Stock Units and Performance Stock Units Activity [Abstract] Number of units, outstanding, beginning balance Number of units, outstanding, ending balance Performance stock units outstanding Outstanding aggregate intrinsic value, beginning balance (in Dollars) Outstanding aggregate intrinsic value, ending balance (in Dollars) Segment Reporting [Abstract] Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Emerging Growth Company Entity File Number Entity Filer Category Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Registrant Name Entity Shell Company Entity Small Business Assets Current assets: Cash Restricted cash Prepaid expenses and other current assets Property and equipment, net Right-of-use assets, net of amortization Right-of-use-asset Liabilities and stockholders’ deficit Current liabilities: Accounts payable Short term debt to related party Derivative liabilities Short term lease liabilities Long term debt to related party, net of debt discount Long term lease liabilities Commitments and contingencies Stockholders’ deficit: Common stock, $0.01 par value – 75,000,000 shares authorized; 36,598,291 shares issued and outstanding Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Operating expenses: Research and development Sales and marketing General and administrative Other income (expense): Interest income Foreign exchange loss Gain on write-off of accounts payable Gain on write-off of accrued product return liability Re-measurement of derivative liabilities Other income Provision for income taxes Basic and diluted net loss per common share (in Dollars per share) Weighted-average number of common shares used in basic and diluted net loss per common share (in Shares) Stock-based compensation expense Relative fair value of warrants and beneficial conversion feature in connection with August 2019 Note Operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Re-measurement of derivative liabilities Reclassification of warrant from derivative liabilities to other income Non-cash interest expense Stock-based compensation expense Stock-based compensation expense (in Dollars) Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable Accrued expenses Investing activities Financing activities Proceeds from short term and long term debt, related party Supplemental disclosures of cash flow information and non-cash activities Income taxes paid Interest paid Warrants issuance recorded to APIC and debt discount Beneficial conversion feature discount associated with August 2019 Note Interest expense Purchases of property and equipment Debt issuance costs Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Significant Accounting Policies [Text Block] Earnings Per Share [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding Derivative Instruments and Hedging Activities Disclosure [Text Block] Schedule of warrants outstanding and exercisable [Table Text Block] Issue Date Number of underlying shares (in Shares) Exercise price per share (in Dollars per share) Exercise price per share Total Outstanding and Exercisable Weighted average exercise price (in Dollars per share) Fair Value Disclosures [Text Block] Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Text Block] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Schedule of Accrued Liabilities [Table Text Block] Payroll and related liabilities Professional fees Credit refunds Interest payable Accrued interest expense Other Debt Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Lease, Cost [Table Text Block] Operating cash flows from operating leases in lease liability measurement Operating cash flows from short term leases Remaining long-term lease term in years Discount rate Incremental borrowing rate as discount rate to measure operating lease liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] 2020 2021 2022 Less: imputed interest Total liabilities Stockholders' Equity Note Disclosure [Text Block] Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock-based compensation expense Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Expected volatility Expected term (in years) Risk-free interest rate EX-101.PRE 13 gidyl-20200331_pre.xml XBRL PRESENTATION FILE XML 14 R31.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - Schedule of Accrued Liabilities - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of Accrued Liabilities [Abstract]
Payroll and related liabilities	$ 188	$ 531
Professional fees	176	335
Credit refunds		164
Interest payable	415	250
Other	107	73
Total	$ 886	$ 1,353

XML 15 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - Schedule of maturity of operating lease liability $ in Thousands	Mar. 31, 2020 USD ($)
Schedule of maturity of operating lease liability [Abstract]
2020	$ 134
2021	182
2022	76
Total future minimum lease payments	392
Less: imputed interest	40
Total liabilities	$ 352

XML 16 R39.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - Weighted-average Assumptions used to Estimate Fair Value of Stock Options	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Weighted-average Assumptions used to Estimate Fair Value of Stock Options [Abstract]
Expected volatility	164.90%	122.00%
Expected term (in years)	5 years 306 days	6 years 18 days
Risk-free interest rate	0.90%	2.30%
Expected dividend yield	0.00%	0.00%

XML 17 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

10. Stockholders’ Deficit

On December 19, 2019, GI Dynamics stockholders approved an increase of its authorized shares of common stock from 50 million to 75 million.

XML 18 R12.htm IDEA: XBRL DOCUMENT

Concentrations of Credit Risk and Related Valuation Account

3 Months Ended

Mar. 31, 2020

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Abstract]

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Text Block]

6. Concentrations of Credit Risk and Related Valuation Account

XML 19 R28.htm IDEA: XBRL DOCUMENT

Warrants to Purchase Common Stock or CDIs (Details) - $ / shares			1 Months Ended
	Mar. 15, 2019	May 04, 2016	Aug. 21, 2019	Mar. 31, 2020	Mar. 31, 2019	Nov. 30, 2018	May 24, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants description	The following series of warrants were outstanding and exercisable at March 31, 2020 and 2019 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio):		GI Dynamics and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant (totaling 8,248,549 shares of common stock purchased for approximately $5.4 million) and the issue and sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI issued on exercise. On December 16, 2019, stockholders approved the issuance of the August 2019 Warrant, which was then issued on January 13, 2020.
Exercise price per share		$ 0.64		$ 50	$ 50	$ 0.72	$ 0.90
(in Shares)		28,532
Warrant expires date		May 04, 2021

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2. Significant Accounting Policies and Basis of Presentation

Recently Adopted Accounting Pronouncements

XML 21 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Lease, Cost [Table Text Block]

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Operating cash flows from operating leases in lease liability measurement	$	53		$	—
Operating cash flows from short term leases		44			—
Remaining long-term lease term in years		2.2			—
Discount rate		10	%		—

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

	March 31, 2020
	(in thousands)
2020		134
2021		182
2022		76
Total future minimum lease payments		392
Less: imputed interest		40
Total liabilities	$	352

XML 22 R20.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

XML 23 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development	$ 1,173	$ 810
Sales and marketing		16
General and administrative	1,543	1,344
Total operating expenses	2,716	2,170
Loss from operations	(2,716)	(2,170)
Other income (expense):
Interest income		3
Interest expense	(284)	(177)
Foreign exchange loss	(10)	(9)
Gain on write-off of accounts payable		29
Gain on write-off of accrued product return liability	164
Re-measurement of derivative liabilities		(1)
Other income	10
Other expense, net	(120)	(155)
Loss before income taxes	(2,836)	(2,325)
Provision for income taxes	5	6
Net loss	$ (2,841)	$ (2,331)
Basic and diluted net loss per common share (in Dollars per share)	$ (0.08)	$ (0.12)
Weighted-average number of common shares used in basic and diluted net loss per common share (in Shares)	36,598,291	19,277,545

XML 24 R41.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - Restricted Stock Units and Performance Stock Units Activity $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($) shares
Restricted Stock Units and Performance Stock Units Activity [Abstract]
Number of units, outstanding, beginning balance	250,000
Weighted average contractual life, at beginning of period	6 years 83 days
Outstanding aggregate intrinsic value, beginning balance (in Dollars) \| $	$ 149
Number of units, outstanding, ending balance	250,000
Weighted average contractual life, at ending of period	5 years 357 days
Outstanding aggregate intrinsic value, ending balance (in Dollars) \| $	$ 23
Number of units, granted
Number of units, exercised
Number of units, cancelled
Weighted average contractual life, cancelled
Aggregate intrinsic value, cancelled (in Dollars) \| $

XML 25 R25.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2020		2019
Research and development	$	13	$	16
General and administrative		199		43
	$	212	$	59

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended March 31,
	2020			2019
Expected volatility		164.9	%		122.0	%
Expected term (in years)		5.84			6.05
Risk-free interest rate		0.9	%		2.3	%
Expected dividend yield		0	%		0	%

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Shares of Common Stock Attributable to Options			Weighted- Average Exercise Price		Weighted- Average Contractual Life		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding at December 31, 2019		3,096,154		$	1.47		8.3	$	—
Granted		90,000		$	0.25			$	—
Cancelled		(60,000	)	$	0.74			$	—
Outstanding at March 31, 2020		3,126,154		$	1.46		8.6	$	—
Vested or expected to vest at March 31, 2020		3,126,154
Exercisable at March 31, 2020		781,360		$	1.46		6.7

Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

	Number of Units		Weighted- Average Contractual Life		Aggregate Intrinsic Value
			(in years)		(in thousands)
Outstanding at December 31, 2019		250,000		6.23	$	149
Granted		—
Exercised		—
Cancelled		—		—		—
Outstanding at March 31, 2020		250,000		5.98	$	23

XML 26 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 01, 2020
Document Information Line Items
Entity Registrant Name	GI DYNAMICS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		36,598,291
Amendment Flag	false
Entity Central Index Key	0001245791
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-55195
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

XML 27 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders’ Deficit (unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2018	$ 193	$ 263,521	$ (267,159)	$ (3,445)
Beginning balance (in Shares) at Dec. 31, 2018	19,277,545
Stock-based compensation expense		59		59
Net loss			(2,331)	(2,331)
Ending balance at Mar. 31, 2019	$ 193	263,580	(269,490)	(5,717)
Ending balance (in Shares) at Mar. 31, 2019	19,277,545
Beginning balance at Dec. 31, 2019	$ 366	280,928	(284,492)	(3,198)
Beginning balance (in Shares) at Dec. 31, 2019	36,598,291
Stock-based compensation expense		212		212
Relative fair value of warrants and beneficial conversion feature in connection with August 2019 Note		2,765		2,765
Net loss			(2,841)	(2,841)
Ending balance at Mar. 31, 2020	$ 366	$ 283,905	$ (287,333)	$ (3,062)
Ending balance (in Shares) at Mar. 31, 2020	36,598,291

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 28 R21.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2020		2019
Warrants to purchase common stock		4,625,425		3,552,672
Options to purchase common stock and other stock-based awards		3,376,154		1,545,719
Total		8,001,579		5,098,391

XML 29 R29.htm IDEA: XBRL DOCUMENT

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable - $ / shares

3 Months Ended

May 04, 2016

Mar. 31, 2020

Mar. 31, 2019

Nov. 30, 2018

May 24, 2018

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]

Number of underlying shares

28,532

Exercise price per share (in Dollars per share)

$ 0.64

$ 50

$ 0.72

$ 0.90

Total Outstanding and Exercisable

4,625,425

1,972,976

Weighted average exercise price (in Dollars per share)

$ 1.00

$ 0.72

Consultant Warrant [Member]

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]

Issue Date

May 4, 2016

Number of underlying shares

28,532

Exercise price per share (in Dollars per share)

$ 0.64

Total Outstanding and Exercisable

28,532

2018 Warrant [Member]

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]

Issue Date

^[1]

May 24, 2018

Number of underlying shares

^[1]

1,944,444

Exercise price per share (in Dollars per share)

^[1]

$ 0.72

Total Outstanding and Exercisable

^[1]

1,944,444

August 2019 Warrant [Member]

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]

Issue Date

^[2]

January 13, 2020

Number of underlying shares

^[2]

4,596,893

Exercise price per share (in Dollars per share)

^[2]

$ 1.00

Total Outstanding and Exercisable

^[2]

4,596,893

[1]	Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018
[2]	Financing arranged August 2019, but funding did not occur until January 13, 2020

XML 30 R9.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

3. Net Loss per Common Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted- average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive:

	Three Months Ended March 31,
	2020		2019
Warrants to purchase common stock		4,625,425		3,552,672
Options to purchase common stock and other stock-based awards		3,376,154		1,545,719
Total		8,001,579		5,098,391

XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 84 283 1 true 29 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.gxacquisitioncorp/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://www.gxacquisitioncorp/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (unaudited) (Parentheticals) Sheet http://www.gxacquisitioncorp/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://www.gxacquisitioncorp/role/ConsolidatedIncomeStatement Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Stockholders??? Deficit (unaudited) Sheet http://www.gxacquisitioncorp/role/ShareholdersEquityType2or3 Consolidated Statements of Changes in Stockholders??? Deficit (unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.gxacquisitioncorp/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 006 - Disclosure - Nature of Business Sheet http://www.gxacquisitioncorp/role/NatureofBusiness Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation Sheet http://www.gxacquisitioncorp/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation Summary of Significant Accounting Policies and Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Net Loss per Common Share Sheet http://www.gxacquisitioncorp/role/NetLossperCommonShare Net Loss per Common Share Notes 9 false false R10.htm 009 - Disclosure - Warrants to Purchase Common Stock or CDIs Sheet http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIs Warrants to Purchase Common Stock or CDIs Notes 10 false false R11.htm 010 - Disclosure - Fair Value Measurements Sheet http://www.gxacquisitioncorp/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Concentrations of Credit Risk and Related Valuation Account Sheet http://www.gxacquisitioncorp/role/ConcentrationsofCreditRiskandRelatedValuationAccount Concentrations of Credit Risk and Related Valuation Account Notes 12 false false R13.htm 012 - Disclosure - Accrued Expenses Sheet http://www.gxacquisitioncorp/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 013 - Disclosure - Notes Payable Notes http://www.gxacquisitioncorp/role/NotesPayable Notes Payable Notes 14 false false R15.htm 014 - Disclosure - Commitments and Contingencies Sheet http://www.gxacquisitioncorp/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Stockholders' Deficit Sheet http://www.gxacquisitioncorp/role/StockholdersDeficit Stockholders' Deficit Notes 16 false false R17.htm 016 - Disclosure - Share-Based Compensation Sheet http://www.gxacquisitioncorp/role/ShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 017 - Disclosure - Segment Reporting Sheet http://www.gxacquisitioncorp/role/SegmentReporting Segment Reporting Notes 18 false false R19.htm 018 - Disclosure - Subsequent Events Sheet http://www.gxacquisitioncorp/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.gxacquisitioncorp/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.gxacquisitioncorp/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation 20 false false R21.htm 020 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.gxacquisitioncorp/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.gxacquisitioncorp/role/NetLossperCommonShare 21 false false R22.htm 021 - Disclosure - Warrants to Purchase Common Stock or CDIs (Tables) Sheet http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIsTables Warrants to Purchase Common Stock or CDIs (Tables) Tables http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIs 22 false false R23.htm 022 - Disclosure - Accrued Expenses (Tables) Sheet http://www.gxacquisitioncorp/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.gxacquisitioncorp/role/AccruedExpenses 23 false false R24.htm 023 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.gxacquisitioncorp/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.gxacquisitioncorp/role/CommitmentsandContingencies 24 false false R25.htm 024 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.gxacquisitioncorp/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.gxacquisitioncorp/role/ShareBasedCompensation 25 false false R26.htm 025 - Disclosure - Nature of Business (Details) Sheet http://www.gxacquisitioncorp/role/NatureofBusinessDetails Nature of Business (Details) Details http://www.gxacquisitioncorp/role/NatureofBusiness 26 false false R27.htm 027 - Disclosure - Net Loss per Common Share (Details) - Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares Sheet http://www.gxacquisitioncorp/role/ScheduleofpotentiallydilutivesecuritiesexcludedfromcomputationofdilutedweightedaveragesharesTable Net Loss per Common Share (Details) - Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares Details http://www.gxacquisitioncorp/role/NetLossperCommonShareTables 27 false false R28.htm 028 - Disclosure - Warrants to Purchase Common Stock or CDIs (Details) Sheet http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIsDetails Warrants to Purchase Common Stock or CDIs (Details) Details http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIsTables 28 false false R29.htm 029 - Disclosure - Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable Sheet http://www.gxacquisitioncorp/role/ScheduleofwarrantsoutstandingandexercisableTable Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable Details http://www.gxacquisitioncorp/role/WarrantstoPurchaseCommonStockorCDIsTables 29 false false R30.htm 030 - Disclosure - Accrued Expenses (Details) Sheet http://www.gxacquisitioncorp/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.gxacquisitioncorp/role/AccruedExpensesTables 30 false false R31.htm 031 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Liabilities Sheet http://www.gxacquisitioncorp/role/ScheduleofAccruedLiabilitiesTable Accrued Expenses (Details) - Schedule of Accrued Liabilities Details http://www.gxacquisitioncorp/role/AccruedExpensesTables 31 false false R32.htm 032 - Disclosure - Notes Payable (Details) Notes http://www.gxacquisitioncorp/role/NotesPayableDetails Notes Payable (Details) Details http://www.gxacquisitioncorp/role/NotesPayable 32 false false R33.htm 033 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.gxacquisitioncorp/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.gxacquisitioncorp/role/CommitmentsandContingenciesTables 33 false false R34.htm 034 - Disclosure - Commitments and Contingencies (Details) - Schedule of other information related to leases Sheet http://www.gxacquisitioncorp/role/ScheduleofotherinformationrelatedtoleasesTable Commitments and Contingencies (Details) - Schedule of other information related to leases Details http://www.gxacquisitioncorp/role/CommitmentsandContingenciesTables 34 false false R35.htm 035 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of operating lease liability Sheet http://www.gxacquisitioncorp/role/ScheduleofmaturityofoperatingleaseliabilityTable Commitments and Contingencies (Details) - Schedule of maturity of operating lease liability Details http://www.gxacquisitioncorp/role/CommitmentsandContingenciesTables 35 false false R36.htm 036 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.gxacquisitioncorp/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.gxacquisitioncorp/role/StockholdersDeficit 36 false false R37.htm 037 - Disclosure - Share-Based Compensation (Details) Sheet http://www.gxacquisitioncorp/role/ShareBasedCompensationDetails Share-Based Compensation (Details) Details http://www.gxacquisitioncorp/role/ShareBasedCompensationTables 37 false false R38.htm 038 - Disclosure - Share-Based Compensation (Details) - Stock-Based Compensation Sheet http://www.gxacquisitioncorp/role/StockBasedCompensationTable Share-Based Compensation (Details) - Stock-Based Compensation Details http://www.gxacquisitioncorp/role/ShareBasedCompensationTables 38 false false R39.htm 039 - Disclosure - Share-Based Compensation (Details) - Weighted-average Assumptions used to Estimate Fair Value of Stock Options Sheet http://www.gxacquisitioncorp/role/WeightedaverageAssumptionsusedtoEstimateFairValueofStockOptionsTable Share-Based Compensation (Details) - Weighted-average Assumptions used to Estimate Fair Value of Stock Options Details http://www.gxacquisitioncorp/role/ShareBasedCompensationTables 39 false false R40.htm 040 - Disclosure - Share-Based Compensation (Details) - Share-Based Activity Sheet http://www.gxacquisitioncorp/role/ShareBasedActivityTable Share-Based Compensation (Details) - Share-Based Activity Details http://www.gxacquisitioncorp/role/ShareBasedCompensationTables 40 false false R41.htm 041 - Disclosure - Share-Based Compensation (Details) - Restricted Stock Units and Performance Stock Units Activity Sheet http://www.gxacquisitioncorp/role/RestrictedStockUnitsandPerformanceStockUnitsActivityTable Share-Based Compensation (Details) - Restricted Stock Units and Performance Stock Units Activity Details http://www.gxacquisitioncorp/role/ShareBasedCompensationTables 41 false false R42.htm 042 - Disclosure - Segment Reporting (Details) Sheet http://www.gxacquisitioncorp/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.gxacquisitioncorp/role/SegmentReporting 42 false false R43.htm 043 - Disclosure - Subsequent Events (Details) Sheet http://www.gxacquisitioncorp/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.gxacquisitioncorp/role/SubsequentEvents 43 false false All Reports Book All Reports gidyl-20200331.xml gidyl-20200331.xsd gidyl-20200331_cal.xml gidyl-20200331_def.xml gidyl-20200331_lab.xml gidyl-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 32 R40.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - Share-Based Activity	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Share-Based Activity [Abstract]
Shares of common stock attributable to options, outstanding, beginning balance	3,096,154
Weighted- average exercise price, outstanding, beginning balance (in Dollars per share) \| $ / shares	$ 1.47
Weighted average contractual life, outstanding, beginning balance	8 years 109 days
Aggregate intrinsic value, outstanding, beginning balance (in Dollars) \| $
Shares of common stock attributable to options, granted	90,000
Weighted- average exercise price, outstanding, granted (in Dollars per share) \| $ / shares	$ 0.25
Aggregate intrinsic value, outstanding, granted (in Dollars) \| $
Shares of common stock attributable to options, cancelled	(60,000)
Weighted- average exercise price, outstanding, cancelled (in Dollars per share) \| $ / shares	$ 0.74
Aggregate intrinsic value, outstanding, cancelled (in Dollars) \| $
Shares of common stock attributable to options, outstanding, ending balance	3,126,154
Weighted- average exercise price, outstanding, ending balance (in Dollars per share) \| $ / shares	$ 1.46
Weighted average contractual life, outstanding, ending balance	8 years 219 days
Aggregate intrinsic value, outstanding, ending balance (in Dollars) \| $
Shares of common stock attributable to options, vested or expected to vest	3,126,154
Shares of common stock attributable to options, exercisable	781,360
Weighted- average exercise price, outstanding, exercisable (in Dollars per share) \| $ / shares	$ 1.46
Weighted average contractual life, outstanding, exercisable	6 years 255 days

XML 33 R38.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - Stock-Based Compensation - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 212	$ 59
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	13	16
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 199	$ 43

XML 34 R30.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2018
Accrued Expenses (Details) [Line Items]
Accrued expenses, description	The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers. Through December 31, 2019, this reserve had various claims and adjustments of $115 thousand. On March 31, 2020, the Company reversed the remaining accrual for $164 thousand and recognized Other Income as the Company concluded that the likelihood that further claims will be made was remote, given the amount of time without such claims after product expiry.
2017 Note [Member]
Accrued Expenses (Details) [Line Items]
Interest payable		$ 394

XML 35 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - Schedule of other information related to leases - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule of other information related to leases [Abstract]
Operating cash flows from operating leases in lease liability measurement	$ 53
Operating cash flows from short term leases	$ 44
Remaining long-term lease term in years	2 years 73 days
Discount rate	10.00%

XML 36 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Share-based Payment Arrangement [Text Block]

11. Share-Based Compensation

●

500 thousand shares;

●

4% of the number of common shares outstanding as of such date; and

●

Stock-Based Compensation

Stock-based compensation is reflected in the consolidated statements of operations as follows for the three months ended March 31, 2020 and 2019 (in thousands):

	Three Months Ended March 31,
	2020		2019
Research and development	$	13	$	16
General and administrative		199		43
	$	212	$	59

The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant.

	Three Months Ended March 31,
	2020			2019
Expected volatility		164.9	%		122.0	%
Expected term (in years)		5.84			6.05
Risk-free interest rate		0.9	%		2.3	%
Expected dividend yield		0	%		0	%

Stock Options

The following table summarizes share-based activity under the Company’s stock option plans:

	Shares of Common Stock Attributable to Options			Weighted- Average Exercise Price		Weighted- Average Contractual Life		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding at December 31, 2019		3,096,154		$	1.47		8.3	$	—
Granted		90,000		$	0.25			$	—
Cancelled		(60,000	)	$	0.74			$	—
Outstanding at March 31, 2020		3,126,154		$	1.46		8.6	$	—
Vested or expected to vest at March 31, 2020		3,126,154
Exercisable at March 31, 2020		781,360		$	1.46		6.7

At March 31, 2020, the Company had unvested outstanding options to purchase 167,673 shares of common stock granted to non-employees.

Performance Stock Units

The following table summarizes information related to PSU activity for the three months ended March 31, 2020:

	Number of Units		Weighted- Average Contractual Life		Aggregate Intrinsic Value
			(in years)		(in thousands)
Outstanding at December 31, 2019		250,000		6.23	$	149
Granted		—
Exercised		—
Cancelled		—		—		—
Outstanding at March 31, 2020		250,000		5.98	$	23

At March 31, 2020, the Company recognized no stock-based compensation related to performance-based vesting of PSUs.

As of March 31, 2020, there was approximately $200 thousand of unrecognized stock-based compensation expense related to non-vested PSU awards that have performance-based vesting.

XML 37 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2020

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

7. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	March 31,		December 31,
	2020		2019
Payroll and related liabilities	$	188	$	531
Professional fees		176		335
Credit refunds		—		164
Interest payable		415		250
Other		107		73
Total	$	886	$	1,353

XML 38 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	36,598,291	36,598,291
Common stock, shares outstanding	36,598,291	36,598,291

XML 39 R27.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Details) - Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	8,001,579	5,098,391
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	4,625,425	3,552,672
Options to purchase common stock and other stock-based awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	3,376,154	1,545,719

XML 41 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2020

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

	March 31,		December 31,
	2020		2019
Payroll and related liabilities	$	188	$	531
Professional fees		176		335
Credit refunds		—		164
Interest payable		415		250
Other		107		73
Total	$	886	$	1,353

XML 42 R7.htm IDEA: XBRL DOCUMENT

Nature of Business

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Nature of Business

When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes.

EndoBarrier^®is intended for the treatment of type 2 diabetes and to reduce obesity in a minimally invasive and reversible manner.

The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled efficacy gap.

Going Concern Evaluation

These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 R42.htm IDEA: XBRL DOCUMENT

Segment Reporting (Details)	3 Months Ended
Segment Reporting (Details)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)
Segment Reporting (Details) [Line Items]
Number of reportable segments	1
Right-of-use-asset	$ 352,000		$ 386,000
Long-lived assets	34,000
Revenues	0	$ 0
Major Customers [Member]
Segment Reporting (Details) [Line Items]
Revenues	0	$ 0
UNITED STATES
Segment Reporting (Details) [Line Items]
Right-of-use-asset	$ 463,000

ZIP 45 0001213900-20-011182-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-011182-xbrl.zip M4$L#!!0 ( #J%IE!P@8F?Q7L /^H! 2 9VED>6PM,C R,# S,S$N M>&UL['WY<^/&SN#O_BNXLY.M27VRK?N8)-[2V)X\Y\V,_8T]R.H9IW__TYMOMT'29YP3ND'GXA79\ M# /*(<]=A@.^UWZ#43_K,ZW:UFK-]\W6^U9-N[RXT^K5>I6_^?A5/P( M;]8ZQ]7:<:,F7WNRYLSQGT^F_5?X)/QD+@&0PZ?P M:_B@=WROZ]/PX9'N#>A!\4/6V-ZQ/YLR+_,=^B7CI7O3F,61<_^D#_\.3,_T M@9&&CHM3X=*C=TS/:=9KG7E8XD_(%VS'MH-)]O.&[YXB<*?PT#$\Q5QS&%&; M."Y\,8L#PSD63Q ?'!\P$L03"VB?\A_EHY[KIY$*7V;@TP)>FH,8_'F@>RQB MS.3SCPUZNM;K]4[IU_!1+^LY&+5V^I_/GVZ'8S;1CT/VI%VI'6G:CSC&>X]^ M_LI&&HWY'A'RTQO/G$PMA(6^&[ML]-,;8HAC2?*3)\]X?,TT M?GHSK/[QT74FM5]T&Y^]:L"DNK-UN=7NW'T^@U9?33:'CQS10([!CJ?( .U[\ J72& ML"&MJC!<]*VF*0\SVU >;0!9<0[^G9PSFH)P^,_SK,YL,F/OF;"N8 M0CRP^PD+24U?<67VGCU-+7-H^APBS3#A.6XL"IOB_:T/","W+\$ \&=H%#HV M_.GUGTSOS9E\++6Z'T\SIPAA #I(J';(R.T$D?J&03:.;MWHIG%EG^M3T]>M MB& OB&1SUYI+/FV_"-A)$/ K\W739L:E[MIPRO%>X%;+7N+SV&_=/ OQ(![+ M(-=.+=M>+FT/4G7#4G6W)YK<8]\<:?QR"+Y-<;Q;.M?BY[ELD?UR"+MUD[:< M@V@M<>PN(GU?#M%V;-261,)&@H0'.;KG>ZX9.X9T#Z*Q[--'MXS31ZV5(--! M-&[QO%\."=L)$AY$XY[ON;B'IKN]7;6;Y7;S7.,'G5#Z$6CK/OU:+Y>Z!U6R M32?'UBE?K^92_J"!7M .K\><' >IO8E[A!(.7/5Z@DP'\;O5F[LR2-A(D/ @ M1_=\SS7C!-M?2[ZLN^S#+ M'D!EEP*H>J'LT\D]"1S8Y]FQS_8/&/DA,-=3Q&V/ <'X!T:+&_U' MW35BVN? 6,!8JR,QG]^>L;#*=U@=N.VE<]O695N#.\GJ@L7NG%IK/\\*22PU MCJOUPEBJM=;$$GY+B*-F7S"CL$2X MV+58@GL2ZOW@GHO%>DU\W&>6 %G7+2X6N\?U=95'_K'\'%1L8"'^Q;'A>=DA MYY;N ;,+V*_=K^;]V%>MB)SUO< 8TD8G%4-Z(.W>AK4UY@4S'.CV,FX\&_EY M&W>/SMW8"3S=-BX108S9TF_SPLB]<*4O4!8WJPE9?"#WALE=MGQNUG+E\X&6 M6]RZ6Y?9S7J^S!:X^))']9= \KEK?)%)=LUD2LB!SL\EFZ>96RWC0,27&2S: M3.:9*#KJECT ^("'+X[/GA&=;\>.Z]\Q=W+!!C[&BN3HX(SU;>PBM^S@_29/ M+JFU?@EPJW8RZ7;+;--QZ3J(&7!,?&"N;PXL=@-[W/0\QYW%*!O!_Z*HNPP6 MMA"1V#FNMNEB9BWRB\@.X97NX/U5B9QPX(+-2_H.^NMKS2*2/F29M21]-RXQ M]LRA7_H.B843=-"4X2JN\\?YF'G>!9LZGNE?P2LN\P2%2Y&B^[]Y<,]< 6[= M (>(^1)S4;,P".#5[=ZB=EI'ZONU2K158W;:@8D/3+R^(5*"'=JJ%7')'RS2 MO6.$G;J(6O4BWN #U^PUUVR_3*ET+.YG2$H\JZ>[OFAM)F)Q]G7A:\7BK,T4 MR8BE$$L%323E,H;OL&^V]W+.R3NWDCXY]KV_6,JM3(7M7)EMEZ6Y;Z_]+.IS M5]MK2CGNR:J'!F2M(3[NL903!E,1EN"/UAIKLD0W/P#BBVFS%RJ]BMI(JZ%@ M"\[^AE_G@=K[IO_CAD_SN%Y?L]*Y*& B5GOG[.O"DUJB6=P:YEA: M1R2T17N.GJPG_MFTS4DP>1XQ,YCC_56W[\6.QC]C\&_C(H[T5ZVW)K/6DV30 MGYXW&53XGP\9&D7\4'=CES%*S*'XL^?Y/.7^#RB0]OY!4R^./;E9&HY,\:\=&;O,R ? 9VT M7?-6]5*W:#O7WWN@;_GTW;IGMBW"43ZR =^_]:[X^,>7RPN1>?Z<9&XV41-+ MV5(5AGKQG5H_KG?7I*2,$I'TB[*+G@/]%I:.2BYG&_JQOG8P2[N7V%\'^NQN MBZT;B-5))C.IRN+Y'!OGDC&]I.<2 M])MHZY82YVE,:VM%1KY9F0*$>3A8>* M[%4]C^-")]DW1ET-'H2^V:;_O(IR9AH<TR4%G+J="0NKJGYRAE2E*5E-=>%B7V)1KTY^0M&!_%LG_];/ MA9U\O\[/S&8N& VVT3!=B@4(+?IEU2#OY[I\#&^R, M#;8O#9(5=;[=[CEE\9P3TO-GYMR[^G1L#N599^@$MN_.WG^[?3;F6'Y)U\_Z MGXY['G@^\+#['-)Z^66E"K1J.V;2 MMA2\UER[I&2WKD1S(3L?2+9IX[Y@'%I$W[4V8D.*JYDP*<2G WTW1=]6VR8GKD6LX)-F$Z5[@LC-__CCJ?R6#X7OA@!%(P6>H=CZ\A73 M2A(H6-1J:0Z8]ZIYF L.8NF7-M+?5 MDUY5FZ*PQ^U1T0:!3X_HQI]@Y#-#\QU\J%.'E[0OS@.7UEA Y\?3V+K.LA;; M=^-LHKM#"39\7+!:\<3I2!_ZQ\E5CX PNV8PWXG0[K@&HU?I'3*'/%:%;@V*'3+-;O&^!AVK7@8_G20/V0Q^ *TLX MYLB9G<+?#-.O6%R^*;,F!X+GQ3(KXWQS=+&&6KERDNR^1? M'8+3L^V;^[4,<_\C'&#M(3"+1O#=@PG?#^[!ED>CO<<-_%% [*09IJ'!V)HS M' :N%MB^:6FP\D!W9UJM4=%PW2DS?Q_T\39Y*MP9M?C.V(R)OS*X:]CW:\^9 M.O/LE6U?%DKS&&&+5OUR1;TW8M*O \+N^&2'"-\TV\PU$$J6)ML'8-^.@-O M=B[';,F*7[7^?&E,LRX SXII2L+V J9)F'%X+R OF@QFON]/F&W@E=A'2[_7 MQ$W45Z3?L)K'U&_.1KKEL1]/4P.<10.?!ZZ+WYK>4+=^9[I[R6_!"L]Q+ MD MSAOM+)SOPAE2D2W^R U=L7V$[[S"$_ZWF"MW)!5O\8<0HN4FXQ;VG)'2*^.0 M+(M&-=(I=[2LE>&U:^%9:M7C_XZ/CZ^'MUWXPR7=M)[#3ZYN78'9]O1O-BL\ M@7KEG#O:67HZSC=?V=1Q?302?=U?@DJ_X[WAHM&BK18]>3EA[CT\\;/K//IC M[!ZMV\47JVRO.<-ES?O1M!@WC9?!['&K5>NUU FC<(I5M'RM1%)[OYROMXOK+^8DZ>WS,]%IOQ\RRUF9<=904)]U.=,OZ$'BFS;SB>])W@_@4ZB@9$B#J MLRY.B)%*UO "G2:4*C4&A"CQ) )JWF@&&YHPF??3FZLO']^<-=JM7K>>$$AS M9@OC.V1#'-W#C!3\S^7?@?F@6T!^K^^?@[;' ^VONA6P"$2,X8C#E\C#4P$\ M;@!\W583-O>/ITM-6#J4C5CI]%X2RGJSUUL?RJ\,>-D<@F3)?GT=-%9CX"V: MZ:PTN!8@;BVX;EPVU4U#I#W T]?^F+E]SV.^)\7:ZBBK-3J=&' %I@MMA9) M7("]6CV!OU5 + M?K7J[%@,F/>UJ\RYBH4ZKM\R\-ZXS9:X_PP)'/IYG@+TH ME>X+6V?YC6:"$OFS)/?]JA M0$RSOC)$UU.T<$!.?6*ZQ^@4>#WZ!AR%J%T' M2:TX3'/G.2L'I$7LTVVO"A)GM'6V3+O9R6#=96=9Q >U;H%9AI2)Y-WH,SS9 MER$.$M(@([D55P)F MD=YHM!K%H8F!$Y;3_>"X<(Z#?;+6!JA6XPHL8_BSM0!8@(D5 +A@+I@C>. I MER9Q..;-,E]:R^=G)9A G>HH2"+E -2=YZMD3%72M:M!=VB$V.M MLR9T"IW7T4N=:B^/?>]M MT_KI#;I7GKQO&"9Z)G7K M!HZF5_:Y/C5]W5H# ?5NHU>-X@G3I%L/R 6H R";S5Y];2") M]\:.93#7PS.M/UL'OBS-:9?A)-&K===:GI%?(+X*A47J=/IHKGF M6%I+P[;LF799V!2Y=:.[UR[=FQ@DPFZ82V[O&'A*8$Q1'-;?G%5/,,MRB3GG MZ8VUX)R#S[+AY'<&_<"'HY3Y#S,67%#,P2#=4'129[0Y<\TA\Y)@S4'8!L"Z M\KQ@;4Q%=SD+YIEK(2P!T"(,&Y3XY7#D:.\U$2S;0F,(719SCU"Z$F#H 5CVI=B.H%DR=(%,9@!9" M(0>T5E\5T-\89=H9_0?8R?=,)I?3FXK7,!?^U5&@\+R9'A/U[](G,I@+("!S*OZ%:'IYV )^<6 M/ANVC%O\DL'K),!+7G1GPY5U1;[H0KA/I0\IGN7.R<$"<<) ]YB!64V@H4CQ M?V4PG ='MEOF/IA#QI,KO[*AJL7I MMNDE907>[ Z)M5R]D:7.BW*@K!"HRSY"DRG1.R M9$IRLC]J2=;L&O;9$Y% 2RM U$K =%R'-9N)%/\2@>PG0"P*(>U.[5$ M3G#)Q[E:_#S73VG&;PJ) M]6HN$I_=R:VPYWH7%%_-N%MOIZXZZ\H;:YZ3I_#T*[#DDA<3ZUJT]9CY6,@_ MNVE[8SF0MF%OU.L)B):V-[K5S0+82 !8V-[H-7L%0%L#LF85$0R=)44O%4E8/6=N*P463F O1? M;BB.TDJLV!NS Z-)#,00#WV6Y!?[*LTG+ MG[^XEHL7,RP\>>9-6A;.>8I4&0R[V.U2POQ+R,XB')\C.'6]ENZ @?RTYX5(,E<%1&=.I64. MR%C!@5/A[7B@-_4>E=?&54LN='= MDA)SFJU>1[& EX5A4_ O=:Y<&_X%#!QV#BM9WX2X7W[^C"""$B OC/5D2;:E M (\5/,BLQ[HM.OFW^4/3UWG.$O)3JL5YRB>#V#7G81 3%'W!DI>TU) M,PXO8%W0>7!$FV5T-U_*X/ MU-G6EK@$YH]^_!_'Q]K__>WSKZW_]W__,YP&3[_;K9[Q3^?A_O>9_>TB>/RY MX_8Z_Z[_^>UNYEF=A^$_5>L7_]2_9;_\TVG\]50;?O*K_^?CQ_KMOT\?GCZ< M_UY],&[=WZ^[U^T_/UO??F6_?K[]]9?)Y=V__OOSI/_D75NWG9GQI_OXR:E^ MJE_;;O_ZYFN[_>>'\T'C]LO_>3QM7?UB?VM?G?_]=_5WZ]YL^W?CVYMO]1O_ MP\=J\/OE8_M)[WE_7W4:OW_X>M/]]^C:;?SKGT^U?G#;OO_[VR^?9I-_>;7' M\_ZI_N6T_IOE7'5__E=P^FDR[%8_5?_S7]ZP?E;_Q?W>YO_S7X;%W8S?Z__K2?/(\-+D___N^??OI_VOGMU^/C1%$?]UZW MQ54=$-%S+-.0UW@W(!M ](N;&F'CZA:5LJ-S'A+9*1/3&OV M?M%D]*QG_L,X;/&1!_BA=H(;_POQO>:,M ^RDQ$^<3J0SY[B2.$?TW (]U1^ MW!P^Q)>F;3 3SC@^Q+>: MZ6FZ-K1,&T2$!0#I]TR;,(/^,AC& P&+\694(VR/QPS-L35_S/!769Q,TVT# M'YM@FT6L[,!OBH VE[;A? #=8#*WPD'3D\.;P," )T/S'%ULL8> M089IV#=2JVN&J0^8#UC!N>!1EQD!O.T,F&?ZLY/72O$+B1;$[00KM&&?/8&S M=Z"6'.TOVWFT-=U+8O)[3GS+L>^/P3"9:%/7N0<9Y)D/R .^/@#I-(3'/6IO MJ0W'.K9-8[P4Y6"FCYQ0^,FTO 'X" GDFA@4-685HQ@EF M:/+W*:^L HQRHMTP9VJQ;'J[&.R @E'K58][K>^0K9#_'AW7,AY-@T6/3ITI M5MZ%(7_@S.;8UDQK'=>JXBU3?0:7#Z_>VPYR=31W+1KPG0Z8!\S R^%W(9(? MQV#-P4+@+Q^ !YZTG7!U.!,MD!G?OUKF_, P#HT( >;*(V4A"XGCV#R0BF.1 M""JVO1!4:'G\X&D?/E_A&_"!>7.1A4DRDZD > M)!%5 7Y EG&F/IX$D%JZ82#M56**I@@@D$C4O'HLA_8X! ?;@[["G7G$C5=3MU'C,F$,A.(IT#CLGM8#@EA MQR;Q/'("5]F2PB+E)V02DG"6MM!2&5J!P4))BZN)VZ9"*!]%4EDQATZT*_'B MD)@:!;('9*/C.,)E>G]Q0 W.&T8%"*#;)&81^1$U-,.!EVS'!_V%0"APJ#*'AAJ076AX'61S)XCMN(X6;.W=+:KIU[X ),9YXF=M]!/R@>7AE2DQH M,-VJ< L%"0['#T *Y\3 'IF6!>S$1KA#AC-@].D)Y^R#U$U*76PR+4[YVH/I MB?,,;/R)_A=3S]VT&6 3 )!P-H<]8B=IB0.D*SP&1H'H#A_IAD@U5- BH]^X<0Z$8S;)A8%CS) S0Q\(PZMF MDHZN$P!$,1<&BEZ"> K03UWTM"((H&+P4(F-V>F7!SAX5TAX\TIU.*TYP1\8 MG1W$V9>;)-[,PP)U%2TL;D@@1HC$70("$K:2-P;<581V>#(GYC^D KTHV!$TK?H*?& R=$BX,ZO"=!S2 !,V!#4K>F1XX%7(B;%%3B M3MTZ_I/]&=C(JD]@H-!V&@I-/$"A25>*\'&JPPG$"T"^NJ_7079KXEXFO]30 M<4%$D&51B6VQL8Z4>' 0@UXP0.L(926:%J"\4&W!5@7)Y.!1'2@EMF_:Y5E! MZXJZ-W"C)'*15NB(+SW54PL8 ;8N/C]T Y,V/;>&0G^J#TP0>F5'(]CU%#9( MDC 4%#I%8@L'FVZ2G!SRG+2X.(Y.G^B-H??1%K?))'89BDX*?0Y!]-@]@K)S MOMFJ^?.S0PZKHW,X&S"PJB]1FA)E#V9'G_N883=$@9OU"H:WBW%ME+.;(BP8Z34A)&0G!OQOH%IY1P*I0+1UX2^5D/&7P M2PD^%2P0S00:6.IS&)6T,3\O/9IHCG);01L%="90M#?L_HE)/CLNZ:<@$[C= ME+[>T,/@,V&D?H,GK;CN1OD[A%5XH\#"W2;MAVR#@;N10+0/N#_98Y8U#[M< M"J'NL?$PA4U9Z(K%YZ86V$KL1,.+8"?P20W9 5(Z@5"762:>1V%)HX"G#CL# MGD6JC5QG@MI,=&*@XZ:R/C(W07_"/Y'DD/)%7#@G<0)G7^V>&J& [31U0'VB MHB2:C^"8Y_$YHR$2<@P$)YSRX*0/AT0_LN5(5PMZA@# 2BS'\X36UJ/.?""9 MJ35?17ASZ:QMHYZ.0/,"/(:8W(/ 4:<:LV K>+ A=7Z3,0*)RTO#[UQ@SIT_UN%K.PN]9+X@>X.IRH_J;^O=CK3& MJC^ 0++"@?%"YR_NT1$]+I51WM9.&IIX/,X0Z$$?#2CB MSF^89P8:&]BL+Y<&N,@4;GRE\?4T3GKI]9#+)UNNG>P=1ZC().EH,V(',G(! M=A Q@;@TP5M"Z3:!Z6T3L'G+ .GP @])\P<:)A-[P!WH)AXR^-'[XOJ(- MJ/XWD&\FQJY7-4'I\!6^N $R-'*6'EC+@51$:?"!@\&):Y^+% M,#VPKFD#0&AL/(?KKB%/T!%))NC\0ZM# MG/N30@1]TH[SESBII["/*$#/L.L$]V-2MMQ?'88Y*,\>,5X:@=O_ S R9+"Z MARS E1NZO855!,C\E_.(DBA])K$=[3[0,;".,>X;S>;H&)\AD[J:.5+XO"(V M-K#<@ FN"QGWBV#(+&9, F$HIIQD28*+Q@<-@ 4[#-2>1YA .@L/T2K82V^9 MZ#DZK4>K&H!9D[>/T X")AZ:4SKI$)21.B#Q+-''GL8Z[#I^?(YM+-H.>.- M>T[E"$E4A0:4U$7;!R\@4 YJ7(R&NRF^BS1]Q"^8T0^@(U[NZ'H:#:0!"@H\ MW04N>>H)?%Q69)!&(#ADS6)H'UXR2(#T!]VT"(PC,E91BW/#$I%=00[!,2TK MI(>R&R(;E&\&Q1B2='?L?-,T0@;(<0L%#I&#-$ 2$C)TE=(?$NG:!P?V,G+/ M!0PU!%N96\C\;@86"#09LI@SQM6&E!,1X;@B+G%X',)19+(K'E&<7QP(XF:Y M%5T*.3'[/^9?)?3I9.33>X:[ ^2VB M YS6[+_<8.H/9Q4D \A+L 70$9TA+'%"Q,4]'K;WSQZZLL.-3IN$[I*.)(;" M>Z8)@\,6^7*EF!O )"JF3>#>*:@QDZM8& >12X4UC(!5LA"OV"*8M\R'@Z.L M;L(^.0HC3_#PXZ.]#).0,G^4>T(WT-=(EV+D2$?4 LQ4D*AF8$\$ 8H M<[,B0J87QB23TN;F_5XBEALEB"R! V5%V0LBCAPPAN=ZL&%0#*(>GN#[ZNF9 M9/8<1(?16!BA/9E:P@Q!WHY\2-*EQOVXM"LLI5Z"C*LU>64_Z7ZQ'7="+ WV M/=EB4B-PJS9_R9D+UHX,AT2:C'<@@SZJ)\@U[,AB8J.!)=(@ M %V-T7Z2&VD)L2I$6K1>8>#AEIY0*8R])?+!,%RI"[&3>T_(,4F_E5EO'P>IR*%$Z\&RE *!=1_\L M'?JS+ UB6?*BH=+7\![MEM^>*0E74P!AY4952A'Y_+EBM>U^X\Y449_R0GA2 M5TS9;6%V:ZP>0N;PR?IAD2-65#J"-VY05&"AN=>C2)'V)K M;,A%O*HJDF>3YH2F2([U@>:M8D*2X.=*&]VCF388^3(164*MNX'%Y*OW8HLJ MONDA^OLD'B^?,)[BGFP!<;V'(+PC]S+!>WMYSC]\?Q*Y\Z-/2"#R*UIPOA66 M!HARE/UZ>.@>.8Y/WETCU.J>,-7(54G&E4&7 V"26"!=8AB)XR1$YB= M_$"DA?2(7:8NC&M.$17\XHJ"%LC#PM_%)7ZSR0E+9@>AJ#\!"@]U[1U?\\_] M_HU8O784H=X!L]-/8!X.C>-LU&?BC9]L,,#&-2<%3%&5$[0CS@O>6)XG70QM M)?39?X+!QS,Z2"VCT1L8M,IBD_"AR;7'+XY"VL1,1C!UP5@\ZMMV &-PD8MV M[D=4^K7J\;_#"R4Z2O&+C LV9(IK&]# ?3VU'OE+C AFX#HX9 MBKFH)2SB6AR998P>"-"8<^9#_RW1$M,8'L)+%@5=V1CRN2ZF R$Z64/]&AX1 MQ,4TQ=5D;P/%"P@F(/(8(2N#]Z.9]^\(>07[(' U9VK:8=@03PV9SV0A2PDC M$+4<"@U$G'JVLADZ83!(@N**N T[TDT7(QE@XFAP?E7NV/R<$L9A)*D>>:UC M7D!:0^3#LXW8C;L,?!N[#"QZ '7L"6:>-P>RV F <;%*@NHERM00Y2#B,/:7*,V%0B*(@)F *:HJGG>QQH2/"X&7^ M]E31HJJXVBC/9:C_KT!SNK[J&P[):57_NX[MX&F6,)E0]7NV,?K!/5Y68MD: MOC&./O9O/\C+WO[M-^V+H^ 9GSNN-2I:&&3^$?A3NYK M!#V$EGMQ>+ RJMG Y*HXF0X=3>RJ$^.DXC>D+VYM (6B=#4L7X=>?PS@0Q?3 M5-Q9D'.4^6/'P!/5["2^%/BO\\"B]!2^U<,'$!-B0@RBAIUE>3*6F7M91/PI MQ2WKGD-G+P23$D#@>(O>9_I8AP.>;GLCAE%SB#\4=.(]/GR#B(((X>B81 3!_$@J7,&,.#KEHN7"HAM?&[4ANI70 MB< X+L/HBU#JB54H/B($0G4?*=9; O$@L12TJU8>7H<*/C2Q0C)W\<'#&.\E MW'I1 $HD#A4\J(L'I6&AUU&:LSP^$U\@C4PG7F5V05QZDLQ<\L*+GK^:SIO^ MXEAJ:(QI3P,\GWH""T>$_>:FGRR$B2GG!\1C"ATZ,012H* MWKC_KP#R ML9>,Q]H+N*!"8E'C_-QV.X1VPLG2,R'B*/C5#QRALQ'V=D%-,] M)05 .MZ4DT"X7\BY1>'D#H:4D-()T8Y$XE9M7#E&1K")]\G\9'*D4(.'.SA3 M[I/K8WPT7+*U3S%CMB,OJF1PZB+[<9'7N9AO)5F%\E%Y-F9G MT)LS_N\=>F9>DZV$W'0PEP[FTL%<.IA+!W/I8"X=S*5RS"6U>/1R]DZZ[+YL MHG;#7&I1LS>FT8;OIQK(/E@%E=H< M-HO!.?1EAX+O=/&ZQKI7M@<"&SH!:U M))*&'$G4;I$BJF%#!"*LV#!%KGOXQH!+&RD[CZ7LM.F"EW2D,AZ(:*6UHQ&0 M/J3\""X53K2;6*H:OH=!M1I3JALC7& )H!# 3,T! M@%NTAMA*^1*/9%A^1;S'I0&7U2+&';\_IIZCFOX(IH=0?T]\VZOAN6*9PARF M>"H1X4-1K"3#V!.&X*)A@+<2H /)V,01E+C*? "@2^B*08L*$>Y+\>*N%P$-)97)N3PA4QOB!!8>D8Q:7$X2J!UPO) M':U0I?.CJ/S+;T6P791D*I>*U2R) &%/'B4O7!)B; M%J,PI_^)=A&$L.;=?&BI"X]*_O9Z9.H"N"60P4P\$"5C8>I^KXB0X5"SD_Z. MK\,(PF)SX3@RGT\D$V"<-2_+.""9Q6WA7*0^ZJ(L')@GFKBM2ED=>Y[AN.G" M*R/'LIQ'?K83$M>::2%1O"CT(+JDBG,U\0/IAA0_A-H@-*4SI#_?\K2/_XW@OPB(107@I#]^-34=9B+#=)-,,'-]W)LI+:.)IY%7QC=B; M*JNA]<]+(2#,:IR).;1D_: )WQQP06.%)*V9U98VLQ:$$C &> M;3%'.P/)&?.FE_.#)F@A0?E@87%( D@C"UME=I2(G[E$O$2)J# '!RY]-SP? M-YF($/M-!;T UD]]5Z!)>Z5,4-\&$Z!0V1I--X7$G>.PUMO!OBB^*V Q /P] M><502CON>\V]'[RK5YN5>J-;J;=:WZL[)W?K"&G>:7\7QYG%1FIU56DPJI:A M:E/-1Y94&=\MWCP+(:W-!;0HHXK!>HG!R/R-1FM6VO56I5EO%5Q>B9 ].UPU M*JU6O=+NU#>)JW"K++-38ON@D Y!:!9*KNMIF#>8N27FGJA7$"Z+^"%O88ND M7ADLLMP<*40T5S6#%Q(.1B1$D8MMC'FR)LBP1O=2K4*_-%9DC>:F]F+A3#] M7%'=JE1[W4JC5]L.JN4FY+4TR4^0&ZN2>XN2S!<:CID16.QZU+=]4[HJHE2. M2^%$P_!W'/P=!W_'P=]Q\'<\HS/\P=]Q\'<< M_!T'?\?!WW'P=QS\'0=_QXOT=R@).:4[+Y)%9M8HGT6IH&39FB:8@& !1E@J90T[04PGKSOZ2HAI@+T'YMY+ M0$PWEV.$D9>)E[YM7*-Y1W^0<=+AN5B"W 5 L, ME&>/K>+UL;J@=T'M/OL5-_/8([7B%J@_T'X;7?%%&,A\96-5;DJ= %[\%S/N MX=U^6$PYHXSA:RSKU<2Z^$>JOT?NY3!_0HUW)E/B5>=1W/$*0E%$K<>H3ZHS MBL+**:A:C7ZE+H$\#T"&M^=$P6KO'K-\;Q1K'N50822M"++%>NA:JXI/*$'1 M5#3G^Y<2,EO"_<'F'00K3E:6"WTY#WI1=W:68SV"Y(M,^TE=.U$Q=0N+^29X M[17=4I2#XTN1/J2B.#P#3UUSR)X[6G=\B1H*XKV^ "IR+9J!FN)H$"8 R5ZV MP%]=WMWI4HM9C\Y7F*2G7>C^@@VS&X%<^G*Y>?#<9$%C8<40>OK9XV9Z\TTY:;M@QJ4FU2]I;A&J+(0#U M;J75V.C]_\J(6@M+;\M 3O6DO>"">S>H.?#/QOGGN6%)N:TO)(Q>LUEI-A<(B)5@*&Q+%YMI M@2R<*P 7Q8:5O[[=D/-XJ\M\81R[HO#94*10XA005<#L1<*LGA9FFXTORSHS M+)@D+%S6X/<+&X%X*:1N+')O041OJ]>N='N-M0?>:JQA:9A=(+Z71VCMI+K: M*7YW<9O/-FSSF3+O,\;X DV^@0#9702VI\-AM>O$9?5E=%F]'$K6"^ LHND6 MSU 6F$N$%V\H%G8NLY8V[M9"=P\(W1)"]SP0NF">U?[@^?G&G,/!K5.'?Q:X MH#<2<[[QHQQ^\UNRCK>LMYH3'%%0X*_NA=C)^7R5(9ZSR^59K7=U']KBT]8S M7^!&G(2I[+/,8A\T5RF1C\N&M1[[SO0]AK6*/Z70K<8B)96%+I:E,.*"6.(( M&]EW!XEJ[0OO&JHG]99ISU,265[_7-*FX+V,B7&J\BMYL]#_1&\#:Z:]K9[T MJE%L;(7J<%-E8FK_R%LZO$5.Q/+!7YP'WGC 55OFJ$6NU[FP M?N1-&/"$ZU(S$&,YCE*#98VQP&KB*7%O/3R M NBOJ8_U9WT6R6\1)5&)]>Z@XS_U*L%6(M1/(["H0XY^[S+>+T5M\RSJZJL/ MCDQW$K5U\GQ7]]D]5A0W'DS/<6<5+A1Y=PXL7QZVWJAHXP 6A=7\G< =BM;1 MNC$!L4+C4-5]T=#94UL"#,RJB$SXD8C^M7XX7N.$37U()@B MQ/P66JF&'^LY+0?H_> E:B)@)ZJ$2:ZD*;"_L3T-%[_MIFS)$@)(L,A[%],# MA*,\?V DM'E.Q=0D>+ AM8BVJ==.M'ZJT#CN63\^>ICTPONW^++L.8?U]9:, MQPUZ)(5=B+R?K[2+F0U##_E>.'=G'GH.^Z0L$YM5*2@?\E&T:ZE]%% =7YUJ@9+LG!SO$,BJORL7M'=WO3CS(P5ZUV36KB) MWA$BY=F(>%+\H@8L<%;A[*/>_?&N!+*K$T4::3I[USF4B'0GR'-R788CX+X=]S/*=$$3P&HJ=:YPV#+JYD*Q>E;\N)!ALB MZD;6EAM":4/B<01CQS[>WR;>I(II&2N6F!3M*VQEYJ3M4$ 213F5ZR1 G@F# MZ,=[TYA9,%38K.QZ))D\EB/9X$F2=9'Q>>?46C+Y\PQE^6ZSY HFR?UXFK_< M='^MN)7KQ:ET :><0,,DYEH_4A.$/6H(=2GU-V=XLEQ[,5M: MB6"O*AQP,U>BEG988R5\+_',P.O1MS /D#*VHS&]!5GEC0:7+)W^%'FH?><( M$K13:>7U+EBF[( MLPG>[6<8VB%>C13@^H%F!ECFS/4J<[_/3 M+BJ"#[/HD1M]AE]1589+M*/I8[,5WWR&K=M<6Z/^;J7MFJ.S95-V"H%C.E^#-1]:E0LD6V(!BL M2@C*'?UKI3(=^U_;X%#:8)DHAT-I@WU(;#R4-CB4-CB4-E@0,70H;;"AY1Y* M&QQ*&ZRCO0ZE#?82AX?2!H?2!J\GZ?I0VN!0VN#Y\<]SP]*AM,'\J9Y1HOB" ML.5G'[6\EW'VA](&Y<2A'TH;%!5[A](&A](&A](&A](&^XGPYXOQ0VF#0VF# M0VF#0VF#YX[0/<^W/Y0VV!JJ#Z4-5O,[K>Z%.*3Z']9[*&VP2R?A@M(&KRGS M//2J',3$\FQB@C M)G)$\CL%1]$68C31IO1,B720*UH1EG+3HY9?RMII4X++MI$ZU8FG0A994]DY M55FT%H_5+<+*RXI3..G-W^L^/+QL-'+I>S=HW,W M=@(/ +^D\QRSY5 2%7%M\).>_] P8^,E[ M;YO63V]\-V!O3L]V@*)F+5?G?YIUO/Y16#B2Q'EL_HX9\F3 MPMK:)\:V92J@E1=9E#-7)T:"+9NM7KO;:VRWN,%:FJ>15 KS$;J"VEENAH3. M0:]C6=5'MBI/GRO++BU)=X+=9KXJ*06[JXZ?H0!?FAA%5/$BD9H MT3XS'9%"M>?HONUT$'J(7V%%32R%=T2><4\;,,MYE$7J--,>.>Z$BAYI^L ) M_/RZJL#+S.<%C"Q3'Y@6+U+DC[&XGY@<7N1DB*!R(%#JRY6'/'11\_ M,;3! M3/O$'I@579>"]6I/ W2?^X"@?V#Y RR\RVT#_@M-!(L_0O+ ('0AY^%=F3ZD MLK[ 1W\AIK$,CXF<@M=)$OWPG8+]$^UC4KQ*$P&-9(<"2[V/5)U>S'8%2>J,"S/AW8!(SQICBB-@! MYG>FFHF8?K01Z<&$R@AQYB7 1NB[C-'N&5Q)X8% MFY/5C^GFV&6,;UI15EFEBPOVL1@+BZ3YR'%8G IHZ,^ [K+&Z FWW*]M+0V. MB5,D( (6!4BH[AH6[0;!95)%KFMB_RM[Z$S8JR7LN>Z-*X!-W,>PK1%-0_H* M],94-ZGP-;,]L;T=0AE*>%0I7%"%Q M0G2YN';0P0 ";'VJQF^"$L;B?K!S"2N)W0R(Q%\&NH45^#QNQ.F@3G52Q]0& M !E;PR+YIMB,HQB$IA^(!@0X/LX)JR &RLHX@2S )[F[H;(!;Z5$P:6R_ 1N4&MW-O@V0WPD7I MHI$#LX><.BX;H'HU HKE4=DHAIF3'"FU$;F3N+J48]QP%0(#]+D.^11I@(PZ MXGLIO39\!.Z<$!\(%7LI]?/A\"M1 M@)K18A':,*MU&A^'>P17WA%/6^?U\, M:_M?Y3,,,=Q2H<]EJR)IL9G**@ 534HVHG*R7%23WD@AX1QB4_$RD'Z$(AY47JI^V^ M+EBMFRY/M \5K_8".:U&;9/(V6+6O<+:KC-BG@?G"&R'P#*8>2Y5=E/N9U&^ M:.EI9SM99J.Q( -YK>2S'0C;?'B%\\EEY-)8@C2[3.\$+=G<G$<2CW#O<&5C>$"GHMP *BVXT>1(H,9;UX'5O[0 MM,6-_[^8;OGC(=Y?PBG4"(:^IWUE]X&E^XX[T_ITS1;O?/[Y7U_CC?;B=Z1\ M3HIQ\;0AP.Y,L%V:QB.37.8'+MY,8" "W@C:- ^ -P9P8I>D&HBE86"):!H- M3$81V>"X8A@/@Z! @GEB-OS#%KWR\.;0E:WJ4EK8=W)?C%E&-" M BN]34/'XR%:R%,\,,_1WG8ZL7?%_>.$31POZBOO1)C $,^[,5@W]^-T>$<8 MY8/188PZJC_HK@G#8R22.>%$XQ4J^$TJPE^KM4(8J'==5B13%(@D,"9Z++L, M+\OI3A71A!X(0/!;.'!$ZY((%5>Q:FR1IL>#$O'.E?<(I)MD_,DR_V*6.78< M\=TH<'D8#%\1P/%H6I8VP&M[@XE(JHGCLXIV;P)%E7MHNN>"C4.W^ACF27?P M$C4C.%F$Q*.>]K.3Q(Y^'7>%5_PV/60OS&+F7" "?F9*X\L.;QN): =@F6UP MAE5YJ-9#MF=/PS'6R2 &F?*.H\1_C5[$*VJ;0\%AO,VGW(1A7*5C)R UDAN MB.Z)UD^^EXZ4$FTIO=381]'@GHGM&OQ53J(KWCIKR9!BA?D M+;C2#K)P:,!&!>H^2-.]D*5[(4@W*$5EF$P^0Z:2.Z2?1[#_.8]YA%WP!18F M B#5C)5DHDI+Y"<"75$0J,G(M\B6F.6%6S6=/W?<>',&(JFJIB@6@":C#W18 M]RY,_P09'$(LBB,G$.0 MQ2'(XA!D<0BR. 19'((L#D$692[S$&1Q"+(X!%EL"=6'((N%[Q^"+ Y!%OL? M9!'Y\8N[Y&5Q,?GFY61J.3/&1.JN\M[YXMN(>KQ88O*VH=;MQFX;%LZ5NBU9 M"[I&[*JDEX0.3O-K0B=PK1ZA/[)2$-=IQT";/U&2I*N#M0!C<"!= ZQS<3GY ME0YY$KVS]<&"\TD,K/D3)<'*O@);@WA@LA>X8SM;%XH%2*DC$,M"069I6H*4 MP-#53@R:^1,E2;0Z6 N0U&DL!Y4*U 4;^(?B!%1[H'NB'>&=LZ?=*.?J'94E MV'I4$8YLTB$6HVJ0=<\=FVQ;O,^FL)FPIPYAP-P-8O8C!@N+BAW]$MA,J:K7 MJH@H3370@RZM>("3H^D!.QSK'M/Z]RZC^H_Q&$P>UW03C\/$"$^\N!DP M_Y&)@ \Y"7Y_=.[./ S%ZN/=;@7FDK6%;K!(U0G.Z@58S P B4*S;OIQ>$W/ M"T2!,P]KN,##J8%OF6TZ+OQG2*4453X!K( >G< H&/A)JZ5J,II^#VN]IR@B M,$%-=--/71.X:8K18V'@RMO6235"*=#(PMBA=PAA&D,P>@Q%>UX)[2X>#T<" MFL+HU. W1)5M!U02: @T01<.X-@5\5>M[R+L8'3_"2IL;32>!BD(5 =+. X-&]6,X(JXHI M[:0C,HLB3CPRR[) XU&9ME3LX!'5_0&Z8YA3U-/-X(4Z$=B0A\*(1T/ EAG< M($(D*8 1BR1-* ZR@A4817@0%F 2AP_B^0FOCJ8=.1@C-M/XYI8Q@OO$59N3 M<7?$%3&^ (1Y8M>C.-)&IHMN:!?$ 1*!?N,5#P4I8?-[P0!Y01 1Z0Y_W9.T MX"53HS]%]="1*I$JM$$P6 Z9"0>V+#;T Q(@#K ?3)>2#^<8+>5C6=2X@,!Z MJ?ALN ]@3P0V7U"X)1+R#JO !OX85OB/:"('_.$!%" X7=WV1B04X>!P;V/! M3=J*C]C$T&!4@ R_I#)E?%$2,$U4ZH1%#!DS/%[L"D!R7(U''W+I?>\XAL"Z MW->DF^4XQ-&C@' +Z&2C$<<._@V[9Q1?CO:(E4CR8!HO7]R3ZZ2"/S ?$E8-L[#P2,_-*JY;);"_-A[=B0\0U M.;P_8&K :X+C9."FB+#FX; 8J2S*KLG0[+'^0"SA:,X Z^$!5L!TQ])K*)2Q M7.2#B%/%86@^XOEHGY)-$K,3$KM/%"SM>U2N#8N1R@=3G6AG:%+MWR&%/!-BZ0D+S!3:G0-FLY$IR@@*><;5-6EI7F$W MABVJ0TS5DP>>:9BZ:_*:R;@]-0JK=U$,:I[NF]X(*RFK56+&TZEG0A*[W 8&.2_%KL F M[AG4&E) ^V/3-1 OGT !'<2IZ+%['O &6!P@A 0%@)TI/E*'F //_3,+'Z MY2#P0QL.JU]&.B(A*[0X5Q\I;$VENC&HGTPNR1*F*_@;#37?8D7KO;Y*)8U6%!D7L50>-&PKFL@1 M<*929,39@,QS/@>)7-X_6B8R""LYQ'LI&,#K-H'L P44"T==!TWM:: %@ !G1N+C-8P?9:P(7H#R/0*-F$8D,0UCW.U/%!1A<#A;\'Y(= M$TSA/5*%I"# 7H\.-+S"]BCL]JO66(\R.712'&$]TK>UK$.F'E/=_XWU9"G5 M,7)[Q+0XREY!%HXM/ H!5D*L(8*2QVFRA[&PK!SSU>X]RF([BHSQ, \FYHGP MP@0BY"+"*%9"1]W%B_BF.8#V0IPBW.9 0>QY7-]0YAHY&6O\=3.=-D(#S$ ;H7WG@BW(&^A9,3&&[ M^A$,-+8E4$W2K@9H/Y,44K04C5-N1F3*';5[W/D2>$_NLPGD$U E/!\4\ M/7C7=:RD'?E.M=\R'N?G!:7>^UCGP M<0DB#6B8,DN! _M.=>Z3D,I;%F87.EW5Y39YH*86F)NU6O4[B8XH,U"U( ); MR +>="1N39QH5_S=/*0)MR"<6NSCK%6F-[B4/'Y1)UP!@X;8(L.HX8B(S!BQ M,?6!\T &)8"(Z8]YLO1$9$9*P]^@/,,!(A]'B-,00,#EV8[/VSK,DHG-RKF% M2KOS$V4,08G" P*5GDH!TPXI --,S&!"CD+.8@@$F/Y@+I,4&3%R#JKER66O M%AC6?-!)G82-5Q)=1BCM%&72C)05VO8#^60H.FSK4PV2/@"L@>-QYBH?]Q/$_=!8,P1AFO#V#[O(Z'=13 MR+YW<"6#P,-*(B2+T-'*X2?9I6>Y;$#,U7\0XY(M#IS'W_0@J M AJPS\*KW7(?'5P#.DA99+]N[(!&@>>[T2:(/Q>UEC!2U+UEQ.M'\I22WBJIXD(A 3$ MRP4BT#4&Q2$$MKR35+ULTR@,P19A"&C.JI$(60$(2I$@(EU* MSAMT(R _"6PO802P@L!D/#^F#LIL%;6$%WR%GJNN4) #Z.WW]W9;L)Z%GNFN9W'5,5XC\^$?WY]%2T*1EGG"CQPY]20 _ M!EQ98\OZ]&4K4.1/. J1?R2\EDBN*67QZRA*B.3$!5FTEYWYYB),/)2Z?9M* MF87'EXK:VXD?Z.!X.?6YV1W>2F3>K?$/TM,0VMG"-LL )=PO(X&VC$?)0'GG M,1%U1>1I[GMPRQ;"$%(XFA.EPK =&!(4#^IAC IW1&3B6V7CBAIY(Z-Q*F0& MKQ]GL\PJ8(!:6X&?;F./2HNS4>XGE-B:D3FB"SX;I9:'5JO@48DBK#T&T"T1 M\!,9[NG5%X=1=?$A$-EW*BO=E(3L\NWV;?6D6H]Z*85,(-?705G9R* MNP\C]R Z7]1KS@S_%MV T>%TRF'?C1:ZJ M%,<7\5AEA&\*CV&6&E+NSD5XDE";.3K(X2$L]#9+ MW!-;0O&ZHK+='CTT\IG0?I5&3EQT7? 5/J.+!ZYE3SS29XZHQJKX5-.&O<3 MQGRQ/:/[1B*#9Z+2/HJ(0R%7*L*4LI4K.2:%"9%ID#HMX-1-6*.S71&(SJD= M'=?N7 3[5,*3X:TX5QORDH\?EJQB9W2%<3(.#!5M 'HW.ESZY@09C^KB>N3; MWCOD;C:#12DB7 O]!)EJ!46R5%^:ZL?)#.VK5<*HT]3^54P-H7JX7\8H>H2N MB//6/1E.MGIJ6GC?<<$E&ACS8YQ!R:+E^^B21J]H_>BJ T;I MUEK'3664IQ786+#7SN1U6" M*O!I'E'!0RZ\:" JL [+A46@!VN^,$"KB:KK< M[D+E'1GU'K?2,GZ9YRU-R3J$Y&W]I)&4=Z)XN4?F*N#(,#VJSQXYG9W1"/WS M>/"-+#D\@AZ3^V%J@BA*7EK$;UUT:T890$?9?._E:B"8,V1K= 02K70UOR!C M%[W[QG>EG(T*-M$U^!)F:$28O1MLQ&5.@^CY+BE6@;&R $GL8; \3X MR:&X*PDT%^B'?X1+/WD_JQ[AI.X O=%*M3-(::Z]$[T?A=43N\;FY_",N^ST M%3;1Y&VOJZEE\E,^48&X$RUSNNR9$DZR1??EM6HU@B&4%H*.NIJW$J-X-D6B MT@0YU0;.4B4)KD(Q_U$?LCZW?.85E&]3B81:ZY? QGO[S(+R/&]9I"TK6+NG,VLL_[F#$R=5MX:\V /"\KP+@+QERZX\T!]=_Y:NW%"IN'KRG8% M"R=* !:&GX;1IS^[CN?="*5X!YO(0PMH+I_UE%(82 E9E*/SQ_F8>=X%FSJ> M&4+!<5PN,[:Q#HGDQN56ED#(31AM?3WZ*KVMUY%+YEOD:[V1KM8;WAGF.G36 M?)LZ]CGY*J]'Y\)3.8_ K6JLF,G6\ ;,4SNIA2C;U-K/,NOAB)8:9+[-X:Y6 M+:_02KDLU'ASULZN[J, NMY*ZNH^Z84KJ?7*7TE]N96LHEY:L@(/F""I"CR@ M'9KM);5#&:)R'E D*B-N+RXJ2U1;K2;Q0%V ASR0"VE[%:63#Z_"0G>8:DG; M4UC8'X6!'8>UE0=K0?D$_[^D%![)S-]D5-(B=C[;X37Z-J[0\RA;@$9GZF;Y M1DL+:Q_/X[PY9;P2:B ^:-0D:.DI%VS&>7.N+9RX[=O.J@ZVI&PJ MZK):0WQ\S=CGLVU=FZTBS[JIONK%8"-)%8F3X$+&;N0 M D$>KS=B]O#<&1>H.F5Q'T('39K7UP<;:RPF*E&N LGZA2!;W;BX5-7:%]-F M*^BTQ#I[W6)%'./U/Q5GP_5(I>"-B'&8LZ;\BH6IDHYQX;APUA3[P*Z?F+S' M8-]&S/"[J6%V \@]*:R8=&-MM=!B3U2543#'@]I5W.VR^.(.BU!^PIRL!&[V M!Q6[+1:0T?$VI\QB^YB%X8K1"66GL'==A\, M#@O,&!EED/!')^A'08C'SN@8\"NPB91J5%KUZEQ:S:<0'TD$)5$ ,=W/A=46 M)UA9Q-"PKF>LB3 G(F9&$A&%5[W.XTDH%(\F1ZM1?]!-BP?686&FX3" ]0UG M\E4Y:A3\&A:4BBI1R*BI4915(^](^!TMA_V:\8219Z7Q6Y\Z6.Z M81T1ES%OJ.-E',& B0[1.&'@$@\1(WZ43(=WJT^P)B58E$QB/@'8E\,@G8D? MWFV((+&85=]N1%<-6EZP(!\^"D/$0BIC4-7'M,OP5Y%NZX<\E !]+X[K\FA@5V1(T:67/+W0EY3;,0%(>4J(R)6& M3W&F->4E^)SQ<1\*_D\!1_%1L36JJ^(9?"86LY2%CE@HTT@X8#P%S4:U:?@A M._3:1'N,MF#(H!3*'Q:;).:GJC1IUM7%^SRCP026T$%4@!"!\\$0!/R#Z3HV MCAJ_S,:P/]N1A([*L1[)T U^ON<)$4P^A\7T7/: _;ZM*,J#/RJNI>6C&'+) M*P(>8H+58I?9!0<3O$N1U",1E2F"?*4[TAN#!O;"%)D"E]!OFTJW=&"9H[@0 MY>5^B05XJ((>"[M]VXB][.M/L3>ESW-$O"$JP\)#3*GV:$31#32UJ+_?U^,-P_=QK?>_KF=@<#26Q??T6;ZS#?3)6XFA? AN??^]K)?2)1-R*UHTG=D 7 5['U?+NPJFO>V@_IU:!Y1 M&MV(# !2YPG#B8[FI#3,Z:[ M>]^MO7Y2WRY_'ABT'#%YH?H*GX,@K*WH^FZFQ[,5ZQM8^1)>^8%^)8"7E']99QH+;J''_)9"Z* MV(7.APB8HEZ(G=*T;.=$MSOW<+B8PPN?G=]DK3=&JNL MNS'O*(=]%%"$]\2TS4D@?04R(F+O/3R-WFO?N)^8Y[W'L*# 5U*@-K&5G^U& M;JYF"N_Y1DYS1G.:VMU*--9R.&@6D>U+<02,J!E. &?5->XAEAHY*2M:2VJX MYII<\-K\(E\Q[DZCH&U16T/V=+*'C(<)IRX.*;PH$2+;Y-TK6FVE*$?1VA^B M?>)E7T7.CO?W))&S4^O$*@-TU52= M*B81*94IHA&CG,WE9FOU:+9ZO3]UD[E9,!MLC6KV=%%B6W@!1DD;F H7GZ(M MTGO$#'=.--E9*AQ]+X+1-QR)+O/STHB+9?J* -A?=4KA TS18[((U^S*OL7[ M1;R] 4[\Y-CW^%&IT07??A4AWWU11?DK"CYG%'BL3R'=2F!52=.Y!7'7Q=E&DK)Y6LV M8ZE\F1.ETO?H1\(]QF.7"4XC!DWF/,F8FKWZ<9E_T(6#S&UAYC:O6;0=<7D(:;VE?)7 M='>4\*REG3XI3U_9XK>1,\]RW1:"9XT-[\M[;IO73&]\- MV)O3U,K)\XQN]O)7GO G9L]TMB8TJZ]\KJ\ZU&+A-41MOE?\[*;^>Z=Q4= 5 MGC'\$A[\Q< U5>@R<;&YZX+EYKX=CID16.QZ])%B:S[ST!KN"I<,\-%Q$][> ME^S$/40&;\2#=0@ WTW3664.WOM(:Q,QG:\!-05JK0]YIKPXX M3KTZUM< &E3V2E GPT?GOO?-EE6+F7'Y-(1'%[<66@!WLUH<[+SIYX? AJ^O M@]U6?8YW/IPA[36/6F)[O$4S=CC9WYX>BABV-MZGHE8533Q4+*F%/K0+ZEC# MS:Y7W;SB.MZ\ K-P>"[.SU?:Q>IO1?%^D_U-C*YL7"==Z6%XN3ZX$_ M=EPJQ)W=ZXF'B[2J8:LLW]$Z+01!?/%JRU[WJ1?S4:K&#.]5H"!65A#G^(P7 ML\'-[IF>3WCOM$Y:(9XY.2KX_>/8A/$[R=\T[%N!S;L]0 =5E<9RY2KM,,&G MI?9>5EZ,OS9UV8A1I6QZON6X.I'.(M2K>B79%)-C;?U M[8DF=7\(^RZ[OVTK[&];8.;R8*PG8=2?\F'LI#I"+P$CYZ]O $YQ\.9IN1;" MTTK"DSE+ I0;R4:K8&R!XDT"-'^N1"/$D!FQN]P$4SZH'KO(C,+K?H]&^(!E MW*5-]+I5#PAA0Q5A4TNW1<>. M#X[N4AKDA>FRH>^@CL;:_:*C#=B7#>UZ8IN#P-.(N;4;>%E[AS]&1M'P!WH0 M?XJ^-'[XGKHA<94A^IIX87KO/;6"A)G_ECV^T2+ MH\/3.HGZB' 6]W8CAT] M&/\9,T"INX'^"(OQ9-./S!IM1VPRM9P9X^H,^RNY\,F0BZ_ ZA],CW_";@R! M[V$W%E2-@>7K&,ZA=J\,IO@G=G.XOW?9O>AGTJO7*]5N6S%C;!?(WCI>,,33(?*_$Q_E1/L6=D F(**AHVT]T6=B MT^3LD\J<34+Y\;YK4KL3GD"N?"%,-+Y]B.]IN:H 0>KP!TZT?D8YPTJBITFK MU:QTV^T\4YZW$HEEV $=W( XTAJ/483:_2H4B4876?RRQ9K#AQN9+FQ>0Z1P@=%]OV 6)MD9ZO/@H3U7E) -XQ//5SO3?A.U,U@"O'T;\T MT,WN]&DK=N(<0; @T&#I-=6;6UU3O344UKTP84:0]1MS-=Q%./IK%ZQZ!'$8#2=^T_@/Z*O M\$A6=R#/9=1-=:6RAEJ\B,:+Z1*QZ](HASI/F\LB>8'4/=1Y.M1YVK/8\6(E MB+XRCY%R09UBL =F.=,2*PKMOF1.[5!-*!"RB,=U M Y-;/!\-L(=T 8WU,R.>;6)$K;>:9%P?[%>73-9<()1VG8-2D@I:/HVDE$&> M72Y*O;:E7)0R4/O,<-M:4JBMF^:S2W_1CGM@QH.N*%J#XBAE= %OFCW7!E; M,^V!+M8?,"X+Q@[<8[J[%U?_4;U_6)0HJL;CNW$H0P12T22O-B9*X/U15+0Y MUGE)&^Q $$P$&0*/.SX!U]14@\=AZ*:K/6"Y?@K$$.%1B:BYP)/^6-IPQ[?# ML6/A70[]?CQU30KO.)HX!K.$FW55;Q8>RUZ,[^J%^38.GJN#Y^K@N3IXKO;, M8S[X+0JN0)0NWFR@.J%H$J7TES1;[5/N*G73XH6?5H& M-\F+WRT58 GYF>H(OY.%A--%OI9GW(T676F==+=]M+RRU5MSQVS#]4*+P0\\YQ'Y\5KX36C5KSI4BONE "7<&41N)/+: M>,$$H(8W/!Z=)\*I=&RYR2N=S,WM4OU3/$=UGWU&M?WV&46$RRQ'N^*=W J' MY 6 K'=JOI79A:H[B9T<&Q M&6KN'3EE\?;C&*VXVUO]ZO*)N4/3BWUWXYK#52[\#U3;%M6PM;9H!*U^_AC8P>0'6 MHR?>:UAV![AC.S(J-N?B7I,Y_K22%[8+MX-.\R2*Z=-#O/%;_/BYV[BURR>XOHY\#'D0^HN3(BU@OI*]\YG@V> M=-358Z3[F0?2+:5ZESEL+(9K+>Y"(WCR(6T#>@IVR#,ZJ)_4% MUY+E8&QY?&STNF*5(;;"'4OO^DTS2''Y6:K0W,F%=FH%\S(ILL7MN6[C=<"2 M K<<9]W"H/=8@LD&).&:DR8X[UV[@#POZAK*7]RRI])R&]ZL#_^"O;[*!"D= MT5EPU%I_%9M.]EJ6 !N"M(BH+6/DDHRM4E,8GP.K%]=V&V3Y379^6N4"(I;8 ME7!6Q;,QUF2O8AEDJZ>0;4OE%9XSY=BJU0LXMC*3SK9Q]EJ%7ML@UKH)@$OZ MQ9;LY;C7Y'FYFZE[\H+HM$2.]"8UZN+A2].GI5%C)3_.;K;G3OBY46>Z9Z2[:,ME] MN>02,8\4ZKP#W?)B%4NG6ZLTVDMZ,??9%-V6&7 XU!T.=1E9E N"4O;;0-M M\:/2R+"/6G$_2R%A@M)$_]-Q,>E(M"[0HDY:\:PCD6]$I88\?G2KM[[38BV- M=-LV0==[NAN.Q[M58:$BWBG.M#5=5C:W9AI6($0:'5NFS2BW%M]RF3Z"WP&4 MP/9-2QL%LE 2'B+%C$[@^N/Y4_+F1[(PD"8+ T4/J"6 L%1/LFH3]DN*ZO<< M4_T>69HIJXI/17O4/>UM]:36Y7-C^["AC=*;UW ML6/4*L$:RI7HK(OCB\@A#8(Y;%E1GVS@,U@^HE2>&:9@(% MW1-:!_#^1#>Q9T&T@$2#<""-ZP3WV )35Q51SL23"3-,+I!0PFN ?/N>&O1A M#V/7L33V &R>'@,7J;[-HJ-O!0L11OSELI"H1&8/5R2_,A"'O-LF @3\D ,N M*)JA# N*31Q,42E3=Q0ND@ A1QYS'Y TNHJJ"L@QBWD>;WRDOF+RYI_ 8X%% M+ TOL1&U6\E!2 6_X7)UB"M+TA8W21KN6EV6X>,V1A*0O+:=RA;U0 UAIUT? MM*@?;NCD_*^V'N.U4$GA-JJU,@1E:&/I2M=@[,$I#,VT(*JEN]JDMCB,("3" M$?P&(J%9U4*)P-E:C(^LCMI8]+DDG@!6YLU^/&E&U9MQM1_5XZ1W 20RI%XM MK?L^IW5RM_@QFPW+GTKK7;%'I+I225UK=RKM3B./P))IX!75FMD] ;:!;%H, M?KAA+IQ6)BC3$/F\^,8WV_1Y.OZKKKIQB?UT$2M3!4F<>0+ 4-PVNKG]%K>) M0%$"VU&'(I)+J WAK\@X C7&T'AQX+@:FAGS6GY%/J8A M.B!I4WU&'FMQN!5Z&,<&$#W>83A51/A$^S85D@P>YIN.'D>PI($$,BOP 8/D M@ YV(R2Q4@/A2I7:7@ MP1?J7:H0&_=AI%M6BB/=D]*U.R]>6[0""(&YD3(@^T*)'1.B>%4/ >J:Q3U6 MK>7Q<@MY9%P6XA<;+02A3E!FG8PE "]E\1M?^ZHU+Y9$Q"XC&H5UT6Y^-W>+ MEEW28HV[U1W4EJZW"F2N[:IUW![AJ7U2W]?^>OO08*]91NWV7=0G6*$('8]9(SXE]@2OS^DG<3ZUVMIERY==FSMY^L;+G4!CSLOF?-C8?=5Z9N MVUA)B-(SV_>^C^G:R=8[*R=P0/D!Y?N,\ITVX-IB18%M)IKL-@2[D$MA?]*\ MGBN:6R>][K/!\7-KIKS(V7-HIEQ:4U]=7M1@ RY^.R/"]=/AR;;CB[!JO.;F M"8 #YX&I01WXT]!RJ*!)9O3BT3IAG,Z#6;;DO#. TENHD' MFR5:#&-L"MW*8R $CSQ;%B8M$68K(D8.K:!QY+QP-*%U)&*3M!(]N#DF@48F M>V 3QB.KAV!DZ,!4 !@\Y-C,.]%^&S,[^1R^&CY#0)B>9C#X'>-KG0&/RE6C M82@V5<;M$Q.H4?UBR"C27H8X$NM0>"+^;DZ 'X56)XX<5T>M2\_!V% M*!C\*2)*>209WQ<>#[D?ZP\LGVX%Z/7C:> =W^OZ]/V%Z:%L#EQV/3I7@/K* M83EW/-^C[DH?<(H;?8;RP+L#>GRP8#EG:-K\* >+'E2'ZKLNQK?CBQ]FJ;'Z MN"[>O^E&!NQ_=%SZFB(:O[+13V]X$-\;"EF$N>F[8;OQQT?7F=1^T6VDRYW3 MJ &E\.,?=X_.G: #]1RG$-(K&^^"0=1@=.%GNNA\ R)L".2SO)_>7'WY^.:L M5Z]7N^T(/V4OZ4R8@^OCC ]2@38Y<6 MYA\41EFKU>RVRT#9@A65Q&LB?>$:-S$LSV7P@'?!Q(783RSQ60=Y%TPB!$U!>*R"GOJ;L^I) MM5D";@J >Z:5OO'Z< K"5W1+,&P HM\E4;]OS+,8Y+.]P4Y3P4ZM%V*GUGL) MV*%__">G6)2$BJ=4M TG(KB%3'O6G,K)RM]TTQ]2^Y0>_%UKZ2$FB] M.:M7A9Q;=O:S#+#7P%8"3[*]]QUS)\6W>>/W>NLBMI3-0%1,8,^C3[N5>[CX MXMB7,J>'X/'2EG&HH!:)[+.U 6WG*>6MJ^3C>'1LX^;X(H;KDO^BUI)H M.@^3['-$18E?.P5]91YC585^LH0M0[/+OP/1G5[;GNP')"W(XW8UU6P &JHP[ MICG;UQ;LTTXUX6=456&.0JBU.^U.8[X:W,122MS"R\Z]"(NU!!:5"@G<5Y&# MRGHA&W0#"TJ8M9+DM_P6+QN,< AN(MUA]3#U=[R,^.+XOS/ BC2!HI'X2TFP MYAELG?H%8*I;UG.D#Y=CZ)9N?JG MVY_PKJ?P*8]"1O8]??Z%YEHQ7:5IGWEMA4NLK:#<*7+@Z*HTECZX M4BSE6EG%2X53/@OJ;B5I?/DPSCW,O-\Y#A>ERFZ$X7>78-QIS\UJ_,H\1L$3 M5/J&/3#+F:+Y,!]'A1- ]R#Y3%KNAK-BYO7\2HNAG9L/) MS"(>UXT)',ZP[#-&36P@P^+9YE?4>JM)QIUELCQ?5#>7#.!^I@DLR\?BEQ70 M_\SB^6OU0Z[$IA)1EA1J&\B54+P[FSKZISUCXEW5/Z$.+6ZFYGI?\J,WI=78 MMXV+R&848^:X]QLQ=TPQ\#:RK-SXI966U=Z79>5?U@KS!U;5CQD_\Q?6ZZVX MLI+7E7]IN]*ZFBOR8;FK*AQA"*IA508K%^+B47]E\$TD*'."M]'[*Z.$="O@ MXM+S@@G_[@YE[PMUC+Y ]]G!.7IPCAZ4:W2?NOIM7+8@.6NV^:QH=9*R$]?CJ:;&1MC MQJT9VQKJ71JL\5Y\STJ90FFWVNVR M%,HQH!5=8E%"H[2*!&BD=9\'C0*>O?7=*#5\)!M+E*UKHS!79)52DRD5*S6" M3$?\J.CF43_JQA_U=FDO7SJ97KY4GYS?M;XZDFFM<@)6 B#%DL_RF@P3\^A; MF3^HTV#T$V*XZ "" M8?0SNFSXRKDU[=#2#Q,L.$6PZ %5^8X[9>ZKA,F"Z7.*U8PU M/#PT>B+UG$,U.FIO3Y6C#XL@5Q+%JJ?7#I!LXQ*+$B_/%0^U+_#[VJMLNDGU M/,4SW6D+S V,8:3TA??9U0]2]MVK]GAPU>DGO'^M!/8&4#O]O:LL1.ZT>L-+ MI>]EL?,HZ6S!+L)$,5R'NS'+4XQ13 M=,H'L0+B)4A*%IIA!]$J*):='J6^]2]U(F,1[L@L]64S2'K]J51IUC?<+(I! M:?,@T^U4@%F2KP*7H D+;GK >3\-!6]6O@39#W/!C$; M,4P(M8IC4?:U_%PC7]5#FD;5JEA9D;.EM-G$);!ZX7F>:HU@!:%#A0,]$]DK MW5W__)?]JS)YJ?>,);8Z6HK$UM'V %7$7I7."E6G%Y2>4:?52VA1=%''\WR% M:=1Z1N>4H9M-F18U>7EE]E39:>3*PY454":W"=MC!CELA F;QOU-_3E_-)BS M'MO[;+5%PTRO8L^HNEY-I00X];66>B'H"T'+)&BEH=[9X_)K'N6$\.IMR[,U M+,-1YZH[R)C%;+(K6I4;\!+4O01U1YH1)!2E--M!*Z%-I;)C:*)5S'25.ML5 MH%0C],H;1=7UIXC<\NGA%2M_OMEX -'(=SM[Z@Q]-+P6W1O6,FFJ8;.FSEV9 M'GWNM,_^%GM1!F'X&8ZFHJ M*81Q%0,/FSSML,!,Y*IF&R:/!\UX0'R6GM,/YE+%.5VUNG\G[#DW7 ^'GEN1 M*=HAL93Q_D M[R<"7L+HS\B>-4C$,(LCH1@5M6(1UE>I%(PZ'<$8=(>.8$?[ MKAW!,_21CN"@1D=0S4CR[)Y5%B]0ZXR5#4_/#FFIS*50!ZB$4+ZUDZ9%=M<1 M^%'C-4-:N-52*Y)X5D*6X:C3'2CT%F+PI9H#GVO]$^:47,%;W>5ARQ2E[H'4 MH?4A<\P %]!1$1!2ZJ@,?<@&G[5^7V%0G0/8 ^E+2(0]@ "#S<)9!^%P6@+@ M4AOC?,?C6BOIMRYU'.X?-&@0MB&=[&OO99^VDPF!64H[DZ:<1,T' MD;X[B0]JP28E>7N2/-^&)$=>>I;>T")3_XH,_3XR=J@HC'SIN.?MW9&1$'56 M9OJNQ:#WZJR(JF[-4> =<0VC)K1^BAMX=0TK;A"=!BVMJ1.=FS#2N:=BE$L= M?19RM%7(=QA5W'5/48.O^&;_,[S:W]SC+0/??+WQU(YI.2Y^03X^DP"^2-]% M<^.+]*FT;:6UME!^0S_;5/NR.E>4>6F\MK8(+R1_(7F325[K/,X*.R-4>6&F MWE+R5"F%YEQ7NU0R]UOCT<70N!0J%[T^=(Z'$Y(]ZB\'%K@)D?$%L,)ZG;?_ M>K#\G07[>U17^,%=\']RK*H9<]RUV#'H=CY_0?B16G8%%5B)X(=IIE(PJ.@,_'KM4I"HXA#"O(-JI7?R3 H6R^:5 MSQ#1!E2S*S;>246;=1OOLGDXA]'+-AVU/[PM7,-9"A:*YJF6;+K/\">:;JW; M(,L=LQQ\@6L]\+6P77CBUG"FIG \.V=9YSJ6!4E3=OF:K71[84!T@X^V]P.> M+Y[C&O-M).8QYDS4ZWU8:5)_3:66L1I7SRL) ^%$E-PB + M5PK_68=+R/JO.#V.H)6^-O4XD8)T>[O5-ZPJ:/1AS?'&&X@$4D20P M ];:Z(8IN\E8,_R ;VBD.5@WX'#/U&USRR9;!@) 0* DZ=9VEV488%GU"PKT43]@;33>!WQ$PL$'"LZ= ']K?8KKC<,?! M1V$Y A6L;8M]A/W]O0&*I0YH6_AK9!8"WZ>.C_B,.W#T0.,9WW!3K.$O6,B; MH\JS_0=!=FP>'\A]W MN^9,8S-#GW#77U9,8&]WV\K#M3D9M%*!_9.+A:VO@>PQ8[2H:R/?$PMP6[6P+_8(Y@4\^VX3M8 59$ M.:0\U[687WL@["@O+ND Y-)O8 U=#H_BR?S8&W194!I(O EP,%-8BVO3V @ M]%O "Y4):HX9K@.K@.2Y6_H!!TNX)KF*[?!CMQ#89Y&MD!2X'2&$&NL*M0Y>G0(BF,]74-_K7X \4FN#0(D5MYUB M,GJ!XA@U6B%3V7PJ%A;\@M@IX*Y4S%2,D2*^:;(W^.;0@PS]@;\X>*P/J 4^ MS#\Y.)D;5, 9MWDXW/>;__GT>.@Z@ZK8\YW/[A5W;B%<\]44/> 4<.*[O3U M#E>.4>5!'M_9+5/=L0._.K)OL.R;'-NE&M&N;KOAZ!1Z_Y ."*7_/55%IP,B M!QCC4V@K ^/1FSA@DH 9WF[07'[?D5/7CYQ"HC!)E3J5_*$'%]?\KR,!CN5K M5FTH-:OO ]P\O'UD-U-PYL'C04>>HR\!OK>I/Z$30"Z%A;E2]NCJZ'B#8[*1 M 0:H=DNLP*4"Y\; :'PJ-?L-1@":7:1C#@O]=C_(=40SA MT&[ 6S19+SBS*,Z.-UD9+L(%) *'T01:$008]!U;FV@#WPAX/NYC:NWVSH/U M@(U\.M[?1T&Z@ZVF4V'/Z+2?#'=)3Q%38!Q*,;+_.\EBM!W\QD:=9F#H[#?K MUAG%R_!\YU7H,A.$9*B%%2Q%*ZQT"(Z)OQ;@ @!/S)GA8A3M.;('^%J73JID MA2WB/A6.BW0"M@?N7DN.0$\"Y)>P=($E760KX#7A85#@+A$R\*S1>0DW>S*0 M8RD(UL&QT>15*#8'U4<0SGQ$ FA;[!:\' *"V],L9"4B)X1BIOO'W$*$'Q. M X:!C6!C0-63)QAP]+ZL\F]+W<.L;?1T=DY^Y&E+&Z90%;3 $' M4O\"E>B6!10CS T\0\Q82#%<@$,KDR,H&G_86]"+)G 7OA ?H!]@81$#I [ MSS8@^(LR#VB)(?M;8!H)>0MW"SQA^#6 0)_TS]$NXOB>,N%O(AE^XA-@DW? M)3>2/> ;[DSM0W*P.[;^Y%O\'TK_U%HP]#@/Q<;$[PV2"3-P:NE6SYQ=YGL M=_J42ZURSI,;=?N_-U\0.0_.U\ M+F.K>V[C]4=]$>FHL890J2C8U'2KW3D%IT6G&XC.UO>5_;]. 75<$]6MA/8TT"FBG2 (G>.O M/W^;V";]^7]02P,$% @ .H6F4#T 76E^$0 #; !( !G:61Y;"TR M,#(P,#,S,2YXW\%ZLZTZ5P5/1S;L1NG(\N/*&=;JB4GEW8Z M-Q0)24A(0 %(V\JO+P"2$D42 "7YP;OCESN'7"SVC<5B";W[UX/G@CM(&2+X M>*?YNK$#(+:)@_#D>.=V4&L/.MWNSK_> _"G=W^NU< %Q)!:/G3 : XZQ)L- M; 2&U,)L3*@'7OG>WT$-3'U_=E2OW]_?O[8Y#+,1A8P$U(9,/ "U&D<8H^Q0 M*! >@<\!: +/8C] ML?[WP/+!>-$71V .<+LR,<>,<["6H>1M1]3>BD[OBT[L]GL,XA M($5V/(!1OR:>L\6PL<5&60S&X \9^/M="=T\/#RL MR[ MJX95:\KO,YH7NYI'FG_H@,S2A\=H;XG(Q[ MOM17FJ_'X\R!XV?GC,^),,KCZ[&XLBWWV;GB<]J!FZ^N%;X$])!S L0?MS== M@^M+Y!V"&7&1(Y:0$\L5KCV80LAC"'(B[G^EORJADB83D['4PGL>P?AR-N"V M)A<;_G<2$XA0 8F+@5ZMH5*.$0B4E5,6 MUMFUY0<4DO%)P!"&++529MZ:''"?:^@4,=LEC _D_P@Q".W$."I]:(-DX'D6 MG9/Q $TPXC'(PG[;MDF ?80G?6[Y-L^>+@0SR-8+I(I9\T%,7GL MVXS'0A\(/( C B$F(%%56:I>19\M2KG5,Y_T VI/^>8TTH-(+PCMG'93T;7( M +TC'J:5%Z,$/@$QTH42!5I N%(YXBJ9,6CSW$+TD^4&\ I:0K@RRUC57SZ( MP>&:C;3.!!H@\8 DHBH>&G)-F_,;;<+(N$,A3_=N$/O&%Y@;Z(KT4,A4OH_6 MH4PNNCX&XR:RV4RK=W4>F:?*F8"82BZ'T61@,5N\<.8Y:64#"QO@4J(!=,X> M9A SF'+.]$MM(&VVTEJ+AH-X?!4O30D*\2'K6W-KY*;SDN0;LP/M9A(2,1Y$ M"*JHJ(^*GH=\N7SPP,(CC\B](1:)=SKXJ0'-*GJ3C7$+=#*BK2"LHIA^QY>H M/D55I]1&+@? 5)IN[F6V: DL?XO+6U54*U*SY-M5Z(@6!;X2Y&VT\V',;I0I MEDA,-8D*)'%5'J17$IR(T',#9X2*L)-23_JM*4'/5C="#&"!(M]M*I4DRU@C M!K\'G.6SN^S&*?/6I)),D6*) 80H*I44R)93M;^3N?QKGDF<57 F-67*$3D% MP'^(?J\0'W@5/ZS.5C:J_PU%1IPNV6L C4M2*U.<4%8#P:L0::[J*L6M4Q7, M4V/Q80:G;&4*$H5KA%H55SI6%B+R])D/8M*=L2Q1J6C[G7&>NLS@61FM:"Y3 MQ=!ND75JK)1HV(WEZ4\+:5!=IKJAVI956MNHQ> 4^A9*]^2I@ RZRI0YLOT& MX%6$JU+3DW4>Y*KT,1":,]9L$>41>A$JFREH,_84.H'+_79&?,XXLEQW[B W M\-$=EX0=4"2:O>&#[08.=,:4>.(SGB"4$!E+4.C<0S29\O];=Y!:$\A$O W7 MV91%/?ET9GO+5(Q8\ M?,%[A\Z/@[O)ESF^/0WN+P[HX<'/K:^WPSES#^[L'PWWHU_W!_#CCX/=;P]- M^])O_.?\O#7XN7[W<-+YTKAS!O1+[VUO_^N5>_L)?KH:?/KHG0T__/O*:S^P MGCLXF#M?Z?TE:5RV>IBV>_V;_?VO)YW1[N#Z/_?UO>Y'?+O?[7S_WOCB3M"^ M/YP.^K>MOG]RW@B^G-WO/UB'['OW8/?+R4W_[<_C'MW]\..RV0X&^Y/OMQ\O MY]X'UKSOM.O6=;WUV27=MQ'TY_>>A>CUMTPF,\:H_ONU+K]=MJX^C Y/OX?Z QNQ">-CQC+[R-; M)($O/G$3GW#R_$'2&W$1)C4AN:"HPV)W>:=3L, M 1,S5N6LXMTV^?OI' !3T\!NIMRXTGI3;8JV+C7FJJH O%%SZY8;=5&T4F5. M#"7^%%+Q#3_U)!TT[-GT.93%# &UT%C#4<#N>CU7RE@K:0$)8D!$C7U^5)F]YII2O-BVH<8W.]I4ISY6JY;FXO^6? M\N4XG +0O"O-=I\9%1<[9L%FSDJKR0+M:GF^S5C@S00($Y/[Y(SYB*]73'F\@\RFRNQ ME=?N4A4/ P?K5PY M*A_SI\@3T0?@W.MD%1>9@O!"W$MB2W2:(>)?M7A<33RJ-5NUW>;K!^;$MTRN M285@.KP/)01S* 33W-^:CN2%O>O10O"UAAPS0?FW^Q8TE7B F'NON! ,%S87L@\^ M-&$;"T0YQA%1$]U&+9]DOUAN? MAMUB\3:S'>XR94+*VB.><5HV%V-XZ:N\\/A(9*%XTO6A)Z+/#K BJ.,=GP;B MME8)->.J),Y0CG,"&D5]C%Q7),DQ+.,++(_4@7A[04DPBR=!''UR37\6-EDE[B/I2H=9;=0!NB.XE->4-* MB:3SR R9733;.%$B:10B4VD&7B9N]03JPG]JX4@486^9L)-,@;BW4B N MD1 >BQ.U&61JI"7B7D.F'Z\8\N5>@NAF&A7!_JJDEM"UORI!R3;"XB[J+?<@W('[4 /N4LG#@:"M1*"BNOU>&!VY'-H0. M$[(:3/D&>@BIQP//)<$3\>CP.LH2^\9ZG*CD<0*Q;$BR7+X9BWX<[!S*3W3CL3Q# M(1Q [-Z1/Q4-QU?$6;@D*[60'H$]]4KT.-O7(7SP3UR> ,2"#'^9Z\B/GV\H MRA?>E2_9*K)G,U9'Y-%NZ42U.0.:N%W\,\;U/PA[YF38\8^F?"2U@Q'L*N+7 M$["IW4@^Q;27"$O^6 FV&T_,H"8>%V2=7$D%U-"3PP.5'AZT),+WXT3$0(AFQ9&WN$Y#,$/YFVI]$2 [^*^%%.*).EYI\D2?!F"](OP;?"$3<@) M?S"PRT,"E?UB3!;LAE,+KQ(JO#(DLPRIPW.R^R2KJ)&.13 LZ*"L1)&I) +1 MAJQ-HJ>1QO9D0N&$N^SJ"K8@O>R+]\L(Y26BVOHK(&O^WCUL(YFHSW3R+Z@L M7^5+2ZBRI) _J$R5)R.)FLV+((*)-D%K!,6]*&06M6&?0F93- M)>_E*42$Z MU?'E,Z'?A%5;,^1;[N+'9)XL2&]_RI1+L-('$U)8E S*H+9J(D7--5/DL44GD6GR5R02UY*D"ASAQ M7Z8[/%A:@>O''1LW/"%-U1'$,>MF87Z+0&@B4;?[_#=/P] 80><<8;[ <+7P MR1B+NS.&4XY%W'12YE:2PCSH!-$/E<R M4"9;=*.K4^_S,*:0Y529=&'I5%G]7 *5[OLNUBV ME_G+]C+Q9_)+#-'Q$G9:M:/6%WE<1L8!$\WI1_ M:4X)8[2.4&7,RA]4JJAL(E$7AO+OT2FA\G2$*I67/ZA4RC.1J&N0;-^<#=JV M?QY@I^VZT2T4):M)FHE47TKI"FMZ\KZ2F@G8#[Q^!ZE/(SDTJ4\M#T[C1;L M\C"0H4E7H\=GWLPE<\@W_B(O*1,;*MHT$3DYIIR>6/4BD(4]BGQ$&.$SN6'MF44Q(9,%+#W@9"P0%U:WO,H7(>Q4&:# MWZ+:-^-!U]&VQ"W.E.%O) [H:2U@#(F8^9N. YOSH5X;.)FMN'6P1$SGD%7@ M^_3<-*X\7!4A4]G(H[D8N40W2Q4B4UJCO(Q,R?(2);*ET>+$,S65@LF6Q80$9(#4XJ^_ +58 M"T%2%"%*F:62XW& S>Z_P=IIL4&'&I#DP\T+)9WN"TR3(%T>"9]I6W>H=&6OY(*WPX M^W!X=EC0KJ]:6C%?S(]_Y;=SR\0_GQ #C=N-V45F#FGX1*WWA#[GBOG\06[Z M8F;\YME0/%AX?W#@O5TX/3W->?\Z>Y69?B_R9@NY;W?5IMX%&V5-S!R$=0' MS#/F/:P2'3D>DZ%V:=(WQ-^RT]>RXE&V4,P>%-X/F9$9\Z9IYY18T(".YEE^ MYHQZ<)%AIMVSA$'>LRZ%SD7FV31&5E90F#\8M_&[]^@[_5XFF!'+- 3[E\@2 MG6EV 9R,)AIO-RH+W7@>(OW%-9DI.J@3VLN)MW+21G(?E1A:X=@V-!W^LPTX MOJW+[0AS5=A;1JQ[8Y%!;$-G#>22U%X,8L.U@'1*NDY=,*HF>C(M;@>P%GH2 M+:UA;WAK8^.3M]Y&CDM-9T0ZI"<<$_=;%O!Y8TT,&&W2F8B-S_5-1Y;N6IX/ MJ/*>+/01A@Y@ XQI+P781C-L.AXXKD7T!2Q+.")"IU 6>@+K(N.R[#-"O>\E MQL!A99=2;P;-DSXQQ_-('<2>/+1 .>.HU%Y4MTL8N(ZE,3 M^8\KLB]Z_\D;.>;:MM=:UN0>:OK['4KL$!T=LC9]A!I ^>J?T09@/G<=\2/O M6AS!&L <:NH3O[6*K4*K4,Q=ERF5AO6/V83LS(Q O]<@CFBK!G$WD^; LS^8AR!1M MI%"?$,3]<%]AM$TD.DS&A\W9I#@>238\E5 0D^R2[9D_ANRZL@T*KB,>J:#+"5)JP0J=<\: M30HI4S*W&F\_R4$F!N,:42RR,9XHN[;@ XPKZ)BZJ63UBX":;C8;3:$HY,FR MITTC<^X=M[,>AF+N3@P9R(DDM ^*Z?>K4U&63KD7WY=>^KTE+\F?YY9.C'S< MRC&2Y<-/FU9+)ANB2D+&59#8[JD!#+C^8H?]"OI@$6\K:]*NHI,) 8#I+B%2 M\99.)@0Q)G--L;(GL/CC9XYTA^A/F+-,218E1TLU"HZD2A!5R=8>QL=]+8Y4 M,FP3F\RA7AU6H3)AD+LO3RAIR9X0F=DT]NI5PM3ZX3F8'?%@JQWW+02]:;;J MM[(;1+WW!)-%4Q1.#SE8_!%4P7U@7F0V;K&"':#\B0K[I5CICJ50#>='E)RO MA.OO-X3R9O"XO*^/O.\LD"ZZN_[H;^_WCT< M_O/W-[WG#A_QX:GQ>MQ_?ASA]I4[N#VFI\=?BC_:K1&SCOOZ:][Z[.2<)GQ^ M/3[X.2SH52?_U\U-L?DEUQ]>EA_S?:-)'VLGM:,?=U;[ 1[NF@^?[>O6IS_O M[-*0U:SF\7_*/U M;!XYK6ZSWB[6G+QLU$^^=&KTX--KM5!RFT?/+^W/ MU9']B14&Y5(.W>>*7RU2.;G]Y.:JMGZ2K^:_O6-ZL574;TO6[;L6>KC/YX[! M.NCU3T^[[T[RW5+UH?SMM5]L?+AICZP_'QOW]N#BXA^MW&R(KZ<2&:SBE$J= M$L/5G08X+L6SC97X0S>@S3U8%&)1):VZQ5HFVI@"LLQ7,*;>JX;?SDPHB0;# M(%.-TM=:"D+)DQU>B!6KB_/BJ^8IB=1)-3?"Q(B. M*KR33&SL\]_D_;>\'JE,8=29FZK?W((.OHGY?/X>N(?^+R E8%K*\I!8-0MP MU):+%@'27W3\^KOHX13*G'!98&;#9&A< H:.FIUP&=2^".I#TNHTFBO^I;0A M-_O(/_Z@X(2(5GC&T3>Y-9>C-A,;?3,G6])Y/*OLT.P:Z/'KK/\^G[6FH@L+ MR2);"9Y-NX(>!=T$C[6]9;1^6:ZB MKU[#0?=\CD5@-8'/,<<5I@;H%F+,[)CC.X9JG:^(4H0=$:_X?B'3(E[V[%=B MD);G-D79RPF9$,')%/7&QO!(4G0DL"XA%5'RR^G6Y#901D:&]+.B>%]&(@J7 MB%LEKC7C ,H6- G27DZ=,/;D9;JXF0\5GW-)D*?);)Q(+!Z?D$FKZN"''CLNX#/ .[/>(B51Q:$@O1-'10_7 M0-_-^"%@)"Q<-+0&R[+3>PF.WQL3(ZRG-7[]T-<>O^/0F3>M QA>47MVN06G M<_[3Y09XGP35$8U\BF/M9G=S< ;(_)9]K$]AV!<[\1Q0K2.0*HRYX@K0,F%J M ML@N+U4,1*/LDV!Y"XMK0,UB;&\1JM0<"W\=!.2.%0M%;DC!TS!'ZO\0KWW M77*#-X]_H=[[>H. 3Y*WN.,7?DUVW"!U!R];6Z\#UW;/(B. R4*ZG8Z$@Z:> MUX<*.S\C(I"8;&CR=LJU XQY=P'80&V@# M.BZ>F:?R7K,0Q+T2*HR]!*]YQJ+^^5(*4]EWIZ^@B(RO1.RW&I>QMKJ\A MB'LU=<+8DVSAI1671?P?/V+?C\+]/(#D9K)I?GJEYK:GR-@;7,P8$>*>"]4: M@-6'.X*=KII;'./:DNZ5CVL.D(5+8V*SG^0U#E&M> 1$6P.2IO13$]*^(&@+ MFL_8EAXK4ZXU5SA5O_9F1,H746]+[C'AP7=<^BVRY[/_HT[P]']02P,$% M @ .H6F4(:9W/8H+P .M," !8 !G:61Y;"TR,#(P,#,S,5]D968N>&UL M[7UO<]LXDO?[^Q0^WYOGJ2VOG60FF4Q-[DJV[(QG'5LKV7EX7_]Y\'!O_WR[T='!Q]1@(@3HNG!_?K@ M#"]7$]<[N"5.0&>8+ _^7[C\_P='!XLP7/U\?/SX^/AWEWV&NAY!%$?$193_ MX.#HB V8#GE&$!_PYX,O;-1/SOK@Y.W!JQ]^_N''GW]\=7 ^O#UX??+Z)/[* MO_WB>\&?]PY%!XSO@'XXS%!ZNB?^WS&9'[\^.7ESG'[P,/[DST_\![G//[X1 MGW[U_OW[8_';S4>I5_1!-NRKXW]]NIJX"[1TCKR AD[@<@+4^YF*'UYAUPF% M)&OY.BC]!/_74?JQ(_ZCHU>OC]Z\^OL3G6Y89)^9AALRV0%^/(Y_>=.T?<5F?O(F)_8?XT>_D M]S,<4.Q[4P[3J>/S64\6"(6'!WSPN_%E;K[S)\?]%GG4XY)P,5D=\T\=EPYR M#,_H[R.'H"!R:XG>R8*)8 M8'_*[,@YXR-.V%$ M$)Z=1M0+$%53U[TOFQ/=)%HN';+&LXDW#[P94_L@'+@NCH*0;141%?.![Y[/@1^H0JIJ4M0)F#3@;$P2H>GY MTPH%%*E)?_>[9M*%2,@<.0XR:)NHMBJ MQC&Z-_-UFVRJ0\1LJ:>FFT7?-^CJ"'/(S#C;2UF@P#1(8[^;(ZO_D+DILT!K\@Q3 M%#O_>"8^BJ:/R)LOV)_. R+.'%$^@5C(:A,'Y\;H+K7A]C%9S3@*>9**9_/8 M?]$3(JY'.=TFHI <'$HODC5_Y3GWGB_$WV0R9:-!<8_#!2)>P).E0D=([-V' MC(9#FTU%:FB#OL>&\)*G'+R0Q>MXQ9/#3"$$23\1ZKK)K"0'-XP7W_6*#9ZZ M\UPRCE&?(&]@!I1&RY4()B/*->"Y](QU M\1AF.!UB-^*"& 33<[8HPO7EUHM78K-RH!1\A[BRO);4**0E!KPXX4)&2RG&_&$+PF'WE./G,\?[7D[4%S"M>.EZ@S6K\[>UY M!P2S"S8$<:-[=+0AK,9OT0 9K041L!#,T1(M[Q%1E&[NJYNM%H)+Q_?5>.-? MV'#$]-0+Q.J[8K1S7*&G$ 53-$WYXE]N5""3T&14?>SF2/F\W@B3E)+OW"/_ MPV%$C^:.L_I]4^S!6$27[*^T4%1BPC.'WHM9)U]F,GOU_ACY(4U_TQNSF;%,Z3(=4(I".KBG(7'<$&*?V*$ M4_L.$OZ.\:N M1.KEKKE%QX3.(L++7^$1V"441P8V<"C6N7T,]D0C89-T@.#5IRS2XW_PAZ2 $R$)5HJ-9Q"1E6(N@#G[;#'TQ%Q#0U=+L M!6KUDJNU?CJ C0A:.5Z:$69D;_B1:XYK",QDR&8=F^[B)B7 !+K7ICRX0B[! M]RM0O\WX7@7H+HP(/[@/UR/?B1.3;)FNN#=SC8!62P6]KH-2+2R9E:&%T4U: M6G'%2RO&_&S_9G9'D6 8 J1J@A9][7J(:F258/3&Z,83CKA MJYY5BZM=T@(&2,^LF)+-6*=>7W,VL$14(''I?DTL+#0EQ*S:/&5XRB0FXU=K M'90M, EO$5F>8D+P(_-'8$[W"LA8=,_48"F4D803K8/'$!'OP>'W MI9-Y7T M[(8Y:B!5"Z[6G380[Z1TUX!PU5#LD:VKDYV$FV[(P6O'L>O.8C+@U $E1J]P M,.=V=HCNPVLGCE")X%K*]&Q6+RQH]43[N\8D! J2$LKP#&P' M^Q_1PFU*F9+VP5XW"("#UPIR?36!E2),.\=K#35)C.A5R]-U8]-AEXZH4F$]G\]3B'9K= M9JTO5VI>KM2\7*EI!L?+E9J7*S4O5VJ>SY6:C$O =LL;(O@4?6?1")&D\S%H M*%Y*M@?E3U+2 SE\R5 69.@@"A>8>']MW2<@O/;(V?1HE6':%Q90:< >S4M* MHY; 24C9C04UH4G%5)]F-(3+S;:C82O@9.GU$J&29>3JP'T5Z%I$!BO#&BB$V"7W4> MH@?D8W$I,"$.<^171=#B:5^MCN[<$Z\2&\P9[03Y[,=S1O.30_Y$&5Y!/*]R M:O9J&I1 JI(7U.V)^!E+G]$<3)=,-E0\OO2 (&J(]D3M&HE!W5]?X_+5C:E M'J2T"@0#E,C:4(I#:?[<#2@(&3*=;[]4*!N9S)46$MW8Q?W9.:&;X OQ0H1GLYO9SDWW/*BE7=[K1NG/\I*4BG'/HI0N MO]@^(G@:N>$8A1$)-G><]+&I&+,OVY.6O* J09ST M.I+VPEDM2U@KP?J;2%H1%>]_M\\P2%150JJ'VU:IU!*0WII>7Z5K.U*GV@=Q$^T7D=\'C5YJ+DNDDJ&YA^Q\4]7.#PJ"9HT>^5AJ9& M9$"M5':[N, A5$*I%\NF3$H@;?>_T^XVNKW3(/N!MW"#L>3:8K=!*+VI:+H\ M@M+K&0@IM[AU'C*YGY,"+S/49Q4(XFB#QX+K\Q[N'I&+EX'DL4 MK!$>.,]=S\[!@P;3)5&&[R\.(4X0PETW5V>B\TD]#;G*5'6\''- 'G-4]H>U M>>>/'0_U]_26+^I)%?;EO_G+?_.6^^@]Q_U'(:TWJ7/2A$$]#MB W.+XK)U9?H^N=7--)[TR< MPX/6P/5\E*-\BSNP.D'XM'G)H&@YE :@QH !NRLW1"O"M@N1$>&7PI>8A-Y? MXI\0ZE!%SF8N$G(YY5_+JQ WU$.MVXL019. SZSRKG0IZ"5?MG=8T Z293*#.2)(JXWSQQ9@YX+[E)[STJP3,EP/"9?P MEP:'*/XSPW!R.@'IC2M0MPE^K9.M(D6@8I9]%D8$K1R//TB$"$'3]")D,!7& M?$ I"D$":$U.+ 91ZHN@&GPYR4.YU_O\5#9!@ *]N&?"@( M/]@J1=>>?P4 YYY000K%ZY+.PFNW[O%ISM01Z#EV!>@<7M<1*R&*N M(FJP)+7\5.PNYF> MXJHVS;B%U[@!*YM(U[%17^->*5L9=X)U3;B-[,ANA?% MF/RYSS-,8:+D*G(=7+82NEYDI@N%:=PNQ]E0QK*+T%2T@YDL, EO$5FR'>$* M!W/^5\[)&(E'FD<.D>XWISQL?]'3E2/4)13YV=BUMSV&7$?4,IT[]6ZO,@Z8 MHO$_N!OWX/CC;+?HP +F:M&'.E#CQ'0;&S+$CGIM4NS,& M\S_(?!)*!?09LMBETIA*-( #ZI!J$JU6<4V[XZ=7("Z#&2;+N' %T.F6)=WY MBTC2,@2[?I1IQ,>O/P%EK7,D[,8_:EI;V $O%15,IY6T<(#3 "J[VB717T1V M1&6VA#WVO),Z')K&2[S.@)&9WN+!Z/),O#IU'PX]*HZ>),,7M3%MFC%U<+2D M9MQ[C;F(FU2Z'F,>!P^(\"L4%\@)(X)2V@-*,:^U1-,O7KBXQB'ZA*>;,BPJ M":@!0GU;A.8D+),Y:O5VY[7@'\].(\IV;TH;-,A+CJ29LS?"/I,3<"%].37- M!-P-F3M!4GR\O?0:%R:/F.WE&A/7*R9>K>-O7!_*-8!!R61YRZ X993^A)BU M<1ZM+L5ZC.CV0%3+N]*Z/ETB%K/)MX\T"8#F96]N3D!%/>AY/B67;F M^M>R^[YV*X4%NB(E*5LN[E=::++"E H*VMW-4,A+)%>(),W6>#5K@RUMM]#9J@ZZL1/U:7H %E*KX_ MI@-,]Q;RA>,1T5GK$W(XLV(^#;:LS7C;^8/ZJ'MIM,N4SQDX=S\.R,H*D7CCWZI\-/?,1A/Y]3'._%3NFA6J@0 M)W'RA&XRA-**^C%R$;,P]SX:E)(N7E"E*3/#1#5O.)KAHF0- L_==B %J3S; M#*-QA&1:;;2ZSI-[#INGW;5=U.3>"]_YQ9B.#[K+59'3;[":O\.3CIV[!M*2 M>ZG+BE7/4D('<.!53,IN M0J\:NGR\5"(J":UNWPM<+KWXDCMS^^(G%>*(@?V2M6T=&+W(0\567?RF"G3RW\HCK7#0UUKO/\N -^<0*OBJBDV MJ/0K'+BE%21/W&87>AFLJU^-*!5I)Q=*<4,438]K,VL6W.5Z[XM(3MQ/V7;G M3R^Q@'IFS3C2]^!DZ9YFZ<)Z>@U9LNP1&E&MG.?8%*(.>IB3N"/Y&*UXH\%@ MWN0]T)VA0/>[,EK:O;1V!FQKAY,@:[4?+]NZ70M_K;^C@M< MK]%C9E"" _97-SYPCF43_Q=T(2CST*?".74!=V_E%);0B7='='-PO2ZBF[@+ M-(U\Y@(/&*I3_N:]]X FR(V(.# X?W+]B(F97U;G3G*4UB"W6GT'P*75MT$5 MJO8@ .IB'D*BX&^S2G4WN.^X[B\^@-\J4RKNS$.;O+G3$R*N1[F7\3-4O]=8P-W;*G>*&1HOO^=0TY QQWN'ZU5+QO@^6$?=YOZF6+B@(M/N MK9**0]WMBGDYVZV8Z!42NST-X1=0&2F[45CC$]M2"8*\1;5=KQ<1OUW[B4EK M&2W'XLIQFB>_P&33"5:PUZIY;,*8Q5+HQHI@"!JIY@L=.*9L9F!?3BOWU>9\ MN?+Q&J6/I!>+?>"+X428F3R@_A=C1W2V$CRVM,I-,VMQY9L_W@3$%.IEA2W+ M>^>N@T>'3$4NX&8EJL>W5>&41LOX9VWN,$8X?&Y'ZJ8!!'KTH8C-K "R;";Q M_]J.;BER93&+THHNJ8($THV^CK%M S_!XAW#@0KM[XXJJ;+X3#=&0_C5M^ZT MX"\GD\2S%68CA)[C^^OT](!N3@]0YN3P_P3'P431^1-U^P/YT'%B_, M$>4"BZVTYF%9PT.,J]T6C$9/I$WQ9B*[V/"P!^H=*L,< CI 3.%+SKP-JR#, M:5WNU:N,IXV#D-F$\[C#VX=#&A=I59D>&^OT=%T\P.#)Z^+2K607R*E:L&\2 M-[I'1^RG;._QMF]][A0Q@1B%W,U!2+#EJF0-*>BULT1#X52TIV49FG"'+JF* M'$USLS-JV606;;W:9"& 2A344?[]Q![\X J 9D[DA[W0 (X#9"/?VZ)BD4^Y M:$*R?6_52!:C'UDKM]^MMU(TAFUR3#F)Q0L)IV^SBG^(2$U$5%0)JP8$K#YM MK8QA$TG6+C<+WN!@N=]0NQ-^7\)8YQ:XF6#$$&J2KP]92F\\)O8.;^NLV'_1 M3IV5ZA%AWI96U"0.4>AX/E7@IR2%4;M# 3&AW9 =A*^"O$6[@MFF)5K)2;2I M9_L^ @1TUC(69[Y#Z:;N\H:,>>82*M]03@SNOE-MPJ"M=9GK%5$N=9@W50H) MPH7\5>0L1_NU"E^+DT*8;A@JF "]%BRKL;DIO*2":JWVB93QSJ@E1)5BL[)O MVPR\)$Q%KC=A\?2-EE#&M&X?\>T"1[Q>^%RJ(VMV$5\'*/;=6+ M4K;MNDX?)\[IB. 9HCPOY?@7"!3#&HI6>H UPZ].AA)5+;_\^]'1P?]\^?3Y MQ__]GW^YJ^CI:_#C^^E?[Q[F7]?!W3!Z_/B.O'_WC]=_W-VNJ?_NP?WKQ/\M M/ XGZ+>_WKWY\^F5>Q6>_/?%Q>O)/XX?GD[/OIX\3"?DZ\U/-V__^.3??4:? M/TT^_[8\O_WUGY^6@R=ZXT_>K:=_D,79]^^G7SUY][;\'8Q&=V]'H6G%R?1U_/'MT_.>_KM\MV;KZ?C MT4__F-V0-[_^=?5J$$W>SK_=_7:U7OY*7SV>#8Z=Z^/77WQ\^=/'7Z/CJZ7[ MT\G5R;_^1MW7MZ_=CP/_X]]NG<_7)\?OD/]F]?#^_>)O/_WTPQ_HIYO1ZV__ MC,CX_O,/P\'[I3/X\.%_#\XFXZ,CS>;G$=OYEHB,T2P*-L"N ?6\AF(/];Q. MAC!QX?:U=]$H A"Q$DHV\J+-@"H3F>3E$V6(1)'1/HN 4-50[.'BJI-A?1C5 M8/MO![1GA5<]5!4!B[UH!7,U\X(9)DM1RD5BGS-DG]HT=]!HV[0K2Z'-EULR MB6M[B^,>$MJAC.RX#3SB?+N+])(@B!$KIM2%_481OYPA*Y$?3(G'9(%)>(O( M$ARM$DH]1ZM,?F8K\8MU8R?M,T9\PNDO.4\@Z7UE'KJ14C"V(F6D;OC\5HH1 M?GF;%Q&/V;1&B+A0GJ,J#\\;_D*IRQW36/)@V/QY=?J:^3+IQ(3OXJ?QJ)'T MZZ>$"I-\3GR;J%?;A9$?N4F7/$H1*AD_-?+#"%TS.&X?D?^ /N$@7(#LF]J\ MV#HI:: $^3Y[NA@ E5C*,O05.>3V$=O4A92%+CA7K2C!1N:2%VA@P6>0@S2$ M4&?"6G65#?QCL8/T(9+EPR;J=I]_T5X@.G!#1<.5].^":>+L\3[=+OLHW%U+ M/4;LMKB#UX!R!&3,OH&0:\,)?&2U)?4,4"V5HD2@;.D]V^+^M[K/UACI"GH% MV9#+-(O-'\DQU$H5OCN724;A]O#2'EU R@G:']?<_5>](W47+]$D=$)!YRIA M%NH";!4YL A/HV46P(+-G\I72!VD^7X)1;@;L-4$P8(YJ2NP$DHO@9;\-5CC M@,'<@ZV'S.I%6).HR768TK2I8T29!^DN!L%TB!Z0CU><@>0]I*([@F;@DR%K M-:Z6LD%9"*4$";/\/J* ^?D^?XIHNF1BXGD=WA ''$4YPC8OZ"K#*"E+J'QG MLDVC:?$NGG !4N4D1]EN5-R"SRR+@*Q%;O>%R7POZ\RS Q'EU5+G-/26_ :L MXQ'^. '"LVR/^29]I/+GLQG*=Y2?]^Y1OLE15CR6-$6MP3L>Q:K'+P;-A:DY M71>_#[%A*<,T5RK>C/TS]MDP/$7#S[5AJH'@V;9WM=RL#N;KC5J &^8EL\W# M =6FF,[H4AI[],\+@E!Z=: 7=K.0:7LU WTQ MF\58RQQE6%?3=&$-O0=ORCR[7JAI(=,O:JJ'=29N0 CQ^?1P.M.!7L-IF'SRJ:ZEK:-,(,+COG^Q NHYPJOJ^/VT7!MLSC+EJU3K -[?HH>CE=!O$!P4>"*= ] M3/-L?C][;B%(QENT27-+E=CMG,MGD'V+5UW,*J!)2&5:OS6)L!NL(32MVD(E M@G.3M#N^(X**/=&1M^T;KQI^+S"9(2^,"**B)^;*(V*$C>YW<7>L9_K9&*KF M\"6J]Z[UE'F=C6\F:Y%AMM7TBXH&MYBE.5[S+6Z;+I?/B/()"!\@KNK _$>] M.-&2YKWC$43[6*;ZV)6BG9OT4'S3?+V[6K?/9+>W54!P4C4R5E9CQ@7(<%KB M0XIH>Y@M VG),]-BK?.G439A2W6PHF;&QN%I9C*27D*W*F4;3*/SZFH5XU1? MJ\XCVB[Q&C,O@473_#H+KX6[8\/S!_#8&A0M^5A M?WY;A&8NGDOHC:HH:98 M)=:(1.O>SSF#)%Q?!HQ^)'(DHA_B[<()$D6[QL&#\.TZZ!4I,V_1/)C0/",N ME3KB<+<^0/A7#Y*[=9P.,D%;<4)_U%Y+;0 OH.@X![63',SG!,V9%YO/4&;F MWBE/T,1\K"5@0%3?FE;(-N1J*]Z&6,^O)%V\CC'==]O>2:%VK!2P=I+YZI]^ M.30[O#\OB]T*VD!OP<)-(#U)GQ9KK 73N\_1BUU5QK"VKK!;1C.I^"C3PJ[; MS7WV[=7J],=V%H N4>K8)>.YJ3/1RV]8,*[J'-LLZ>B+ =;0 XG*RA9+D70C MT\W$H4N2FC/XC)P(2PC75EFV?61US1^N0'AV&E$O0)0.4>AX/M7K2E RV%5Q M2^]2#:\=1M'WJARUH'6V*F.9IM:M]+16$_96\:LET+C/M HDE(2_WWHA;ZA\ M&4QY[PYFUB5;2[/O9AQ6]J]=9[5\<,"-N+:5M+P6N!"/ MQW&KMO!6M_@\")GMDVX*K8=1#5D[K:%K5;44KCHI&CV+U.! JE,+74\"@=BB+E1SJ3H2<<&#.DN,B#MYG>(5)R+?,2>R3@!0] M5%"S%0BIP"4C-*AV?F/.5X"FYP[AH3L+RMQH&8G':(=,8JX'\IZ8!%5KQS$Z MR,E(L;[3G49W:4S^Y D79^6%CE\(6'FOZ,+O]LK"E4R__EA*9Z6<.73!_\]S M"P^.SY?E-MO!?S$(IOD?9#X)L8B:,=0GP]A0]))M)]KM,1DMEPY9X]G$FP<> M4UPG")G5X,\',HT>89^I,N(ER:<.]2B>C0BB;#;)_AUG?A)-!FF8[Q!QUAOB M443=U31$A '$7Y#(9.D8C+^BZ9P)(,D-,A'P M%\T97$QGBBNBS:RE)NSHF>Z,$W8S2\0M:;D+OVIAOS2(Y=:F%\M%(GK0M.J^ M0^F&T T9\R.-W(7[S2]I\MO=@BU#UER+$;O/CA@"OB$6QMM))AM5XHW?,?M) M_#6;CSAKV#(HG22O'^A9P"@OML[U)M^V@QEVK0/Y#FOMNVU B]T85A(=Q-MV M[I@CQVA/DS>1-#VE>#D5#Z5Z3EF.%$ M*+C&8>$CGN5G/-6#6 RA:TQ#YE"G1@XRJ\/ /J]ZNE8Q@,6,<_,M7^4@3>\% MZ?A-)^8 \UWL+"*$^\'!])KYF_$_(*R3#-E^X*8D2*DV_^T6_6%^!,FJ1TW@8B!QU+=A" MW%!(!\Z6R!;[U:AAUI042PJD7<4N*;B H802W,T>J6BA2BFK(%&(%$ D]-@2'['I>)1BLC:2Z%4B8[<@HU$V6$V<,-P':GT+.6O*TV@"T];QMC_SD4S 'BD]4G9:%,BE\DI!+N! M3(TFHV+&SA:B6'N%J1>FR70E""L&L'*4(.O);;&I$@%(^B_/VH7CHL&25XC# M.S(96O8NXD@FU.NEU4I8EFK$V G1,"*\BA^LN9,D99O=;)JA5RY,LT]QIS7G M6=K#V*O.LB!IXNK'L=O&K-] MSD5H2F\9!'2!?=D>/-+#==[,J8K'["VXF#I;A"Z_A31'_)9JTNXIT^CT+G!C MUP1-1VS1NM[*\9/:W9M[WYN+LMV[%0[.%KS,]V8F6D5A7Q),,/)]699P\I>Y M(]>H@B4IUN"&!;)B)4NF\TNZ4D:&NP,6[[.92$*T:A,:P7["TTL72%S5A/=? M9)CH#98:\@7ICG<7K!QOFFJ6I('=^5(?_,?BVG3R\R<:3Y M79?]B*Q4OM5C]$?<-;*H?7C6J.$Z18&X^>_X=FU7%1_==S":B5GBN5=SY:^0 M_L,.I?[@5B8JH(=/!TO,U.(O)[ZGG5W^(X*67K2$ *F>:!],J(((99X;;;LD MF3>"\$)Q^Y,%'3R 8($'"GB["MT*YR3+:C6\VL:\&96R$9,8$<5-ZL$+]*',ROD$.1PFOS!5^T>;JD+>ER,< < M&:[B-C;Q0T^SVP42%*\\Y][S1<=F<2K*#\K8/-(SL_37;#:BT8_+>9L.1$M" M-!5](/ LHFA *9+UQ%M@I,<*T09,4)59>67>Z5&?[K \A9TDTR LL#(/=NM- M&AMJ=9F#O'.59R/)IL'CFQ*RUYO#,( ;R:\_?I:("$UZ M:V8#/*TG6TJ'W(N4Z]Y6D1A)[XRS?&25BZEUH\ %9B774Q5$GWF I4X6S2^K MJG;.'_.#2Y/O3VP'M'MW2U+OTK;W&3D8#HTWHQ>5]S64]!A5ZR6GFJ0$:KQ.P5\_$]LGLMH:597\X-:2:*5K,)4K#O3-MWV M19!PG@ DFQNTDY+-3]MT'BSK3R;]E.,&F8,H7&#B_;7[O)RYS'89.7N'7(I. MB93L@(I]DR;S\0UM_)1BWE+,.\DO;RF^O*78^EN*&U_$=P)^&1.JVTEN?##?&L1, M%HL(*.Y)B<"U-]FA8+>I29':%?R= M"<7D"?7/32L1D[5476O94R);!8 IOQT#XM&L-"Q>"TBLN6M@ =8:"8!:J M11Z0*EFU\%:T":B1U34.SIU^7R0[F]8+K M\^&-:-*OB-'NUZP6T[<$S9ZH0)KTCA"98;)T A?%66;I0T9U-[>$U/->:+6" MEG'6]!I$;.CQ,P1Q^*.TZJI&L%>WV<[JJY0>Q/OAF6YCO'-(3/4RX"7:W@/B M[.IV::L>SF(=9QT&\B(QWHUYCX%SGS=U- =*S7A6]S<%7.K$ N#NG;$=D?FU M3J#8\V[W:]8*7C0/.S+-[_8D *3_6>]0VZ>VV/'1B+2+A #5F5_S'=;8GTB? MAY]>8")^;"4<5N719FF&\JDV'%)09S?:G*:/1R>E)P],)CSYR#C^&+\#WR'= MJN/59BL""TI6"YW9QHV-^4W"W)MP@0CS(HBXE#-$R5\N [CFG= L?U_&319' MF7:5K2I@MI=?IH6?<&N3&N1.:9\,OQ9K5-O7/"D :V_06ME?!].I@,;QVZB3 MA62W_920]1VV"CRP-I[:7(O_?$8TW/1P?M4I'2OB[SM2JD)X)%J/-M"B^WHV M[W?9/']:>41\&-@O,\))#-<O@D4UUK<+IP@F>8U M?P^(I\?B?6'G?$\Q"07"4*^TKWVX4I6#2:>W,8E.;>;*S/=*/2U@F^IG15)= M4T'3(NL)(@]>(O[:O.N2>B$8NB/",^)LUIXKMG. M>.4$K#=]DM#%M#%7A9B,]U-+^,I2,ML!KYP 7!*WMME=K2)NH"@7#T"3PE)J MYMK8UI?*OT(NQC>)4EKF[%(-"M;L4@,@(!IFBK?UR/KWN\F^ MX&DZ58KE:%X1+.CMQH_H=6[X\S$HW MT0N_:J'GA92QW(8&Q3.&Z7"97F:)-Q:^FR28@V1&*JA92UTH1&XR0H.ZRYU_ MMDY48M_,[@H?VX5X 7"7H(55I(]7C>Q@;D1?X\"-".'95DX&9CWMTNC5*MH3 M$-3=X#'O4Q/M5F6;@6 SMM5: WQ;X4BVW3QH=$_1MXC-Z/R!6]5F>=#B MP93SH'7#Z.5!BT=5RH-6#=%Z'E12V)D\:*4$6LV#;D[4\BQ!-J N(]6!5M02 MFID[ABP3&E03X7UZ@"VE2XFUTLRWHC-TC:[6(*20,#4+$E"[YBJ8+#9<-@&2 M7,K" $AP+6"+"5EL)EIG0BJ @>V4?#88GT\&;G@1!=.!+SXISM.I2[S5_N6C M\KZ'M>-8+-=7=A4DI (5?0_1?;BME+EP7#18\K07Q#(II64OYE: JEYB,.%V MGMXE\Q()HN'8"='Y;(9;]$XKR1U91+@V5\O"P(.ORLC$"CE&Y !;(]TU#D!NT M%WM D3 ,=X#+^UEE?3@:.)RY[AC]$'A6$O7=T?3-_*4X L%QUWUQ4?(LO@US MAJ?F+MG;P'Q-Q@)XD%#0)4.'R/+%29@"2Z8)4? M-?YRS"GQKES\8_\'4$L#!!0 ( #J%IE#H9;"U>&H +9[!0 6 9VED M>6PM,C R,# S,S%?;&%B+GAM;.V]:7/D-I(P_/WY%7@\;TS8L9*[U=ZQQW,] M4:VC1[O=DE92V^MU3$Q0)*K$,8LL\Y!:_O4O$N!9Q$60!%A>1\RXNR4"R M M9B*/O_R_3]L(/>$T"Y/XKY^=?/GZ,X1C/PG">//7SS[>':_N3B\O/_M_?T/H M__SE_QX?HWO7G]YC4;\G_^$H7Q3P]>AA&!.\[^^EEKI4\/:?1EDFY>O7G] M^JM7U8>?L2__] E^T/G^^2OZ]1^2:4]>_?>']W?^(]YZ MQV&,_O!]XGLYI:02+B3\ OYU7'UV##\Z/GES_-7)EY^RX#-& M-X3^DB81OL5K1"'_4_ZRPW_]+ NWNP@ HC][3/&:#TB4IJ]@_*L8;X#TL,BW ML,C)U[#([\H?O_<>@FR4)@U^HARU//S[F4HY"LO>R!@E-.1\ Z^?85CO*L^LDQ_.3X]4G) MJ-\-6I>0J\0)@.Y@56V<091BC#.FPS^CAXAN!C(8S@$<'W^\^^QO]5"4K%$] M&%6CT8_5^'_\A8'PMX97\,]5VF68E_H5D.2O"L3*+U[Y"=ESN_RX@^,Z3;9F MK,X3 ]*\,I;"59;A/#LMTI0L,X>X=1=@@$XJ6WF2>]%[B8!U(!!(TCU,@GSV M#?+H"+?A]Z#V%$3@L\ MYP;GK.)BE_?!T-KJ43/,K2R(F=66"P&6QCN_-=_,LF']#&BM+96$)4J @O4C MSX6[//%_>DRB@%A9YS\78?XRCY[96\7%N= '0RH-6>OSW__NCV].OODS"O Z M],.\E@XG&J2(95U]D8OKJ[]-3/0=3L,D(-IIF@\G_6L.[=_B31C'Q,1'#UX$ M-FRS$P^,V*^[^W)"I>QGVQQ;=G/Z>D1+37#-2QS\ C $ @7 M^QHUKAVN$\?)::5@75N"9#@;*^O7._!TD[/[_-,.Q]D\*GM_$?OG4@\&Z4&4 M5%\C7'[N\KP1,JDM'GP$#4^4>C(F=.^3;%[!:"WSZF^N)*,!0B ;\"L$K*GD M(XG;]IU3T>@SBBL<>SAVC^U!(G*5Q$EWUE+PYA 4\6+3J\9*@1$"(Q";Z_P1 MI]5!M_ MQ1_(5EX_7MOEV1_1FP2GA7O-A!#S71!)(:"0H9&W-VC1[AZ7>00PP7^V5E$ MK[>(LZ>!?4@$TM5[&$"?AS%BH[]PZ[H6,:PC-EPT)]8B]9X'>)#PKH+NZP"? MW(=%[]?&ED^]Z]D^A^C2)";_S%:?PEET+_F"4WM;M*X$'B2"S5H>]&S+9-8GJ'?,#;!YS.(4;]1:RJ$[WE!?+"OF-* _J1 M?>I86(3L:0L('S_#BW\5!#2>TXMNO#"XC$^]74CLH_F$0[Z@S3-&"HE 9IHQ M" 8=D^NI',:3("=!?3H,[<3Z*[R(DN?,DC'<7\_R.[4,%AWC%P8A M.HK[9NW6W!5R4V#E\BE@_'1]A7.8\29-GL( !V]?/F:8''7U4]?*S\.GV<)0 M!ZQN_[%;'SB)*]0'V2O(0$0NQ.9!W*O'.KX4A_-_S_$WA$2&9Y]@EZHN140YP*AG=E5- M1O&Z&LZ7T^6(J40$-,141"5#,84E5G$ ?X 3YO+N838'*!9'AF4[SJC8!:Y"06RC;P@8EJUDL3B*&0O0^40] U8B% MQ+ZHV==YE) C;AYW5?FJB1)'7^OGE"'A6C9?N41 B![1J\<(\CV+O%A,&1L5 MZ]KR(\7:X!#:A,%+]$^H=!44$;Y>WR0Y.=1"+XI>SL*H($8KOL-^D5+3]?R3 M'Q7$NF6QN]M=D=.8W>LU_10'W^-P\TC^7#WAU-M@%C7"%T2Z[C$4_'K]52E= M%D&Q(:?VT!$]HI1+4]VM61P%Y>HHJY='N%R?9?;X#00P.& PH.<2".0Q*%!& MP7"^C^S+,.Q(R_PU+T)$@ KT =H_8-Z^\">8*U1K3G!M*CCSH2'2D%H#4#-B M/U;,A88TOP1V5*R923]<1V-'Q?=>FGK$8+A/;HBD/7H95@2M">](G9DF][Z* M;%)MD 1R6XU$>8)VY5BX@2"$+1.%L#FX7P:PK[D>=,DR^'1GTU_O:,X4=W9B ML]*D2_H/J# :K)Z]-.!&*@DE;<0"]E)RQH(J2EEE$XKE$GPE".!HY'DE<<[/V#*?ADP=7H+INYZL8B4TY]-4I>Y)-8]K7(H1&Y!XM-D>4(KDVQO-@7%RWN MM&1%C;JQH_S""]/OO*C C5G;Z'I]FN(@S&_#[*%S(Q&GA1;.>U++EK.;A2@ 1"'LU@HIP-490^]?!.:W! MR/8QK<)_8%K%ODN$SHF#=IEJ4Q^:9"HW3C,Q0!I>LG(P:HUV?-$/9QW/!Z8@ MRKB@SKV9Y^P%)ES,0658(3"R8M.NRV JV;47PRG!T)HQJ 4.+]:_VLV]LMZ' M3?G7YJ;?&7[(;3T@RJD7P81"^^SWDBN<\)W(C9UGWK4Z(KFD:9K+=AGGU MYL>JV&YP[%M[AAX&@.67CR&P22I8E7-0Q;4SR_(>EXWD8;_RU3":F;VC-)H/ MC=BXC*&7,[7/2GOM/GD/.9_F>J_NO);\6X;@::C$+/ G;*9":>D@R!,4T=D6 MT&)E)-MY.O,0$HZTQSYX.01?OI!%JY(D=)'J_A?4$]804_V9W5AKVO!I2.JV MG(M*;5W"AHIHW6R*6TC8K:@.9CY/6(?1<82]]QYG&<:"16Z\%WJVGQ6S5&70 M7MN!-:@+F[03T;K(X;+?AG&X+;:EZ.[*P:Y-QZ&<[S1$&T(=\VJ[^X6UKY)\ M5O54L:)=?50.C+ G:C@.@Q>B-JIQUAYQ\<>+4REK-%3K]>07X'CK*T>G"99 MGM'\"AHA7,GVK*;V.(CLFN2C8!4),0PHH]++(6@%[^4;60= %[;\)++3L?G' MT]-,=X4-]A;F;*\Z5$V53V(Q>54*B.SH/*:C4'N8<\_1$ ZU=$DU#8S=CGO= M+-_#QS#Y3+&QLN6LGG820'2[EU9C^J7PW771DC)2TL6TA[^A6_(69Y@ #=5* MSO 3CI(=K;;/O/QS%JA6+VM7Y=. 2%B[FHVD7L?66%0.=AHR9\#G;E5K/:J8 M:H#O<$SLF C>Y@,PU3(:+/*$9Q= O86MGG!:( EDL!S+(C8ZH\52Z.C<&\3R MMBSJT\=(#=LKI[#*LF++,ABA+.=]6IE1\^(1O,%7,I -,#Z:;*Z^1XR.2>1CYWZQGD>1H^%#D->28' M=,)F/6KGQAZU2L.6O>Q<*R&SB6BO ][DK'%407869'B19J,$#7"; M-/1G>5FW!?H,F]2^RB'#4&4GUB4ER[(;&.U@F$KUH&UTSY(H\M(,ZI.SBI1? M_$KN"AUIGVGK*WDY4X-K>XJ+"D.>.C-07'&_Y;-$5G\3UOE8.4/@DT4=2(6? M0#-J]&TJG$KY.WBE:,$B>-(505?ZTV5,#*\X"WWJ2URXQK0'[-1A#_85I"Y" MHCH=FTV*-^ 6#ZO/T1-\/T07^C7M:K[,SK2/.2R:33>WI^OTL>*F!6I*GEBM M^;4HWHY%[K79HV?3H88^$7V,0YI-=(-3FJM!"-CZN=E#SZ@E[,6MC0%3'!A2 M=4!B#Y1T,'VC;TW;^9W\1](4XM&\.(TFL7'0G/'68P'/K7JM-)/I_M&+ MRTUYE="FLCA8X$O58.#G>EJ83V$:BJ*HA2?]);PY%"!\ UZO#NG2,A7F22XQ M(T[-H[_/I429H,A3JN32*'CB^DT6YV:4O?*>3A#D>83::@IS"U&); OD0:KO M!R=])R-UGP3J M_'"\-7I'BDLV._5;.42L(SIZ\+U[(J M/ (@1,)3?X[8]XL1'@7C.L(CP]E > (<_G-%Q#$ D;R(/(XFG57BDF'_RTWR M](J,89)"_K(O(/WY+(8W]!87/6-6WR#XR(V334AXX#8?$4/VEE4H+\+,]Z(? ML)<2'>F,7&$3<%HX]<0I"E*.BX 0E>]CGR/V/8(!Z!P2:LD0=Z*@8E(E%5)D MAR;'PH1GB4]5'3;C#56B+\C/.$G^@\5#/+<]%Y<4#E%9T?+[2D;8"$2'.+(D MM5A5"8DFWDC0BA4DE&>&KV[Q9%,<#FS+Q%]! =:LNW)[LEW$XH G2SE3"8$808/M74[6]-AFB932UQA3P9 M8M/& M4(.C$!<6\4Z''J$R\_2:\[AI7V?09^>>-*F(86*-E%,S(Z?VD$$QJDE43>GT MEO5-&2P*82HMV,8+RD:YU#QU&+DH,G$V23GUKYQTUE=S/475MVXU M5RXS^GSO8F:N6D!URY3<./1%F!:Y/(76CRE19X(IC%6=5>PZ/S4@DDM+9^@1 M*W.*$B(_; ($,SC77[7XVA4K-4G,/*75[(0K'B07X#,O]X0-]HPEC#N]$QV6 M#XM*J.HQX!WS*J76_2TD9]R^" DQ'Z7#WN(-K3H9YU?>=KIC:6]:%^=0%P2Y MC#3?(OC8M9[*9TI7(#CHC3E$[AYQ%$UMPG0F=7)@M"&0BP#]DF.HN)$ 'CNZ M_.]A-NH8N-MZ4?2VR,(89].Y/[JSVE=4.^LKV ^?HNI;MXHJEQE[W.]A9EJN M>I5E>-X(KKT5[#>&[:PO"M2A'[D.;^4SH]/ZM8_,F/;,=+92F9A?!O87LG4B M2*%0!.]X=,R?7.8$2;G4%PX>?N9E5TZ]#$KEPQ\0L_SD1308,#_UTO0EC#>S ME5#16]A^!IL67"*A(H.<=F@=PLQ.9U9MI,V;=I2)]/REYI PY9KVA4L%DKHL M@]\6,4=M.;0XN=>30XVVH63=I'CGA4'94H',33,M.D?E',*ELZR#>FP:8 ED MK!R),!O*BGZP]K]^YZYT>< -8'9;_G2I8JIDWZ30<39_N2$4S$G5WQ4F!OG G=[9EZ"]7WKM]XTQ>+=:V MI4Q-BQEV_A-.'Y*1/.*EJK:9=$R9Y'K33\\/X^3-JC=RB*'85+^;[9R6O/;: M#I0;7=@$!T-K.+UTLG;WX]_]\!2C&2IH4,'HG&=H_3[=LD39-GWT1BB"7BML25D&/=TAI\9$<\=YSA-'RB M#3;[!]<<0B-=SX49+@-(E'94#VG?4:Z5<1U.MH5)B?A$%G@U^\N,4J58T8'> M+8=(?41%,$P@7LXM/1%+Q:8>EP#&JG02;^ 4/"/'^!6!?3ZY$JQD7Q/B R(R MVLC'DHNN]NS0WP9A1O4/U\>7G*D=#5M,"T.%22"K\\J6>E$7UZ$2*J7,R4ZN M)9U=V%.JYS!TUX2PU(X]@FY9@D!3 ,D2.V.7HVF14\$\J02V<1YF'^O5]9A"B_6X(SB5)7>R'*TX"!6L1 M,J6HHZY5XL?L)3D(0HCF\J(;+PPNXU-O%^9>-(=@B99R(5,"6$3/R?77".)@ MCXDRY;,!CC5U!?-'MO+]8EM0__(9LZ3G$"2- M5:V_/:MA$H\3M=>V#(,?=:D3/%B+M\/]X$1->JI MOJ^3$5S[LY2\X[K;N>B:&G:W.,,$8LB>.<-/.$IHA'FYQ#RGE&Q!!P>4!!QQ MWA0=0_U303/*]0&EP H@MXA1B5?!-HQIX1((QIE1D%1+ MVI8F!3P"D2I'4:'R.N.4,Z0CT>:E8?>$T&%V;JVU!T\/?V"*\I(U,X7YED]/"7.0GA6T )( MI'"142B)T3.,.R8#:5:P*-O&HDP-XA5(D3X5#(XUX>1I@8.;- D*/[_%>9'& M=32AN1Q)YK1V$1H -U#"8"*T8S.AE$Y5!Y8ZR=<9P6.I_"DH9JR9?8Q3[$7P MFET=C]=QD_H0 MP]SBI.92W]:8Q5@N0(PQ'F(+I::8Z^Q3%> MS_-^*%K*A< (8!$7_7D*,Z+A(J+85LZ(W/N$7:OR"NYU34@QQL;24ST[5C& M;[TL],'?'T9%/D^PE6I)VY>; AZ!1-&OV/L.^XXFA(%Q2.-$_3*0!B94!9&Z MD#M-OK?E3X=.YO?>]Q@*V>!@]43.QDW9)>5Z35=J!>U8D$]#2*S[SLS@%(AS M-=FQQV9#,9T.E+:V*&>HR(BH$WE^&"C_+/SJ"[M(I5<5RJQ9)D=B/S+#!B1*TA#?"^]U)HM3%? M9/MP(.S7T1\*HM#=$#'7PMH+J_0= NN@JR9U;F\9"-73C]"D^XMZZPCE47J96 M6("#MR\?R8:\C.N M14T(&*UX^9\5Q\.A8.@Q>%0*J,9O7J(VV=W8RGHO,.; MT<>XCTE[K\ -$?O0Q!&7[[C@_KM/%B#FU'.!=2K0YBP%IUEN?89;+E[*>= M2J 15EUK1K#@/UYA:B>%UY1\[-9=DV-NF'+:/./PGG9F*JJO7M1M23\!5%,] M^CFN\Z=@-+_8GXPDAM$RY#R-O"P+B75"Q?AZ76K@%P1P;IG!^X2^)_'>!X51 M$&-7L7?&30*O4$:[L[;,1 1R(A!94 @2[LNC]>B)B:2EB:>8@M##725L[:LD M!JVA"HGD!N\+)5HPV)934 :$0/K(Q\=4IPRK:-:^!\^!2,FYT$B*!%=3&ZMZ M3NHZZ>:X:P4KV5?=^(",=_VZ*;PL8U^W]K(0ZXDWK$;_$#$PO,8A*AZT'WF_ M<.TEG((CKXVW,[D24BCX>(;9GRT#L'0NSND(&;"Z_6VO#YRH0 <-0L_V7!&T MV1"UYY;2[V&X#.R%N@PADZ&UUU^E[-=VAMC-4).Y'*M3;\1/K+^JM)4C+E$FI^YX5J ]=(W)'U1EB&1DH2-8;B/B4/M M3P\Q^2V;T9J@[:]K.T9$!RBQJ-&4C>I8=!HF.(2I2EGCX3\B-9O_#L@2+5V_ M*C87!(UG916)3&TDP7(78>S%OFOIE4&Q'.F5 M0"G*Y:U&+%]Z-01!0WI5)!HJOVW^E/#S"1'[HUFO8\BA)XZ,UH ME@"\:*S)="ALYJ,B'5?O';Q#UX5S=)A<=+RE \@WSF!GF5XX@YC,F:RFSA(. MKO4]$(0:9Y.K1XO(NK:'>)SAINFUT#+WI+-'-IAHINB3_26<"$('!%7MGZX0 MN)$"+ENZ4M#'R4S;*M_A:4ETHLQA"+Q+B8YWGZQN+D]I:<:'_*QL0*>I:@V; MTW(QC$' B=+9JJ#_L)R$QG?"+!#$ ?.4I3D7T+QO!)L;W6HXT0SCE-[6&12G M=0+%!XPL61O"(UR<@A#DSE:0WD.*1FP M^G2>$WWYT0=/Y#HWC:J3C9[GA_&]+XD "&08]5*M3 (TR9(#IBK4;Z\*7;0TV#@SRQ$F%LVNXYW7AQF7)! MKMXLB<*@2L>X(LU!X^, M@ZG#34RU6W)GL/B.,-[<$)"@0?*LVTUS91=Q/WJ@B=S>S6#4C$;5\.7(^C#6 M=QS;^O29K-38K+(H7LS!&2X$1B!PU?>(#&"%D_@RMH"Z85*IDN-M?,#YCS@H M(GR]7A$QI=6GPB=\A_TBI8]+YY_\J AP ,^,$-1>5(>O50&< 4H'62J3(R$Z M8LN%0+5H+X6:M5"U&'LW;RT'@[A;!H(:$?=P=G,\SR:XG:-\'IX9F@DC85AM M^Z\:$]7+F 0P^P4RI@!;%'G:WGA9L_%P9^/YW8U75?][WB\@N+SFL9/*8J
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end XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events
3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events [Text Block]
13. Subsequent Events

On March 27, 2020, the CARES Act was signed into law in the United States providing economic assistance for American workers and families, small businesses, and preserves jobs for American industries. GI Dynamics qualifies for the Payroll Protection Program (“PPP”) administered by the United States Small Business Administration (“SBA”) and existing lending institutions. On April 4, 2020, GI Dynamics submitted an application to a lending institution for a loan of approximately $200 thousand under the PPP. In accordance with the provisions of the PPP, the loan accrues interest at a rate of 1% and all or a portion of the loan may be forgiven if it is used to pay for qualifying costs such as payroll, rent and utilities. Amounts that are not forgiven will be repaid 2 years from the date of the loan. Due to backlog, the application was not received by the SBA before funding for the CARES Act was exhausted. Additional CARES Act funds were allocated on April 23, 2020 and GI Dynamics was notified by our lending institution that the application was approved by the SBA on April 30, 2020.

The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]
9. Commitments and Contingencies

Lease Commitments

In December 2018, the Company entered into a 6-month membership agreement with WeWork for 985 square feet of office space located in Boston, Massachusetts. The committed lease term expired in May 2019. The WeWork agreement contained no explicit or guaranteed extension provisions.

On April 22, 2019, the Company entered into a right-of-use lease for 3,520 square feet of office space in Boston, Massachusetts. The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. The lease has defined escalating rent payments and contains no extension or expansion rights. On lease execution, the Company recorded the approximately $463 thousand present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset. The right-of-use asset will be amortized to lease expense and the liability will be reduced by the rent payments over the term of the lease.

The Company’s leases generally do not provide an implicit interest rate and therefore the Company uses 10% as an estimate of its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company had no leases currently classified as finance leases or previously classified as capital leases in either reporting period.

The Company’s operating lease is reflected in the balance sheets. In the three months ended March 31, 2020, $44 thousand of lease expense was incurred and an additional $3 thousand of tax expense was accrued for property taxes associated with the leased facility. Other information related to leases was as follows (in 2019, leases were all short term and excluded from the adoption of ASU 2016-2):

Three Months Ended
March 31,

2020 2019

(in thousands)

Operating cash flows from operating leases in lease liability measurement $ 53 $ —

Operating cash flows from short term leases 44 —

Remaining long-term lease term in years 2.2 —

Discount rate 10 % —

The maturity of the Company’s operating lease liability as of March 31, 2020 is as follows:

March 31,
2020

(in thousands)

2020 134

2021 182

2022 76

Total future minimum lease payments 392

Less: imputed interest 40

Total liabilities $ 352

Rent expense on non-cancelable operating leases was approximately $44 and $56 thousand for the three months ended March 31, 2020 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]
5. Fair Value Measurements

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability.

On March 31, 2020, the classification of the Consultant Warrant was reevaluated and the Company re-classified it as an equity instrument. On March 31, 2020, this reclassification resulted in a credit to Other Income.

Cash, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses, short-term debt to related party and other current liabilities at March 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Notes Payable (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended

Jan. 13, 2020

Aug. 31, 2019

Jun. 15, 2017

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2017

Dec. 31, 2019

Dec. 06, 2019

Notes Payable (Details) [Line Items]

Principle amount $ 4,600 $ 4,600

Interest rate during period 16.00%

Unpaid interest 10.00% 8.00%

Debt instrument conversion description On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note was immediately convertible. On January 13, 2020, the Company issued to Crystal Amber an immediately exercisable August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).

Unpaid interest 110.00% 110.00%

Fair valiue of warrant $ 2,300

Debt instrument, convertible, beneficial conversion feature $ 435

Accrued interest expense $ 415 $ 250

Amortization of debt discount 100

2017 Senior Secured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Principle amount $ 5,000

Interest rate during period 5.00%

Interest expenses 65 $ 62

2017 Senior Secured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Qualified financing least amount raised $ 10,000

Percentage of remaining outstanding unconverted principal payment obligation upon change of control 110.00%

2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Accrued interest expense $ 98

2018 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI.

X

- Definition
Percentage of interest rate during default.
+ References
No definition available.
+ Details

Name: gidyl_DebtInstrumentDefaultInterestRate

Namespace Prefix: gidyl_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: gidyl_FairVlueOfWarrantDebtDiscount

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: gidyl_NotesPayableDetailsLineItems

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of remaining outstanding unconverted principal payment obligation upon change of control.
+ References
No definition available.
+ Details

Name: gidyl_PercentageOfRemainingOutstandingUnconvertedPrincipalPaymentObligationUponChangeOfControl

Namespace Prefix: gidyl_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Qualified financing least amount raised.
+ References
No definition available.
+ Details

Name: gidyl_QualifiedFinancingGrossProceedsThreshold

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: gidyl_UnpaidInterest

Namespace Prefix: gidyl_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644
+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644
+ Details

Name: us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=gidyl_TwoThousandSeventeenSeniorSecuredConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=gidyl_ChessDepositInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=gidyl_TwoThousandNineteenSeniorUnsecuredConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=gidyl_TwoThousandandEighteenSeniorUnsecuredConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Deficit (Details) - shares

Mar. 31, 2020

Dec. 31, 2019

Dec. 19, 2019

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized 75,000,000 75,000,000

Capital stock, shares authorized 75,500,000

Preferred stock, shares authorized 500,000

Minimum [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized 50,000,000

Maximum [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized 75,000,000

X

- References
No definition available.
+ Details

Name: gidyl_StockholdersDeficitDetailsLineItems

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04.16(a))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996
+ Details

Name: us-gaap_CapitalUnitsAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Notes Payable
3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]
8. Notes Payable

2017 Convertible Note Financing

On June 15, 2017, the Company entered into a Note Purchase Agreement (“2017 NPA”) by and between the Company and Crystal Amber, a Related Party. Pursuant to the 2017 NPA, the Company issued and sold to Crystal Amber, a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”).

The 2017 Note accrues interest at an annually compounded rate of 5% per annum, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on the original maturity date of December 31, 2018, and, as amended, is currently scheduled to mature on May 15, 2020.

The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, Crystal Amber, is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if Crystal Amber were the absolute owner thereof.

The ASX provided the Company with a waiver to allow all asset liens (the “Security”) to be granted to Crystal Amber, without the customary requirement of having to obtain stockholder approval for the grant of a security to a Related Party of the Company. As a result of the waiver, the Security contains a provision that provides that if an event of default occurs and Crystal Amber exercises its rights under the Security, neither Crystal Amber nor any of its associates can acquire any legal or beneficial interest in an asset of the Company or its subsidiaries in full or partial satisfaction of the Company’s obligations under the Security, or otherwise deal with the assets of the Company or its subsidiaries, without the Company first having complied with any applicable ASX Listing Rules, including ASX Listing Rule 10.1, other than as required by law or through a receiver, manager, or analogous person appointed by Crystal Amber exercising its power of sale under the Security and selling the assets to an unrelated third party on arm’s length commercial terms and conditions and distributing the cash proceeds to Crystal Amber or any of its associates in accordance with their legal entitlements.

The entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CDIs (i) prior to the maturity date, at the option of Crystal Amber at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs traded on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing.

In the event that the Company issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective Optional Conversion Price, Crystal Amber has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that Crystal Amber may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains Crystal Amber’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing.

In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the 2017 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends.

The 2017 NPA contains customary events of default including a failure to perform obligations under the 2017 NPA, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 NPA and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

For the three months ended March 31, 2020 and 2019, the Company recognized interest expense of $65 and $62 thousand, respectively, related to the 2017 Note.

August 2019 Securities Purchase Agreement

On August 21, 2019, the Company entered into the August 2019 SPA by and between the Company and Crystal Amber. The August 2019 SPA detailed a timeline wherein Crystal Amber would exercise the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant. Additionally, pursuant to the August 2019 SPA, the Company issued and sold to Crystal Amber a senior unsecured convertible promissory note in an aggregate principal amount of approximately $4.6 million, or such lesser amount as may be set forth in a notice delivered by the Company to Crystal Amber (the “August 2019 Note”), to be funded on December 6, 2019, or such earlier or later date as may be requested by the Company (the “Funding Date”). In conjunction with the August 2019 Note, the Company agreed to issue to Crystal Amber a Warrant (the “August 2019 Warrant”) to purchase CDIs, subject to the receipt of required stockholder approval approving the issuance of the August 2019 Warrant and the funding of the August 2019 Note (see Note 4).

The August 2019 Note accrues interest at a rate equal to 10% per annum from the August 2019 Note Funding Date, compounded annually, other than during the continuance of an event of default, when the August 2019 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the fifth anniversary of the Funding Date. The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI. In the event that the Company issues additional CDIs to a stockholder other than Crystal Amber in a subsequent equity financing at a price per CDI that is less than the conversion price under the August 2019 Note, the conversion price shall be reduced to the lowest such price per CDI. In addition, upon a change of control of the Company resulting in cash proceeds, Crystal Amber may, at its option, demand that the Company prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. The Company may not prepay the August 2019 Note without the consent of Crystal Amber, a Related Party. If the stockholder approvals required to issue the August 2019 Warrant or to approve the conversion rights under the August 2019 Note are not obtained, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance on the earlier of the Funding Date or the date that is six months following the date of the stockholder meeting at which the requisite approvals were not obtained. The Company considers the change in control premium and the stockholder approval premium to each represent a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premiums, the fair value was considered immaterial upon issuance and through the end of this reporting period.

The August 2019 SPA contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the August 2019 Note may be accelerated. The August 2019 SPA and related August 2019 Note and August 2019 Warrant documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

Prior to December 6, 2019, the Company notified Crystal Amber that it had elected to receive the full amount of approximately $4.6 million under the August 2019 Note, but agreed to timing extensions.

On December 16, 2019, stockholder approval was obtained pursuant to ASX Listing Rule 10.11, for the August 2019 Note conversion feature and the issuance of the August 2019 Warrant, contingent on receipt of the August 2019 Note proceeds.

On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note was immediately convertible. On January 13, 2020, the Company issued to Crystal Amber an immediately exercisable August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).

On issuance, having already obtained the required stockholder approval to reserve the CDIs underlying the conversion feature and the August 2019 Warrant, the August 2019 Warrant was determined to be a freestanding instrument meeting the requirements for equity classification in accordance with ASC 480-10 Distinguishing Liabilities from Equity, ASC 815-40 Contracts in an Entity’s Own Equity and ASC 470-20 Debt with Conversion and Other Options. Accordingly, proceeds from the August 2019 SPA were allocated to the August 2019 Note and Warrant based on their relative fair values. The relative fair value of the August 2019 Warrant of approximately $2.3 million was recorded as a debt discount with the offset to additional paid-in capital. Additionally, the Company analyzed the conversion features of the August 2019 Note to determine whether a beneficial conversion feature (BCF) existed. The Company determined a BCF with a value of $435 thousand existed and was recorded as a debt discount with the offset to additional paid-in capital. The total debt discount will be amortized to interest expense through the January 2025 maturity of the August 2019 Note.

For the three months ended March 31, 2020, the Company recorded $98 thousand of accrued interest expense. For the three months ended March 31, 2020, the Company recognized interest expense of $100 thousand from the amortization of the debt discount.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants to Purchase Common Stock or CDIs
3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]
4. Warrants to Purchase Common Stock or CDIs

The following series of warrants were outstanding and exercisable at March 31, 2020 and 2019 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio):

Number of
underlying
Exercise
price March 31,

Warrant Series Issue Date shares per share 2020 2019

Consultant warrant May 4, 2016 28,532 $ 0.64 28,532 28,532

2018 Warrant (1) May 24, 2018 1,944,444 $ 0.72 - 1,944,444

August 2019 Warrant (2) January 13, 2020 4,596,893 $ 1.00 4,596,893 -

Total Outstanding and Exercisable 4,625,425 1,972,976

Weighted average exercise price $ 1.00 $ 0.72

(1) Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018

(2) Financing arranged August 2019, but funding did not occur until January 13, 2020

On May 4, 2016, the Company entered into a consulting agreement pursuant to which a consulting firm provides strategic advisory, finance, accounting, human resources and administrative functions, including chief financial officer services, to the Company. In connection with the consulting agreement, the Company granted the consulting firm a warrant (“Consultant Warrant”) to purchase up to 28,532 shares of the Company’s common stock at an exercise price per share equal to $0.64. The Consultant Warrant is fully vested and expires on May 4, 2021. As of March 31, 2019, the Consultant Warrants had not been exercised.

On August 21, 2019, GI Dynamics and Crystal Amber entered into a securities purchase agreement for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant (totaling 8,248,549 shares of common stock purchased for approximately $5.4 million) and the issue and sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI issued on exercise. On December 16, 2019, stockholders approved the issuance of the August 2019 Warrant, which was then issued on January 13, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Reporting
3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]
12. Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity.

Geographic Reporting

The Company has historically reported various geographic segments but does not do so currently as the right-of-use asset of approximately $463 thousand and all long-lived assets, comprised of property and equipment of approximately $34 thousand are all held in the U.S. at March 31, 2020. Additionally, the Company did not have revenue in any geography for the three months ended March 31, 2020 and 2019, respectively.

Major Customers

The Company did not recognize any revenue for the three months ended March 31, 2020 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 56 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Details)
$ in Thousands
1 Months Ended 3 Months Ended

Apr. 22, 2019

USD ($)

m²

Mar. 31, 2020

USD ($)

Mar. 31, 2019

USD ($)

Dec. 31, 2018

m²

Commitments and Contingencies Disclosure [Abstract]

Rentable area of leased premises (in Square Meters) | m² 3,520 985

Operating lease term The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019.

Present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset $ 463

Incremental borrowing rate as discount rate to measure operating lease liabilities 10.00%

Operating Lease, Expense $ 44

Operating Leases, Rent Expense 3

Rent expense $ 44 $ 56

X

- Definition
Operating lease term.
+ References
No definition available.
+ Details

Name: gidyl_OperatingLeaseTerm

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset.
+ References
No definition available.
+ Details

Name: gidyl_presentValueOfTheLeaseLiabilityInShorttermAndLongtermLiabilitiesAndRecordedARelatedRightofuseAsset

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Area of land held.
+ References
No definition available.
+ Details

Name: us-gaap_AreaOfLand

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 57 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Share-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended

Feb. 28, 2020

Feb. 15, 2020

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Share-Based Compensation (Details) [Line Items]

Annual increase in number of shares available for grant 500,000

Percentage of common shares outstanding 4.00%

Number of shares available for issue, additional shares 500,000 500,000

Stock options, vesting period 4 years

Stock options, expire period 10 years

Percentage of stock option grants vest 25.00%

Weighted average grant date fair value (in Dollars per share) $ 0.18

Unrecognized compensation expense (in Dollars) $ 2,000

Share based Compensation Arrangement by Share based Payment Award Options Weighted Average Expected Term 3 years 25 days

Stock-based compensation expense (in Dollars) $ 212 $ 59

Options granted 90,000

Exercise price (in Dollars per share) $ 0.25

Company granted option to purchase common stock 3,126,154 3,096,154

Common stock price (in Dollars per share) $ 1.46 $ 1.47

Option vests expires 8 years 109 days

Performance stock units outstanding 250,000 250,000

Non Employees Awards [Member]

Share-Based Compensation (Details) [Line Items]

Unrecognized compensation expense (in Dollars) $ 119 21

Stock-based compensation expense (in Dollars) $ 50 $ 4

NED Options [Member]

Share-Based Compensation (Details) [Line Items]

Options granted 30,000

Exercise price (in Dollars per share) $ 0.20

Performance Shares [Member]

Share-Based Compensation (Details) [Line Items]

Performance stock units outstanding 250,000

Performance Stock Units [Member]

Share-Based Compensation (Details) [Line Items]

Unrecognized stock based compensation (in Dollars) $ 200

2003 Stock Incentive Plan [Member]

Share-Based Compensation (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 922,086

2011 Stock Incentive Plan [Member]

Share-Based Compensation (Details) [Line Items]

Shares available for future grants 554,866

Consultant [Member]

Share-Based Compensation (Details) [Line Items]

Company granted option to purchase common stock 10,000

Common stock price (in Dollars per share) $ 0.40

Option vests expires 10 years

Non Employees [Member]

Share-Based Compensation (Details) [Line Items]

Unvested outstanding options to purchase shares of common stock 167,673

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
No definition available.
+ Details

Name: gidyl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1

Namespace Prefix: gidyl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: gidyl_ShareBasedCompensationDetailsLineItems

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of share based compensation unrecognized expenses.
+ References
No definition available.
+ Details

Name: gidyl_ShareBasedCompensationUnrecognizedExpenses

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average expected term for option awards in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: gidyl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageExpectedTerm

Namespace Prefix: gidyl_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of additional shares authorized for issuance under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares purchased for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=gidyl_NonEmployeesAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gidyl_NEDOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gidyl_PerformanceStockUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gidyl_TwoThousandThreeStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gidyl_TwoThousandElevenStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=gidyl_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=gidyl_NonEmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Nature of Business (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

Mar. 31, 2019

USD ($)

Dec. 31, 2018

USD ($)

Nature of Business (Details) [Line Items]

Types of diabetes population, description Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced).

Number of reportable segments 1

Accumulated deficit $ (287,333) $ (284,492)

Working capital deficit 1,300

Cash and cash equivalents, restricted cash $ 3,884 $ 2,529 $ 1,316 $ 3,836

Type 2 Diabetes [Member]

Nature of Business (Details) [Line Items]

Types of diabetes population, description Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

X

- References
No definition available.
+ Details

Name: gidyl_NatureofBusinessDetailsLineItems

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of types of diabetes population.
+ References
No definition available.
+ Details

Name: gidyl_TypesOfDiabetesPopulationDescription

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of working capital deficit.
+ References
No definition available.
+ Details

Name: gidyl_WorkingCapitalDeficit

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_TitleOfIndividualAxis=gidyl_Type2DiabetesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets:

Cash $ 3,854 $ 2,499

Restricted cash 30 30

Prepaid expenses and other current assets 1,377 1,230

Total current assets 5,261 3,759

Property and equipment, net 34 42

Right-of-use assets, net of amortization 352 386

Total assets 5,647 4,187

Current liabilities:

Accounts payable 521 636

Accrued expenses 886 1,353

Short term debt to related party 5,000 5,000

Derivative liabilities 10

Short term lease liabilities 170 169

Total current liabilities 6,577 7,168

Long term debt to related party, net of debt discount 1,950

Long term lease liabilities 182 217

Total liabilities 8,709 7,385

Commitments and contingencies

Stockholders’ deficit:

Common stock, $0.01 par value – 75,000,000 shares authorized; 36,598,291 shares issued and outstanding 366 366

Additional paid-in capital 283,905 280,928

Accumulated deficit (287,333) (284,492)

Total stockholders’ deficit (3,062) (3,198)

Total liabilities and stockholders’ deficit $ 5,647 $ 4,187

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Operating activities:

Net loss $ (2,841) $ (2,331)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 8 8

Re-measurement of derivative liabilities 1

Reclassification of warrant from derivative liabilities to other income (10)

Non-cash interest expense 282 175

Stock-based compensation expense 212 59

Changes in operating assets and liabilities:

Prepaid expenses and other current assets (147) (26)

Accounts payable (115) (583)

Accrued expenses (631) (768)

Net cash used in operating activities (3,242) (3,465)

Investing activities

Purchases of property and equipment (5)

Net cash used in investing activities (5)

Financing activities

Debt issuance costs (50)

Proceeds from short term and long term debt, related party 4,597 1,000

Net cash provided by financing activities 4,597 950

Net decrease in cash and restricted cash 1,355 (2,520)

Cash and restricted cash at beginning of period 2,529 3,836

Cash and restricted cash at end of period 3,884 1,316

Supplemental disclosures of cash flow information and non-cash activities

Income taxes paid 5 6

Interest paid 394

Warrants issuance recorded to APIC and debt discount 2,330

Beneficial conversion feature discount associated with August 2019 Note $ 435

X

- Definition
Beneficial conversion feature discount associated with 2017 Note modification.
+ References
No definition available.
+ Details

Name: gidyl_BeneficialConversionFeatureDiscountAssociatedWithNoteModifications

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Non cash interest expense.
+ References
No definition available.
+ Details

Name: gidyl_NonCashInterestExpense

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from short term and long term debt, related party.
+ References
No definition available.
+ Details

Name: gidyl_ProceedsFromShortTermAndLongTermDebtRelatedParty

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reclassification of warrant from derivative liabilities to other income.
+ References
No definition available.
+ Details

Name: gidyl_ReclassificationOfWarrantFromDerivativeLiabilitiesToOtherIncome

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrants issuance recorded to APIC and debt discount.
+ References
No definition available.
+ Details

Name: gidyl_WarrantsIssuanceRecordedToAPICAndDebtDiscount

Namespace Prefix: gidyl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants to Purchase Common Stock or CDIs (Tables)
3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of warrants outstanding and exercisable [Table Text Block]

Number of
underlying
Exercise
price March 31,

Warrant Series Issue Date shares per share 2020 2019

Consultant warrant May 4, 2016 28,532 $ 0.64 28,532 28,532

2018 Warrant (1) May 24, 2018 1,944,444 $ 0.72 - 1,944,444

August 2019 Warrant (2) January 13, 2020 4,596,893 $ 1.00 4,596,893 -

Total Outstanding and Exercisable 4,625,425 1,972,976

Weighted average exercise price $ 1.00 $ 0.72

(1) Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018
(2) Financing arranged August 2019, but funding did not occur until January 13, 2020

X

- Definition
Tabular disclosure of warrants outstanding and exercisable.
+ References
No definition available.
+ Details

Name: gidyl_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock

Namespace Prefix: gidyl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R43.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events (Details) - USD ($)
$ in Thousands
1 Months Ended

May 03, 2020

Apr. 04, 2020

Mar. 27, 2020

Dec. 06, 2019

Aug. 31, 2019

Subsequent Events (Details) [Line Items]

CARES act fund allocation, description On March 27, 2020, the CARES Act was signed into law in the United States providing economic assistance for American workers and families, small businesses, and preserves jobs for American industries.

Loan amount under payroll protection program $ 4,600 $ 4,600

Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Loan amount under payroll protection program $ 200

Percentage of accrue interest per annum 1.00%

Loan maturity 2 years

Loan maturity term description The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.

X

- Definition
Description of CARES Act fund allocation.
+ References
No definition available.
+ Details

Name: gidyl_CARESActFundAllocationDescription

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: gidyl_SubsequentEventsDetailsLineItems

Namespace Prefix: gidyl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Notes Payable (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		12 Months Ended
Notes Payable (Details) - USD ($) $ in Thousands	Jan. 13, 2020	Aug. 31, 2019	Jun. 15, 2017	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2017	Dec. 31, 2019	Dec. 06, 2019
Notes Payable (Details) [Line Items]
Principle amount		$ 4,600						$ 4,600
Interest rate during period		16.00%
Unpaid interest		10.00%	8.00%
Debt instrument conversion description	On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note was immediately convertible. On January 13, 2020, the Company issued to Crystal Amber an immediately exercisable August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).
Unpaid interest		110.00%		110.00%
Fair valiue of warrant		$ 2,300
Debt instrument, convertible, beneficial conversion feature		$ 435
Accrued interest expense				$ 415			$ 250
Amortization of debt discount				100
2017 Senior Secured Convertible Promissory Note [Member]
Notes Payable (Details) [Line Items]
Principle amount			$ 5,000
Interest rate during period			5.00%
Interest expenses				65	$ 62
2017 Senior Secured Convertible Promissory Note [Member] \| Chess Deposit Interest [Member]
Notes Payable (Details) [Line Items]
Qualified financing least amount raised						$ 10,000
Percentage of remaining outstanding unconverted principal payment obligation upon change of control						110.00%
2019 Senior Unsecured Convertible Promissory Note [Member]
Notes Payable (Details) [Line Items]
Accrued interest expense				$ 98
2018 Senior Unsecured Convertible Promissory Note [Member] \| Chess Deposit Interest [Member]
Notes Payable (Details) [Line Items]
Debt instrument conversion description		The entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is immediately convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI.

Stockholders' Deficit (Details) - shares	Mar. 31, 2020	Dec. 31, 2019	Dec. 19, 2019
Stockholders' Deficit (Details) [Line Items]
Common stock, shares authorized	75,000,000	75,000,000
Capital stock, shares authorized	75,500,000
Preferred stock, shares authorized	500,000
Minimum [Member]
Stockholders' Deficit (Details) [Line Items]
Common stock, shares authorized			50,000,000
Maximum [Member]
Stockholders' Deficit (Details) [Line Items]
Common stock, shares authorized			75,000,000

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Apr. 22, 2019 USD ($) m²	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 m²
Commitments and Contingencies Disclosure [Abstract]
Rentable area of leased premises (in Square Meters) \| m²	3,520			985
Operating lease term	The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, 2019 resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019.
Present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset	$ 463
Incremental borrowing rate as discount rate to measure operating lease liabilities		10.00%
Operating Lease, Expense		$ 44
Operating Leases, Rent Expense		3
Rent expense		$ 44	$ 56

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Feb. 28, 2020	Feb. 15, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-Based Compensation (Details) [Line Items]
Annual increase in number of shares available for grant			500,000
Percentage of common shares outstanding			4.00%
Number of shares available for issue, additional shares			500,000	500,000
Stock options, vesting period			4 years
Stock options, expire period			10 years
Percentage of stock option grants vest			25.00%
Weighted average grant date fair value (in Dollars per share)			$ 0.18
Unrecognized compensation expense (in Dollars)			$ 2,000
Share based Compensation Arrangement by Share based Payment Award Options Weighted Average Expected Term			3 years 25 days
Stock-based compensation expense (in Dollars)			$ 212	$ 59
Options granted			90,000
Exercise price (in Dollars per share)			$ 0.25
Company granted option to purchase common stock			3,126,154		3,096,154
Common stock price (in Dollars per share)			$ 1.46		$ 1.47
Option vests expires			8 years 109 days
Performance stock units outstanding			250,000		250,000
Non Employees Awards [Member]
Share-Based Compensation (Details) [Line Items]
Unrecognized compensation expense (in Dollars)			$ 119	21
Stock-based compensation expense (in Dollars)			$ 50	$ 4
NED Options [Member]
Share-Based Compensation (Details) [Line Items]
Options granted	30,000
Exercise price (in Dollars per share)	$ 0.20
Performance Shares [Member]
Share-Based Compensation (Details) [Line Items]
Performance stock units outstanding			250,000
Performance Stock Units [Member]
Share-Based Compensation (Details) [Line Items]
Unrecognized stock based compensation (in Dollars)			$ 200
2003 Stock Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			922,086
2011 Stock Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Shares available for future grants			554,866
Consultant [Member]
Share-Based Compensation (Details) [Line Items]
Company granted option to purchase common stock		10,000
Common stock price (in Dollars per share)		$ 0.40
Option vests expires		10 years
Non Employees [Member]
Share-Based Compensation (Details) [Line Items]
Unvested outstanding options to purchase shares of common stock			167,673

Nature of Business (Details) $ in Thousands	3 Months Ended
Nature of Business (Details) $ in Thousands	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Nature of Business (Details) [Line Items]
Types of diabetes population, description	Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced).
Number of reportable segments	1
Accumulated deficit	$ (287,333)	$ (284,492)
Working capital deficit	1,300
Cash and cash equivalents, restricted cash	$ 3,884	$ 2,529	$ 1,316	$ 3,836
Type 2 Diabetes [Member]
Nature of Business (Details) [Line Items]
Types of diabetes population, description	Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 3,854	$ 2,499
Restricted cash	30	30
Prepaid expenses and other current assets	1,377	1,230
Total current assets	5,261	3,759
Property and equipment, net	34	42
Right-of-use assets, net of amortization	352	386
Total assets	5,647	4,187
Current liabilities:
Accounts payable	521	636
Accrued expenses	886	1,353
Short term debt to related party	5,000	5,000
Derivative liabilities		10
Short term lease liabilities	170	169
Total current liabilities	6,577	7,168
Long term debt to related party, net of debt discount	1,950
Long term lease liabilities	182	217
Total liabilities	8,709	7,385
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.01 par value – 75,000,000 shares authorized; 36,598,291 shares issued and outstanding	366	366
Additional paid-in capital	283,905	280,928
Accumulated deficit	(287,333)	(284,492)
Total stockholders’ deficit	(3,062)	(3,198)
Total liabilities and stockholders’ deficit	$ 5,647	$ 4,187

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net loss	$ (2,841)	$ (2,331)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8	8
Re-measurement of derivative liabilities		1
Reclassification of warrant from derivative liabilities to other income	(10)
Non-cash interest expense	282	175
Stock-based compensation expense	212	59
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(147)	(26)
Accounts payable	(115)	(583)
Accrued expenses	(631)	(768)
Net cash used in operating activities	(3,242)	(3,465)
Investing activities
Purchases of property and equipment		(5)
Net cash used in investing activities		(5)
Financing activities
Debt issuance costs		(50)
Proceeds from short term and long term debt, related party	4,597	1,000
Net cash provided by financing activities	4,597	950
Net decrease in cash and restricted cash	1,355	(2,520)
Cash and restricted cash at beginning of period	2,529	3,836
Cash and restricted cash at end of period	3,884	1,316
Supplemental disclosures of cash flow information and non-cash activities
Income taxes paid	5	6
Interest paid		394
Warrants issuance recorded to APIC and debt discount	2,330
Beneficial conversion feature discount associated with August 2019 Note	$ 435

Subsequent Events (Details) - USD ($) $ in Thousands			1 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	May 03, 2020	Apr. 04, 2020	Mar. 27, 2020	Dec. 06, 2019	Aug. 31, 2019
Subsequent Events (Details) [Line Items]
CARES act fund allocation, description			On March 27, 2020, the CARES Act was signed into law in the United States providing economic assistance for American workers and families, small businesses, and preserves jobs for American industries.
Loan amount under payroll protection program				$ 4,600	$ 4,600
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Loan amount under payroll protection program		$ 200
Percentage of accrue interest per annum		1.00%
Loan maturity		2 years
Loan maturity term description	The Company announced on May 3, 2020 that it reached an agreement with Crystal Amber to extend the maturity date of the 2017 Note from May 1, 2020 to May 15, 2020.